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 The advent of rational drug design to target a single molecular event, as so aptly 
demonstrated with tyrosine kinase inhibitor (TKI) therapy and Bcr-Abl, has set a 
precedent for the ability to attack malignancy directly at the level of the oncogenic event. 
However, in the last decade it has become clear that new therapeutic strategies for 
chronic myelogenous leukemia (CML) must move beyond the mere inhibition of Bcr-
Abl’s tyrosine kinase activity if a cure is to be found. TKI resistance, persistent leukemic 
stem cells, and the acute blast phase crisis remain major problems to be solved. This 
work describes the efforts to use the central leukemogenic protein of CML, Bcr-Abl 
(oncogenic event itself), to selectively destroy the diseased cells that harbor it.  
 The subcellular localization of Bcr-Abl determines its function. This is also true 
for Bcr-Abl’s normal counterpart, c-Abl. When localized to the mitochondria, c-Abl is a 
potent inducer of cell death. However, c-Abl pro-death activity is disrupted in CML. The 
mitochondriolytic mechanism of ‘death-directed’ c-Abl is unknown. Yet, under 
conditions of cell stress from a variety of sources (e.g., endoplasmic reticulum stress, 
genotoxic agents, and oxidative stress) active c-Abl migrates to the mitochondria causing 
dysfunction and cell death. Our direct targeting of c-Abl and Bcr-Abl to the mitochondria 
demonstrated the sufficiency of c-Abl alone to kill leukemia cells and of Bcr-Abl’s 
ability to recapitulate this function.  
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 The central hypothesis of this study is that forcing Bcr-Abl to the mitochondria 
will selectively induce the death of leukemic cells by converting Bcr-Abl into an apoptotic 
factor. This approach restores a defunct apoptotic pathway (i.e., the mitochondrial ‘death-
directed’ c-Abl pathway) and does not rely on the indirect engagement of (often 
dysregulated) cell death mechanisms like many chemotherapeutics. c-Abl requires a 
mitochondrial chaperone (protein kinase Cδ). Therefore, we designed a protein 
chaperone, the intracellular cryptic escort (iCE), for Bcr-Abl that selectively functions in 
the pro-oxidative environment of CML cells. Though, the iCE did not move Bcr-Abl to 
the mitochondria, it did synergistically and selectively kill CML cells as a combination 
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BACKGROUND AND SIGNIFICANCE 
 
Tyrosine kinase inhibitors (i.e., imatinib and, more recently, nilotinib and 
dasatinib) represent the current gold standard for CML therapy but are not curative (
Summary 
1). 
The ever present threat of relapse and/or disease progression from the retention of a “Bcr-
Abl enriched” CD34+ refractory leukemic stem cell (LSC) population has been described 
as the sword of Damocles hanging over every CML patient (2-8). A commonality across 
therapy-indifferent CML is high Bcr-Abl expression (8). Nonetheless, it is now clear that 
new therapies with a curative aim must operate beyond the mere inhibition of Bcr-Abl’s 
kinase activity (9). 
 The oncogenic fusion protein Bcr-Abl and the normal c-Abl are essentially two 
forms of the same protein but in different “moods” (10). The functional specificity (often 
antagonistic) of both Bcr-Abl and c-Abl is dictated by subcellular location (11-17). For 
instance, c-Abl can promote mitogenesis when located in the cytoplasm, cell cycle arrest 
when activated in the nucleus, and upon translocation to the mitochondria it can induce 
the loss of mitochondrial membrane potential (ψMIT), depletion of ATP, and 
apoptotic/necrotic cell death (13). Likewise, in CML cells, Bcr-Abl is oncogenic in the 
cytoplasmic space but causes cell death if moved to the nucleus (12, 18, 19). While the 
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nuclear entrapment or targeting of Bcr-Abl to the nucleus of CML cells has proved 
effective in killing some CML cells, the effect is relatively mild and does not kill CD34+ 
leukemic stem cells (LSC) (12, 19-21). 
Targeting the mitochondria to induce irreversible cell death, selectively for 
malignant cells, is considered a prime strategy for success in hematological malignancies 
(22) and is reviewed in Chapter 2. Broadly, the mitochondrion in a cancer context is an 
attractive target because the mitochondrion is central to cell death induction (23), is often 
in a state of precarious apoptotic balance described as, ‘primed for death’(24), and 
exhibits structural and functional differences that can be exploited for therapy (25).  
The mitochondrial translocation of c-Abl from the nucleus (e.g., genotoxic agents 
(26), ionizing radiation, TNFα, and Fas signaling), the endoplasmic reticulum (e.g. 
unfolded protein response (26, 27)), and the cytoplasm (e.g., proteasome inhibition (28) 
and ROS (29, 30)) has been determined, in many cases, to be essential for the induction 
of apoptosis (31, 32). Moreover, two highly effective CD34+ LSC killing agents, arsenic 
trioxide and bortezomib (proteasome inhibitor), both induce cell death through the 
intrinsic apoptotic pathway by a c-Abl dependent mechanism (28, 33-35). However, the 
c-Abl death-directed pathway is suppressed in CML (36). Chapter 3 demonstrates, for the 
first time, without an external cellular insult (e.g., genotoxic agent), that restoring c-Abl 
translocation to the mitochondria is a viable mechanism for killing CML cells.  
Since Bcr-Abl shares many of the same substrates as c-Abl (37-40) routing Bcr-
Abl to the mitochondria may reiterate ‘death-directed’ c-Abl function (Fig. 1.1). Chapter 
4 demonstrates the toxic consequences of targeting Bcr-Abl to the mitochondria and that 





Figure 1.1. Conversion of Bcr-Abl to a pro-apoptotic factor. Within its cytoplasmic niche 
Bcr-Abl suppresses apoptosis and stimulates proliferation (left). If relocated to the 




This feature makes the Bcr-Abl-to-mitochondria strategy compatible with current 
tyrosine kinase inhibitor therapy. The proficiency of mitochondrial Bcr-Abl killing of 
CML cells led to the development of a small protein (the intracellular cryptic escort 
(iCE)) intended to force Bcr-Abl to the mitochondria (also described in Chapter 4). While 
the iCE bound to Bcr-Abl it did not translocate to the mitochondria. Yet, the iCE was 
uniquely toxic to CML cells with an equivalency to high dose imatinib and, as a 
combination with imatinib, strongly potentiated cell death. Therefore, the iCE is 
selectively active against CML cells by a mechanism that is separate from the inhibition 
of Bcr-Abl tyrosine kinase activity. 
This endeavor has been based on developing a ‘biologic’ pharmacological 
approach to restore a suppressed apoptotic mechanism by converting Bcr-Abl and 
causative agent of CML, into an apoptotic instrument for eliminating leukemic cells (Fig. 
1.2). The intent of this project has been to develop potential avenues that could be used to 
address the three major obstacles in current CML therapy all typified by high Bcr-Abl 
expression: resistance to tyrosine kinase inhibitors, persistent LSCs, and therapy-resistant 
blast phase crisis. 
Philadelphia chromosome positive leukemia 
Background 
 Chronic myelogenous leukemia (CML) is the most common form (>90%) of the 
Philadelphia (Ph) chromosome positive leukemias, which result from the 
t(9;22)(q34;q11) reciprocal translocation (41). From this translocation the oncoprotein 
Bcr-Abl, with its exclusively cytoplasmic distribution and aberrantly active tyrosine 





Figure 1.2. Schematic of major hypothesis. Exogenous Bcr-Abl targeted to the 
mitochondria (MTS-Bcr-Abl) will establish the proof of concept that mitochondrial Bcr-
Abl induces CML cell death. The ccmut3 and cryptic mitochondrial targeting signal 
(cMTS) together create the intracellular cryptic escort (iCE) that is designed to bind to 
endogenous Bcr-Abl and then upon activation of the cMTS, translocate the iCE/Bcr-Abl 




oncogene) and BCR (breakpoint cluster region) can occur at different breakpoints giving 
rise to three main variants of Bcr-Abl each with a distinct molecular weight (38). The 
p190BCR-ABL1 (i.e., 190 kDa Bcr-Abl) gives rise to rare cases of CML and to almost 70% 
of cases of Ph+ B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The p210BCR-ABL1 
variant is present in 90-95% of CML and around 30% of Ph+ B-ALL patients, and finally, 
p230BCR-ABL1 is present in patients with chronic neutrophilic leukemia (40, 41). All of 
these BCR to ABL1 fusions (but not the ABL to BCR) disrupt structural c-Abl 
autoinhibition and result in the constitutive activation of the tyrosine kinase (41). The 
precise manifestation of the leukemia is dependent on cellular context and intrinsic kinase 
activity of the Bcr-Abl fusion (1). 
 The Ph in CML presents across all hematopoietic lineages and the 
interchromosomal recombination phenomenon is more probable in primitive 
hematopoietic cells because of the closer spatial association of the BCR and ABL genes 
in early stages of the cell cycle compared to mature phenotypes (42). Accordingly, there 
is a general consensus that the origination of a Ph+ translocation in a primitive pluripotent 
stem cell enables escape from the regulation of self-renewal mechanisms to establish a 
small population of leukemic stem cells (LSCs) (43). The rare LSCs are thought to be 
responsible for the maintenance of CML, by cycling between quiescent and active states 
(44). Progenitors of the LSCs preferentially expand in the myeloid lineage but the Ph+ 
translocation is also found in erythroid and lymphoid lineages (45).  
Both Bcr and c-Abl have intricate domain arrangements (Fig. 1.3) and when fused 
together, as Bcr-Abl, activate a variety of signaling pathways (41). c-Abl (within Bcr-




Figure 1.3. Domain arrangements. There are two isoforms of c-Abl that are identical 
except for the extreme N-termini of the so-called ‘cap’ region where the residue sequences 
vary. c-Abl 1b contains a 14-carbon myristoyl moiety (Myr) as does c-Src and the viral 
Gag fused v-Abl. Upon fusion to Bcr (dashed red line indicates approximate fusion points), 
the cap region of c-Abl is variously truncated to produce the p210 version of Bcr-Abl. 
Abbreviations used: Src homology 2 and 3 (SH2/SH3), catalytic tyrosine kinase (YK), 
DNA binding domain (DBD), actin binding domain (ABD), nuclear localization signal 
(NLS), nuclear export signal (NES), coiled-coil oligomerization domain (CC), 
serine/threonine kinase domain (S/T kinase), Dbl homology/pleckstrin homology-Rho 




kinase domain, four proline-rich SH3 binding motifs, a DNA binding domain, an actin 
binding domain (ABD), three nuclear localization sequences (NLS), and a nuclear export 
sequence (NES) (41). Essentially, the wild-type NH2 “cap” region of c-Abl is, to varying 
degrees, replaced by Bcr depending upon the breakpoint in ABL1 (41). Bcr itself (within 
p210 Bcr-Abl) contains a coiled-coil oligomerization domain (CC), a serine/threonine 
kinase domain, and Dbl homology and pleckstrin homology domains (DHPH) (41). Not 
only does Bcr disrupt the autoinhibitory mechanisms of c-Abl upon fusion but it also 
facilitates via the CC domain the association of antiparallel Bcr-Abl homodimers that can 
stack to form a tetramer (41, 45). The dimerization of Bcr-Abl instigates 
transautophosphorylation of tyrosine residues in the activation loop of the catalytic 
domain and thereby reinforces its own aberrant tyrosine kinase activity (41).  
The abnormal tyrosine kinase activity of Bcr-Abl successfully cancels out, in 
several ways, one of the most crucial cellular homeostatic regulators that can engage cell 
suicide mechanisms, that is, c-Abl (46-48). While c-Abl primarily promotes survival and 
suppresses apoptosis from the cytoplasm it can also induce apoptosis through a 
cytoskeletal cytoplasmic cell fate pathway (CAS/Crk cell suicide program) (49). Bcr-
Abl’s annexation of c-Abl’s physiological tyrosine kinase function thwarts the 
cytoplasmic regulatory actions of c-Abl (e.g., by phosphorylating CrkL (which activates 
the RAS signaling pathway) instead of Crk) (28, 50), blocks c-Abl translocation (49), and 
as Bcr-Abl expression levels increase, c-Abl expression levels decrease (36). Perhaps 
most importantly, with diminished c-Abl function genetic damage accrues, the fidelity of 
DNA repair decreases, and the cell death threshold is drastically increased (13). Beyond 
the effects on c-Abl, Bcr-Abl blocks the intrinsic apoptotic pathway at multiple points. 
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Bcr-Abl expression decreases the free releasable calcium in the ER and attenuates 
ER/mitochondrial apoptotic coupling (51). Cytochrome c release is blocked by Bcr-Abl 
stimulated pathways inhibiting the proapoptotic protein Bad (via PI3K) (52) and 
antiapoptotic Bcl-2 family proteins are upregulated (via STAT5) (53). Downstream of 
cytochrome c release, Bcr-Abl interrupts the association of caspase-9 and apaf-1 
preventing apoptosome formation (54).  
It is difficult to appreciate Bcr-Abl’s transformative power by dissecting 
individual pathways because there is a cumulative effect from the numerous downstream 
pathways often converging at common nodes which lead to cross-talk and reinforcement, 
thereby becoming something more than the sum of its parts (41). This has been 
demonstrated by introducing dominant-negative versions of STAT5, PI3K, and RAS 
where functional cooperation was required between any two of the three (in any 
combination) for the complete fruition of Bcr-Abl’s oncogenicity when expressed in 
K562 cells (55). The originating cytosolic Bcr-Abl stimulation of these ramifying and 
converging pathways culminates in the intense promotion of cell survival and 
proliferation while suppressing apoptosis (41).  
The expression of Bcr-Abl consequently manifests with the overproduction of 
immature white blood cells (56). The vast majority (90-95%) of patients are diagnosed 
with CML in the chronic phase where there is an excess of myeloid cell production (54). 
Without intervention, CML typically will progress, through an indolent (chronic) phase 
lasting 3-5 years on average, through a brief “accelerated phase” before transitioning into 
a therapy-resistant acute leukemia (blast phase crisis), which is fatal (1). Progression 
from chronic to blast phase, mechanistically, is not well understood, but is considered to 
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be dependent upon achieving a threshold of genetic damage that limits the capacity for 
differentiation beyond a primitive blast cell (55). 
 
Therapy for chronic myelogenous leukemia 
In 1998 clinical use of imatinib (Novartis, Basel, Switzerland) began and was 
approved by the FDA in 2001 ushering in the tyrosine kinase inhibitor (TKI) era of CML 
treatment (1, 57). Therapeutic success is defined specifically in CML by different levels 
of patient response. The scale ranges across ‘complete hematologic response’ (HR: 
normal blood cell counts and the patient is asymptomatic), to a ‘complete cytogenetic 
response’ (CCyR: no detectable Ph+ metaphases), and finally, optimal response is a 
‘complete molecular response’ (CMolR: absence of Bcr-Abl transcript as determined by 
q-PCR) (58). Prior to TKIs, CML was treated orally with hydroxyurea or busulfan which 
allowed patients to achieve normalization of blood cell counts (HR) but disease 
progression was not changed (59). With the introduction of interferon-alpha (IFN-α), 
CML patients could attain an improved hematological response and an increase in overall 
survival compared with hydroxyurea (60). IFN-α was generally paired with the 
antimetabolite agent cytosine arabinoside (cytarabine) as a standard therapeutic regimen 
until the advent of TKI therapy (61). There is a continued interest in the ‘old’, and 
arguably the original (62), anti-leukemic agent, arsenic trioxide (As2O3), as a potential 
candidate in resistant and/or residual stem cell forms of CML as well as in other 
leukemias (63, 64). It exhibits selective toxicity to Ph+ versus Ph- cells (the array of 
mechanisms of action attributable to As2O3 seem to be contingent upon cell type and 
context (65)) that is independent of Bcr-Abl kinase activity (35, 45). The proposed use of 
IFN-α in CML is also being revisited as an adjunct to TKI therapy for potential activity 
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against LSCs (66). However, the use of both As2O3 and IFN-α for the elimination of 
persistent LSCs remains tentative (67) and their use as adjunctive therapy still needs to be 
borne out in clinical trials, thus, for now, TKIs alone dominate the current therapeutic 
landscape for CML (68). 
 Imatinib mesylate (Gleevec®; originally STI571 for Signal Transduction Inhibitor 
571) therapy is the current gold standard for CML and has revolutionized the treatment 
and outcomes for patients with CML (69). Administration of imatinib in the chronic 
phase very effectively delays, and in rare cases eliminates, the progression from chronic 
phase to blast phase crisis for most patients with CML (1). It takes on average 5-6 months 
for patients newly diagnosed with CML to achieve CCyR (70). With non-resistant forms 
of CML, TKIs suppress the pro-survival/anti-apoptotic signaling of Bcr-Abl and restore 
cellular apoptotic control (3). Most patients initially respond to imatinib therapy but, over 
time many ultimately become resistant (i.e., ‘acquired’ versus ‘primary’ resistance) and 
progress to blast phase crisis (69, 71, 72). With acquired resistance being determined as 
the loss of CCyR or HR during therapy (72).  
 Since the introduction of TKI therapy, resistant forms of CML have emerged as a 
major problem (69). Resistance to TKIs can manifest in a variety of forms (72). For 
example, in cases where the Src kinase, Lyn, is overexpressed, Lyn effectively keeps 
Bcr-Abl perpetually in an active state conformation (5) where imatinib cannot bind (4). 
Additionally, mechanisms such as increased drug efflux (73), clonal cytogenetic 
evolution, high expression levels of Bcr-Abl or STAT5 (74), and point mutations in Bcr-
Abl are contributing factors to TKI resistance (6). At present, there are over 50 reported 
residue mutations in the tyrosine kinase domain from CML-resistant patients. These 
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residue substitutions can either influence Bcr-Abl conformation (e.g., conformations that 
less readily bind imatinib) or disrupt a contact/binding site for imatinib (72). 
 There are now two second generation TKIs, which are more potent inhibitors of 
Bcr-Abl (and inhibit a wider spectrum of kinases), nilotinib (Novartis) and dasatinib 
(Bristol-Myers Squibb, Princeton, NJ), which have been approved for imatinib-resistant 
forms of Bcr-Abl (75, 76). The notable exception is resistance due to the T315I Bcr-Abl 
kinase domain mutation that is currently untreatable and in these cases an allogenic stem 
cell transplant is recommended (72). However, in the last few years there has been an 
intensive effort to develop agents that are active against T315I mutants. Ponatinib, the 
most advanced third generation TKI, is active against T315I and other Bcr-Abl mutants, 
and is in the planning stages for phase III clinical trials (77). It may eventually supplant 
the use of nilotinib and dasatinib in imatinib-resistant CML (78). Additionally, several 
‘multi-targeted’ kinase inhibitors developed initially against the S/T aurora kinases (and 
currently progressing through early clinical trials) have also shown efficacy in blocking 
the Bcr-Abl T315I activity (79). Pre-clinically, several small molecule agents are in 
development that allosterically inhibit Bcr-Abl (e.g., Genomics Novartis Foundation-2 
(GNF-2)) or induce the degradation of Bcr-Abl (e.g., WP1130 and phenethyl 
isothiocyanate (PEITC; found in cruciferous vegetables)) with high specificity for and 
activity against Bcr-Abl (including T315I) (80, 81). Bcr-Abl activity can also be blocked 
by disrupting its coiled-coil domain mediated homo-oligomerization with an optimized 
coiled-coil (e.g., ccmut3) (82). Peptide inhibitors such as the ccmut3 are also less likely 
to succumb to Bcr-Abl point mutation acquired resistance or be subject to increased drug 
efflux mechanisms compared to small molecules (83). 
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Accompanying the emerging problems with resistance is the increasing literature 
on the longer term consequences of TKI therapy (84). Most adverse events are 
hematologic in nature; however, these toxicities seem particular to each TKI and the 
alternate use of another approved TKI has been effective in circumventing intolerance 
(85). Still the potential for compromised genetic stability/DNA repair and cell 
homeostasis in non-CML cells due to c-Abl inhibition (4, 73) as well as possible 
cardiovascular risks (74) are problematic. For instance, nilotinib has a black box warning 
for QT prolongation (78) and ponatinib is associated with platelet dysfunction (86). 
Moreover, some situations are considered ill-suited to TKI use such as those requiring 
combination chemotherapies, which depend on c-Abl-induced functional DNA mismatch 
repair activation responses for efficacy (6). 
With TKI therapy the durability of response, response rate, and rate of 
progression from chronic to blast phase CML are all critically dependent upon both early 
treatment and the level of Bcr-Abl expression (1, 41). Postponement of treatment 
increases the risk of resistance and narrows the time to blast phase crisis (41). The only 
known cure for CML remains allogenic stem cell transplantation but is rarely used due to 
the high associated morbidity and mortality (87). The vast majority of patients on TKI 
therapy have persistent CML and relapse if therapy is stopped, even in patients that have 
undetectable levels of Bcr-Abl (i.e., cMolR) (69, 88). Therefore, TKI therapy is currently 
recommended to be continued daily for one’s lifetime (89). 
Linked to the problem of molecular resistance in CML is the issue of persistent 
LSCs. LSCs may be responsible for the emergence of TKI-resistant strains of Bcr-Abl (2) 
(perhaps through clonal evolution and/or selective pressure from treatment (90)) with 
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drug target mutations (1, 3, 91). LSCs are generally considered to be the true crux of the 
problem in finding a cure to CML (63, 88).  
A model developed to fit with the kinetics of the molecular response to imatinib 
by Michor and colleagues (43), fits with the general consensus regarding LSCs (44, 92, 
93) and describes four ‘compartments’ aligning with the development of hematopoietic 
cells. After the chromosomal translocation occurs in a leukemia-initiating cell 
(presumably phenotypically indistinguishable from a normal Lin-CK34+CD38-  
hematopoietic stem cell (2)) a subpopulation of LSCs is established that can continuously 
renew. Derived from the LSCs are the progenitor cell (non-self-renewing), differentiated 
cell, and mature terminally differentiated cell populations (43). Each of the four 
compartments of leukemia cells are killed by TKIs except the LSCs. Failure by TKI 
therapy to eradicate LSCs is thought to be due to the LSCs adopting a quiescent state or 
another molecular mechanism circumventing the necessity of Bcr-Abl activity for 
continued survival (2, 93). 
The TKI refractory LSCs are, to a point, dependent upon Bcr-Abl-mediated 
tyrosine phosphorylation and stabilization of β-catenin (44). The cooperativity between 
Bcr-Abl and β-catenin provides an alternate route by which CML cells can survive TKI 
therapy (2). However, TKIs do eliminate a portion of the LSC pool initially (providing a 
basis for some of the debate over whether or not LSCs are sensitive to Bcr-Abl inhibition 
(94)), but the residual LSC levels return despite continued TKI treatment (2). It is thought 
that cells with less Bcr-Abl are more readily killed thereby selecting for LSCs containing 
higher levels of Bcr-Abl (95). Other studies have determined that the refractory LSC 
population is “enriched” for Bcr-Abl (7, 94, 95). It seems likely that both increased 
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expression of Bcr-Abl and states of dormancy serve as mechanisms for LSCs to escape 
TKI therapy. 
 It has been proposed that stimulating quiescent cells to enter active cycling could 
make them vulnerable to current therapeutics (43). The use of granulocyte-colony-
stimulating factor (G-CSF) has been evaluated for the induction of stem cell mobilization 
in patients who achieved complete cytogenetic conversion in order to obtain enough 
peripheral blood stem cells for autografting (even suggesting that PBSC collection yields 
were enhance by withholding imatinib (96)) (96-98). The strategy of stimulating 
quiescent leukemic stem cells as a means to sensitize them to TKI therapy has been 
pursued, based on promising in vitro studies (99). Several pilot safety and clinical trials 
have investigated the combined use of imatinib and G-CSF (100-102). However, the 
stimulation of quiescent stem cells is thought to carry a significant risk for the acquisition 
of resistance mutations in addition to increasing disease burden (or progression to blast 
phase) if leukemic stem cells are not responsive to imatinib. Treating with G-CSF even 
raises the possibility that the stimulating factors themselves could lead to the protection 
of LSCs (43). The premise of using G-CSF is particularly brought into question when 
recent work by Corbin et al. demonstrated that inhibiting Bcr-Abl kinase activity does not 
decrease CML stem cell survival (103). This has revealed a different dynamic between 
Bcr-Abl and Ph+ primitive cells. Instead of being ‘oncogene addicted’ the LSCs can 
merely revert to a normal dependence on cytokines for survival (89, 103). For that 
reason, therapies that biochemically ablate Bcr-Abl will not be sufficient to address the 
problem of LSCs (78). 
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 Other approaches to target the LSC population have been to engage the immune 
response (e.g., ‘immune engineering’ (58) or IFN-α treatment (66))  or stimulate the 
activity of tumor suppressor proteins (72). Clinical trials using Bcr-Abl junction-specific 
peptides as immunogenic tumor-associated antigens to vaccinate patients in CCyR on 
imatinib showed overall improvement in disease stabilization (104). While there is 
promise in this strategy the optimization of antigenic peptides is proving to be non-trivial 
(e.g., uneven response profiles across CML cell subpopulations) (105). LSCs have also 
been shown to be susceptible to the induced activation of the tumor suppressor p53 (88). 
However, the p53 loci is the most frequently (~25% in blast phase (106)) mutated as 
CML progresses (72, 107) and several genes responsible for the up-regulation of p53 are 
also mutated at a high frequency in CML (72) making this strategy difficult to widely 
implement.  
 Intrinsic to the LSC debate is the interpretation of the recently completed STIM 
(STop IMatinib) trial (108). The STIM trial assessed whether CML patients who had 
achieved cMolR (>2 years) could safely discontinue imatinib therapy. The findings 
indicated that, at least in some patients, the discontinuation of imatinib was possible, but 
overall disease relapse was more common (108). However, whether or not a patient is 
‘cured’ of CML remains both to be determined and a tremendous technological challenge 
(109, 110). 
 
Subcellular location dictates function 
Bcr 
 Bcr is expressed in 130, 160 (major variant) and 190 kDa versions and is 
associated with endosomal membranes as a part of the endosomal sorting complex (111). 
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The functions of Bcr are generally not well understood but Bcr is known to play a key 
signaling role as it relates to the negative regulation of Rac (a small GTPase of the Rho 
family) in macrophage phagocytosis (112). Bcr contains a coiled-coil oligomerization 
domain, serine/threonine kinase domain, a Dbl/Pleckstrin homology Rho-specific 
guanine nucleotide exchange factor (RhoGEF) domain, and a C-terminal Rac-GTPase 
activating (Rac-GAP) domain (Fig. 1.3) (113). The Rac-GAP domain is not included in 
Bcr-Abl, but is included in the complementary non-transformative Abl-Bcr which is also 
expressed in most CML patients (113, 114). Interestingly, Bcr can act as a negative 
regulator of Bcr-Abl (115), but the S/T kinase function is required (116). This implies 
that Bcr does not act as a dominant-negative via the coiled-coil domain as Bcr and Bcr-
Abl are, for the most part, spatially separated (111). 
 The CC is of central importance with respect to the transformative potential in the 
Bcr portion of Bcr-Abl (117). However, key phospho-tyrosine sites and RhoGEF activity 
also contribute to the oncogenic capacity of Bcr-Abl (118). The Bcr RhoGEF is 
constitutively active in Bcr-Abl and functions, independently of tyrosine kinase activity, 
to catalyze the exchange of GDP for GTP for the activation of the only known substrate, 
RhoA (119, 120). The pharmacologic inhibition of RhoA signaling synergized with 
imatinib to block the proliferation of CD34+ patient-derived CML cells (121). This 
demonstrated the therapeutic relevance of inhibiting the activity of the Bcr portion of 
Bcr-Abl in addition to the tyrosine kinase. 
  Additionally, the Bcr phospho-Y177 residue is a particularly important binding 
site for Grb2 which activates the RAS pathway (122). Although the kinase activity of 
Bcr-Abl is usually responsible for the auto-phosphorylation of Y177, a Src tyrosine 
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kinase (Hematopoietic cell kinase (Hck)) can also phosphorylate Y177. This allows for 
Bcr-Abl kinase-independent RAS activation, with Bcr-Abl acting as a scaffold for 
oncogenic signaling complex formation. 
c-Abl 
 The 140 kDa nonreceptor tyrosine kinase c-Abl is one of two tyrosine kinases 
(i.e., c-Abl and Arg)  in a subclass of the Src family of kinases (11). Normally, c-Abl is 
found widely distributed intracellularly within the nucleus, endoplasmic reticulum, 
cytosol, with the cytoskeleton, and at the cell membrane with only a small fraction 
associated with the mitochondria (< 4%) (11, 26). The activity of c-Abl is tightly 
regulated through autoinhibitory intramolecular interactions (10), posttranslational 
modifications (11), and protein interactions (e.g., 14-3-3 proteins (123) and 
retinoblastoma protein (124)).  
 As the ‘central apoptotic tyrosine kinase’ the pro-death activity of c-Abl has been 
extensively studied (125). c-Abl can trigger apoptosis at the level of the nucleus, 
cytoskeleton, and/or mitochondria via a host of interactions (10, 11). For instance, c-Abl 
stimulates and typically amplifies cell death induction cascades via direct interactions 
with p53 (11, 123, 124), p63 (126), p73 (37, 127), phospholipid scramblase 1 (PLSCR1; 
a major regulator of PS exposure in apoptotic cells that is also present in the 
mitochondria (128)) (37, 129, 130), p38 MAPK (131) and initiator and effector caspases 
(37, 126, 132, 133). c-Abl has an interdependent, but indirect, relationship with the pro-
death signaling of c-jun NH2-terminal kinase (JNK) (134). c-Abl is an early amplification 
factor in apoptosis through positive feedback mechanisms relating to direct interactions 
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(cleavage into constitutively active forms) with caspases 3, 7, 8 and 9 (126, 135-137) 
before cell death is morphologically apparent (138). 
 
c-Abl translocation to the mitochondria induces cell death 
c-Abl has been termed a “mitochondrial wracking factor” (32) and was the first 
tyrosine kinase found to associate with the mitochondria (139). In leukemic cells, 
treatment with H2O2 stimulates c-Abl translocation (mediated by the novel protein kinase 
C δ (PKCδ) (140)) to the mitochondria resulting in an increase from ~4% to ~20% of 
total cellular c-Abl followed by mitochondrial dysfunction and cell death (30). Moreover, 
the H2O2 induced cell death effect can be blocked with imatinib (29). Likewise, under 
conditions of ER stress (e.g., unfolded protein response (UPR)), c-Abl is activated and 
translocates (again mediated by PKCδ) from the ER to the mitochondria and is essential 
for ER-stress-induced mitochondrial-dependent apoptosis (26, 27).  
At present the submitochondrial location and substrates for c-Abl are unidentified 
(29). The JNK and p38 MAPK pathways have been proposed to be involved in 
mitochondrial c-Abl mediated cell death (26, 27, 141). In a reciprocal manner, c-Abl is 
essential to the activation of the p38 and JNK stress pathways (131, 141) in response to 
genotoxic agent (e.g., cisplatin, etoposide, and doxorubicin)-induced cell death (126). 
Interestingly, both c-Abl and Bcr-Abl directly activate p38 in response to cisplatin and 
can do so independently of their tyrosine kinase activity (38). The kinase activity of c-
Abl and Bcr-Abl is, in certain cases, dispensable for the induction of apoptosis (31, 38, 
142). Furthermore, under conditions of genotoxic stress, ionizing radiation, TNFα and 
Fas signaling, active c-Abl relocates from the nucleus to the cytoplasm in hematopoietic 
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cells and activates the JNK stress pathway (26). Both JNK (JNK translocates to the 
mitochondria in response to DNA damage (143)) and c-Abl have been found to 
coimmunoprecipitate with mitochondrial Bcl-XL (27, 38). Since JNK mitochondrial 
translocation is also stimulated by the phorbol ester response (i.e., agents that activate 
protein kinase C) (144) this raises the possibility of a JNK-cAbl-PKCδ complex that 
targets the mitochondria.  
 Mitochondrial dysfunction and cell death from active c-Abl translocation does not 
require any new gene expression and has been shown to be independent of p53, p73, Bax, 
retinoblastoma protein (Rb) and Fas receptor presence (145, 146). The residues that c-Abl 
interacts with in p53, p63, and p73 are highly conserved, and since Bcr-Abl interacts with 
p73 at these same residues, it is possible, but unconfirmed, that Bcr-Abl could also 
interact with p53 and p63 (37, 126). 
 
Bcr-Abl 
The oncogenic capacity of Bcr-Abl is uniquely suited but limited a specific 
cytoplasmic environment (13-15). As with c-Abl, Bcr-Abl has demonstrated opposing 
functions that are dependent upon its subcellular location (12), and c-Abl and Bcr-Abl 
broadly share many of the same substrates (e.g., p38 (38) and p73 (37)) (39, 40). 
Although Bcr-Abl is mostly bound to actin (~70%) (16) this binding interaction 
can be overcome with imatinib (19, 147). Aggregates of Bcr-Abl in discrete cytoplasmic 
foci relocalize in the nucleus upon treatment with imatinib (18, 148). However, these foci 
are very rapidly exported back into the cytoplasm (12). Vigneri and Wang demonstrated 
Bcr-Abl’s dual nature by trapping Bcr-Abl in the nuclear compartment which caused 
CML cell death (12). Entrapping Bcr-Abl in the nucleus using imatinib and leptomycin B 
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(nuclear export inhibitor) was partially selective for Ph+ cells (12, 20). Yet nuclear 
entrapment by this method is not clinically viable as the imatinib dose was 10-fold higher 
than used therapeutically and leptomycin B is extremely neurotoxic (20). The Lim 
Laboratory used a different approach to ‘trap’ Bcr-Abl in the nucleus, either through 
expression of an exogenous Bcr-Abl fused to NLSs (i.e., 4NLS-Bcr-Abl) or by moving 
endogenous Bcr-Abl to the nucleus with an optimized Bcr-Abl-binding coiled-coil fused 
to NLSs (i.e., 4NLS-ccmut3) (19, 147). Corroborating earlier results by Vigneri and 
Wang, the exogenously expressed Bcr-Abl targeted to the nucleus caused CML cell death 
(19). This also provided evidence that Bcr-Abl was actively toxic in the nuclear 
compartment and that cytoplasmic depletion was not the cause (or sole cause) of cell 
death.  
The original study by Wang suggested that after nuclear entrapment of Bcr-Abl, 
washout of imatinib was required for cell death and therefore, kinase activity was 
essential (12). Later however, Wang discovered that nuclear c-Abl could efficiently cause 
cell death by a kinase-independent mechanism (149). Work in the Lim Laboratory (by 
Emmeline Tran) demonstrated that the direct nuclear targeting of a kinase-dead Bcr-Abl 
mutant (i.e., 4NLS-Bcr-Abl-KD) in K562 cells caused cell death equivalent to the kinase 
active 4NLS-Bcr-Abl (150). At a later time, it was shown that the forced nuclear 
translocation of Bcr-Abl by the 4NLS-ccmut3 (Andy Dixon, Lim Laboratory) did not 
induce cell death beyond control in K562 cells (personal communication, Andy Dixon, 
PhD). Taken together, the implication is that the homodimerization of Bcr-Abl but not 
the tyrosine kinase activity is the mechanistically important feature underpinning the 
toxicity of nuclear Bcr-Abl. Bcr-Abl may be acting only as a partial proxy to c-Abl 
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whether in the cytoplasm (prosurvival) or nucleus (prodeath) (12). However, if nuclear 
Bcr-Abl is operating in an analogous manner to nuclear c-Abl, the relatively modest 
amount of cell death may be explained by the interrupted nuclear DNA damage response 
in CML cells and/or through layers of negative regulation present for nuclear localized c-
Abl (138, 151, 152). 
 
 
Mitochondrial translocation signals  
Protein localization to different subcellular compartments is directed by signal 
sequences encoded in the protein itself (19). Mitochondria are unique cellular organelles 
in that, like the nucleus, they contain DNA (mtDNA). Nonetheless, the vast majority 
(~99%) of mitochondrial proteins are coded for in nuclear DNA requiring the import of 
~1000 different cytosolic proteins (12, 153, 154). The mechanics of protein import at the 
level of the mitochondrial membranes are intimately linked to mitochondrial function 
(e.g., membrane organization, respiration, and endoplasmic reticulum-to-mitochondria 
contact) (155) and the import of proteins (i.e., cytosolic versus mitochondrial balance of 
proteins containing an import sequence) can be influenced by the physiologic status of 
the cell creating an adaptive system for regulating homeostasis at the cellular level (156, 
157).  
Mitochondrial protein import can occur by at least five different pathways. 
Conventional protein import into the mitochondria is conducted by the pre-sequence 
pathway or the carrier pathway for proteins with internal noncleavable MTSs (158). For 
example, most matrix-targeted proteins (e.g., ornithine transcarbamlyase (OTC)) are 
recognized and imported via the pre-sequence pathway through positively charged N-
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terminal sequences of about 20-60 residues with an amphipathic (one face is positively 
charged and the other is hydrophobic) α-helical structure (159, 160). Import signal 
structure becomes more complex to accommodate variations in sorting to 
submitochondrial locations (including specific regions of the matrix) and are encoded by 
internal and/or pre-sequences (158). Recently, the β-barrel import pathway, 
mitochondrial intermembrane space assembly, and α-helical insertion pathways have 
been elucidated (155).  
Each pathway, to varying degrees can facilitate protein targeting to four general 
mitochondrial regions, the OMM, IMS, IMM and the matrix (161) (Table 1.1) . Central 
to all of the import pathways are the protein translocases located at and within the 
mitochondrial membranes (152). These translocases recognize signal sequences or motifs 
on proteins and direct the import and submitochondrial localization of the sequence 
bearing proteins (138). The outer membrane (OMM) of the mitochondria hosts the 
translocase complex of the outer membrane (TOM) while the inner membrane (IMM) 
contains translocase of the inner membrane complexes (TIM) (162). The precise system 
of mitochondrial protein routing and distribution is achieved by the decoding of signal 
sequences, regulation (e.g., posttranslational modifications such as phosphorylation at the 
level of the imported protein or the import machinery), and the dynamic coordination of 
the import/sorting machinery. 
A cryptic MTS is a sequence that is not imported into the mitochondria unless it is 
activated or revealed by a molecular event such as, proteolytic cleavage (153), 
phosphorylation (163), or a point mutation (164). For instance, phosphorylation can 
induce a conformational change in a protein allowing chaperone proteins to recognize  
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Table 1.1. Sequences for targeting proteins to specific submitochondrial compartments. 
Well characterized residue sequences that specifically target proteins (hetero-proteins) to 
the various submitochondrial compartments listed. These MTSs are used in Chapters 3 and 
4 to target c-Abl and Bcr-Abl, respectively, to the mitochondria. 
Target 
compartment  
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and bind a formerly cryptic signal (169). The glutathione S-transferase A4-4 (GSTA4-4) 
cryptic MTS (cMTS) translocates from the cytoplasm to the mitochondria upon serine 
and/or threonine phosphorylation (163). The activating cMTS phosphorylation is mediated 
by the PKA and/or PKC families of protein kinases based on the intracellular level of 
reactive oxygen species (ROS) (163). Under conditions of increased oxidative stress, as 
found in CML cells (40, 170-172), the cMTS is robustly targeted from the cytoplasm to the 
mitochondria (163). Bcr-Abl strongly stimulates the production of ROS causing CML cells 
to have a high cellular oxidative stress background (40, 172). cMTS targeting can be 
further enhanced with the addition of PKA/PKC activators, several of which have 
demonstrated antileukemic properties (144). Chapter 3 confirms and extends the oxidative 
stress activated translocation of the cMTS which is robustly targeted to the mitochondria by 
the inherent level of ROS in K562 cells. 
 
K562 cells and ROS 
The multipotential undifferentiated blastic Ph+ K562 cell line was derived from a 
CML patient in terminal blast phase crisis and is considered a highly relevant model of 
CML (173, 174). K562 cells have high basal levels of ROS due to Bcr-Abl’s stimulation 
of the PI3K/mTOR pathway leading to overactivation of the mitochondrial electron 
transport chain (175). Elevated intracellular ROS can lead to the activation of 
transcription factors (e.g., HIF-1 and NF-κB) leading to a host of protein expression 
profiles that contribute to malignancy such as, proliferation, survival, and metastasis (25). 
The K562 cell line serves as a prototypical example of elevated ROS in oncogenically 
transformed cells (176). Bcr-Abl signaling also induces the expression of NF-κB which 
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acts to temper ROS production. Thereby, Bcr-Abl elevates ROS levels while keeping the 
total ROS below a cytotoxic threshold (177). Overall, the elevated ROS in a leukemic 
context are not solely dependent upon Bcr-Abl. Elevated ROS is common in many 
cancers, and as mutations in mtDNA or nuclear DNA accrue this affects components of 
the mitochondrial respiratory chain and results in ROS overproduction and oxidative 
damage to mitochondria and other macromolecules (DNA) in a vicious spiral (178). 
Imatinib, while inhibiting Bcr-Abl, also induces cytotoxic levels of ROS 
production by a mechanism separate from that of Bcr-Abl. In cells with and without Bcr-
Abl (K562 and melanoma B16F, respectively), imatinib treatment induced cytotoxic 
levels of ROS via a JNK-mediated mechanism (177, 179). However, in Bcr-Abl-positive 
cells imatinib leads to an initial decrease in ROS by Bcr-Abl inhibition (via block of 
PI3K signaling). Yet, imatinib treatment induces apoptosis by both classical and atypical 
routes (e.g., via Omi/HtrA2 serine protease activity) (180). The classical route is typified 
by ROS overproduction while the atypical apoptotic pathway can occur in a ROS-
independent manner (181). Bcr-Abl’s activation of NF-ĸB prevents cytotoxic levels of 
ROS from developing but this is blocked by imatinib (177). Therefore, ROS levels are 
elevated due to the presence of Bcr-Abl, and when Bcr-Abl is inhibited by imatinib ROS 
production initially dips but then rise to cytotoxic levels via classical apoptotic 
mechanisms. This situation leads to a seeming ‘ROS paradox’. However, an increase in 
magnitude of the already elevated ROS in cancer cells is likely to exceed the antioxidant 
capacity of the cancer and cause cell death (25). Furthermore, the Bcr-Abl/ROS scenario 
of K562 cells mimics the situation with other oncogenic kinases (e.g., epidermal growth 
factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), and B-Raf) 
27 
 
where the current spectrum of kinase inhibitors similarly kills in a ROS-dependent 
mechanism (182, 183). 
Additionally, many antineoplastic agents like imatinib exert their cytotoxic effects 
through the generation of ROS (179). However, the underlying mechanisms for the 
essential ROS-mediated killing by chemotherapeutics and radiation therapy is not well 
understood (184). Imatinib presumably blocks any contribution to chronic ROS-mediated 
by Bcr-Abl, but as with other antineoplastic agents its killing mechanism can rely on an 
apoptotic process that induces ROS levels. 
Bcr-Abl is considered a highly toxic protein when put into the right cellular 
context (Chapter 4). Forcing Bcr-Abl to the mitochondria may seem more akin to 
“throwing a wrench into the system” but this gets to the point that under contingencies 
such as genotoxic damage, c-Abl acts as the wrench to prevent the system from becoming 
malignant in the first place (16, 147). The intracellular cryptic escort (iCE) is uniquely 
suited to confer selective toxicity to CML cells over nonmalignant cells by virtue of two 
conditions, oxidative stress is required for activation of the iCE and Bcr-Abl is exclusive 
to CML cells. 
Overall the aim of this study was to investigate the feasibility of converting the 
oncogenic Bcr-Abl tyrosine kinase into a mitochondrially targeted pro-apoptotic factor. 
This would restore a suppressed apoptotic pathway in CML using the cause to become 
the cure.  
Statement of objectives 




Major hypothesis: Forcing cytoplasmic Bcr-Abl to the mitochondria, via an intracellular 
cryptic escort, will selectively induce cell death in chronic myelogenous leukemia cells. 
1) Specific Aim 1: Bcr-Abl containing a mitochondrial targeting sequence (MTS-Bcr-
Abl) will induce cell death in leukemia cells upon localization to the mitochondria. 
Four previously characterized MTSs (i.e., matrix, intermembrane space, and inner 
and outer membranes) will be subcloned into pEGFP-Bcr-Abl (wild-type p210 Bcr-
Abl). The MTS-Bcr-Abl constructs will be transiently transfected into leukemia cells 
and assessed for mitochondrial localization and apoptotic activity. 
 a. Hypothesis
 b. 
: MTS-Bcr-Abl will localize to the mitochondria of leukemia cells. 
Hypothesis
2) Specific Aim 2: The intracellular cryptic escort (iCE) will bind and facilitate 
endogenous Bcr-Abl translocation from the cytoplasm to the mitochondria.  
: MTS-Bcr-Abl will induce cell death in leukemia cells. 
3) Specific Aim 3: The intracellular cryptic escort will selectively induce cell death in 
Ph positive cells. 
 The hypotheses and aims are discussed in Chapters 3 and 4; these chapters have 
been published in (185) or submitted to (Molecular Pharmaceutics) peer-reviewed 
journals, respectively. Chapter 2 reviews the targeting of peptide/protein agents to the 
mitochondria in the context of malignancy and has been accepted to the peer-reviewed 
journal Therapeutic Delivery. Chapter 3 builds a foundation for the use of a cryptic 
peptide to selectively target the mitochondria of cells with a high ROS phenotype and 
sets a precedent for the restoration of the c-Abl death-directed pathway in CML. The 
results of Chapter 4 focus on addressing the major hypothesis.  
29 
 
1. B.J. Druker. Translation of the Philadelphia chromosome into therapy for CML. 
Blood. 112:4808-4817 (2008). 
References 
 
2. E. Nicholson and T. Holyoake. The chronic myeloid leukemia stem cell. Clin 
Lymphoma Myeloma. 9 Suppl 4:S376-381 (2009). 
 
3. F.P. Santos and F. Ravandi. Advances in treatment of chronic myelogenous 
leukemia--new treatment options with tyrosine kinase inhibitors. Leuk 
Lymphoma. 50 Suppl 2:16-26 (2009). 
 
4. T. O'Hare, C.A. Eide, and M.W. Deininger. Persistent LYN signaling in imatinib-
resistant, BCR-ABL-independent chronic myelogenous leukemia. J Natl Cancer 
Inst. 100:908-909 (2008). 
 
5. J. Wu, F. Meng, H. Lu, L. Kong, W. Bornmann, Z. Peng, M. Talpaz, and N.J. 
Donato. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl 
protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood. 
111:3821-3829 (2008). 
 
6. A. Quintas-Cardama and J.E. Cortes. The next generation of therapies for chronic 
myeloid leukemia. Clin Lymphoma Myeloma. 9 Suppl 4:S395-403 (2009). 
 
7. R. Bhatia, M. Holtz, N. Niu, R. Gray, D.S. Snyder, C.L. Sawyers, D.A. Arber, 
M.L. Slovak, and S.J. Forman. Persistence of malignant hematopoietic 
progenitors in chronic myelogenous leukemia patients in complete cytogenetic 
remission following imatinib mesylate treatment. Blood. 101:4701-4707 (2003). 
 
8. R. Hehlmann and S. Saussele. Treatment of chronic myeloid leukemia in blast 
crisis. Haematologica. 93:1765-1769 (2008). 
 
9. A. Hamilton, G.V. Helgason, M. Schemionek, B. Zhang, S. Myssina, E.K. Allan, 
F.E. Nicolini, C. Muller-Tidow, R. Bhatia, V.G. Brunton, S. Koschmieder, and 
T.L. Holyoake. Chronic myeloid leukemia stem cells are not dependent on Bcr-
Abl kinase activity for their survival. Blood. 119:1501-1510 (2012). 
 
10. O. Hantschel and G. Superti-Furga. Regulation of the c-Abl and Bcr-Abl tyrosine 
kinases. Nat Rev Mol Cell Biol. 5:33-44 (2004). 
 
11. A. Sirvent, C. Benistant, and S. Roche. Cytoplasmic signalling by the c-Abl 
tyrosine kinase in normal and cancer cells. Biol Cell. 100:617-631 (2008). 
 
12. P. Vigneri and J.Y. Wang. Induction of apoptosis in chronic myelogenous 
leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat 




13. J. Dierov, P.V. Sanchez, B.A. Burke, H. Padilla-Nash, M.E. Putt, T. Ried, and M. 
Carroll. BCR/ABL induces chromosomal instability after genotoxic stress and 
alters the cell death threshold. Leukemia. 23:279-286 (2009). 
 
14. A.Y. Ting, K.H. Kain, R.L. Klemke, and R.Y. Tsien. Genetically encoded 
fluorescent reporters of protein tyrosine kinase activities in living cells. Proc Natl 
Acad Sci U S A. 98:15003-15008 (2001). 
 
15. L. Veracini, M. Franco, A. Boureux, V. Simon, S. Roche, and C. Benistant. Two 
distinct pools of Src family tyrosine kinases regulate PDGF-induced DNA 
synthesis and actin dorsal ruffles. J Cell Sci. 119:2921-2934 (2006). 
 
16. J.R. McWhirter and J.Y. Wang. An actin-binding function contributes to 
transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive 
human leukemias. EMBO J. 12:1533-1546 (1993). 
 
17. P.J. Woodring, T. Hunter, and J.Y. Wang. Regulation of F-actin-dependent 
processes by the Abl family of tyrosine kinases. J Cell Sci. 116:2613-2626 
(2003). 
 
18. H. Patel, S.B. Marley, L. Greener, and M.Y. Gordon. Subcellular distribution of 
p210(BCR-ABL) in CML cell lines and primary CD34+ CML cells. Leukemia. 
22:559-571 (2008). 
 
19. A.S. Dixon, M. Kakar, K.M. Schneider, J.E. Constance, B.C. Paullin, and C.S. 
Lim. Controlling subcellular localization to alter function: Sending oncogenic 
Bcr-Abl to the nucleus causes apoptosis. J Control Release. 140:245-249 (2009). 
 
20. J. Melo. Inviting leukemic cells to waltz with the devil. Nat Med. 7:156-157 
(2001). 
 
21. E.K. Allan, A. Hamilton, S. Hatziieremia, P. Zhou, H.G. Jorgensen, P. Vigneri, 
and T.L. Holyoake. Nuclear entrapment of BCR-ABL by combining imatinib 
mesylate with leptomycin B does not eliminate CD34+ chronic myeloid 
leukaemia cells. Leukemia. 23:1006-1008 (2009). 
 
22. E. Solary, A. Bettaieb, L. Dubrez-Daloz, and L. Corcos. Mitochondria as a target 
for inducing death of malignant hematopoietic cells. Leuk Lymphoma. 44:563-
574 (2003). 
 
23. S.W. Tait and D.R. Green. Mitochondria and cell death: outer membrane 





24. M. Certo, V. Del Gaizo Moore, M. Nishino, G. Wei, S. Korsmeyer, S.A. 
Armstrong, and A. Letai. Mitochondria primed by death signals determine 
cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 9:351-
365 (2006). 
 
25. S.J. Ralph, S. Rodriguez-Enriquez, J. Neuzil, E. Saavedra, and R. Moreno-
Sanchez. The causes of cancer revisited: "mitochondrial malignancy" and ROS-
induced oncogenic transformation - why mitochondria are targets for cancer 
therapy. Mol Aspects Med. 31:145-170 (2010). 
 
26. Y. Ito, P. Pandey, N. Mishra, S. Kumar, N. Narula, S. Kharbanda, S. Saxena, and 
D. Kufe. Targeting of the c-Abl tyrosine kinase to mitochondria in endoplasmic 
reticulum stress-induced apoptosis. Mol Cell Biol. 21:6233-6242 (2001). 
 
27. X. Qi and D. Mochly-Rosen. The PKCdelta -Abl complex communicates ER 
stress to the mitochondria - an essential step in subsequent apoptosis. J Cell Sci. 
121:804-813 (2008). 
 
28. M. Holcomb, A. Rufini, D. Barila, and R.L. Klemke. Deregulation of proteasome 
function induces Abl-mediated cell death by uncoupling p130CAS and c-CrkII. J 
Biol Chem. 281:2430-2440 (2006). 
 
29. S. Kumar, N. Mishra, D. Raina, S. Saxena, and D. Kufe. Abrogation of the cell 
death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571. 
Mol Pharmacol. 63:276-282 (2003). 
 
30. S. Kumar, A. Bharti, N.C. Mishra, D. Raina, S. Kharbanda, S. Saxena, and D. 
Kufe. Targeting of the c-Abl tyrosine kinase to mitochondria in the necrotic cell 
death response to oxidative stress. J Biol Chem. 276:17281-17285 (2001). 
 
31. M. Le Bras, I. Rouy, and C. Brenner. The modulation of inter-organelle cross-talk 
to control apoptosis. Med Chem. 2:1-12 (2006). 
 
32. J.Y. Wang. Nucleo-cytoplasmic communication in apoptotic response to 
genotoxic and inflammatory stress. Cell Res. 15:43-48 (2005). 
 
33. H. Yan, Y.C. Wang, D. Li, Y. Wang, W. Liu, Y.L. Wu, and G.Q. Chen. Arsenic 
trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in 
leukemic cells: the role of protein kinase Cdelta. Leukemia. 21:1488-1495 (2007). 
 
34. N.B. Heaney, F. Pellicano, B. Zhang, L. Crawford, S. Chu, S.M. Kazmi, E.K. 
Allan, H.G. Jorgensen, A.E. Irvine, R. Bhatia, and T.L. Holyoake. Bortezomib 
induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC 




35. E. Puccetti, S. Guller, A. Orleth, N. Bruggenolte, D. Hoelzer, O.G. Ottmann, and 
M. Ruthardt. BCR-ABL mediates arsenic trioxide-induced apoptosis 
independently of its aberrant kinase activity. Cancer Res. 60:3409-3413 (2000). 
 
36. M. Gupta, L. Milani, M. Hermansson, B. Simonsson, B. Markevarn, A.C. 
Syvanen, and G. Barbany. Expression of BCR-ABL1 oncogene relative to ABL1 
gene changes overtime in chronic myeloid leukemia. Biochem Biophys Res 
Commun. 366:848-851 (2008). 
 
37. A. Vilgelm, W. El-Rifai, and A. Zaika. Therapeutic prospects for p73 and p63: 
rising from the shadow of p53. Drug Resist Updat. 11:152-163 (2008). 
 
38. E.M. Galan-Moya, J. Hernandez-Losa, C.I. Aceves Luquero, M.A. de la Cruz-
Morcillo, C. Ramirez-Castillejo, J.L. Callejas-Valera, A. Arriaga, A.F. Aranburo, 
S. Ramon y Cajal, J. Silvio Gutkind, and R. Sanchez-Prieto. c-Abl activates p38 
MAPK independently of its tyrosine kinase activity: Implications in cisplatin-
based therapy. Int J Cancer. 122:289-297 (2008). 
 
39. J. Zhu and S.K. Shore. c-ABL tyrosine kinase activity is regulated by association 
with a novel SH3-domain-binding protein. Mol Cell Biol. 16:7054-7062 (1996). 
 
40. M. Sattler, S. Verma, G. Shrikhande, C.H. Byrne, Y.B. Pride, T. Winkler, E.A. 
Greenfield, R. Salgia, and J.D. Griffin. The BCR/ABL tyrosine kinase induces 
production of reactive oxygen species in hematopoietic cells. J Biol Chem. 
275:24273-24278 (2000). 
 
41. A. Quintas-Cardama and J. Cortes. Molecular biology of bcr-abl1-positive 
chronic myeloid leukemia. Blood. 113:1619-1630 (2009). 
 
42. H. Neves, C. Ramos, M.G. da Silva, A. Parreira, and L. Parreira. The nuclear 
topography of ABL, BCR, PML, and RARalpha genes: evidence for gene 
proximity in specific phases of the cell cycle and stages of hematopoietic 
differentiation. Blood. 93:1197-1207 (1999). 
 
43. J. Foo, M.W. Drummond, B. Clarkson, T. Holyoake, and F. Michor. Eradication 
of chronic myeloid leukemia stem cells: a novel mathematical model predicts no 
therapeutic benefit of adding G-CSF to imatinib. PLoS Comput Biol. 5:e1000503 
(2009). 
 
44. M. Savona and M. Talpaz. Getting to the stem of chronic myeloid leukaemia. Nat 
Rev Cancer. 8:341-350 (2008). 
 
45. J.C. Chomel, C. Villalva, N. Sorel, F. Chazelas, F. Guilhot, and A.G. Turhan. 
Evaluation of beta-catenin activating mutations in chronic myeloid leukemia. 




46. N. Takao, R. Mori, H. Kato, A. Shinohara, and K. Yamamoto. c-Abl tyrosine 
kinase is not essential for ataxia telangiectasia mutated functions in chromosomal 
maintenance. J Biol Chem. 275:725-728 (2000). 
 
47. Y. Shaul and M. Ben-Yehoyada. Role of c-Abl in the DNA damage stress 
response. Cell Res. 15:33-35 (2005). 
 
48. S. Kharbanda, Z.M. Yuan, R. Weichselbaum, and D. Kufe. Determination of cell 
fate by c-Abl activation in the response to DNA damage. Oncogene. 17:3309-
3318 (1998). 
 
49. M. Mancini, N. Veljkovic, V. Corradi, E. Zuffa, P. Corrado, E. Pagnotta, G. 
Martinelli, E. Barbieri, and M.A. Santucci. 14-3-3 ligand prevents nuclear import 
of c-ABL protein in chronic myeloid leukemia. Traffic. 10:637-647 (2009). 
 
50. K.H. Kain, S. Gooch, and R.L. Klemke. Cytoplasmic c-Abl provides a molecular 
'Rheostat' controlling carcinoma cell survival and invasion. Oncogene. 22:6071-
6080 (2003). 
 
51. K. Piwocka, S. Vejda, T.G. Cotter, G.C. O'Sullivan, and S.L. McKenna. Bcr-Abl 
reduces endoplasmic reticulum releasable calcium levels by a Bcl-2-independent 
mechanism and inhibits calcium-dependent apoptotic signaling. Blood. 107:4003-
4010 (2006). 
 
52. M.S. Neshat, A.B. Raitano, H.G. Wang, J.C. Reed, and C.L. Sawyers. The 
survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -
independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell 
Biol. 20:1179-1186 (2000). 
 
53. M. Horita, E.J. Andreu, A. Benito, C. Arbona, C. Sanz, I. Benet, F. Prosper, and 
J.L. Fernandez-Luna. Blockade of the Bcr-Abl kinase activity induces apoptosis 
of chronic myelogenous leukemia cells by suppressing signal transducer and 
activator of transcription 5-dependent expression of Bcl-xL. J Exp Med. 191:977-
984 (2000). 
 
54. M. Kurokawa, C. Zhao, T. Reya, and S. Kornbluth. Inhibition of apoptosome 
formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-
induced leukemias. Mol Cell Biol. 28:5494-5506 (2008). 
 
55. J. Sonoyama, I. Matsumura, S. Ezoe, Y. Satoh, X. Zhang, Y. Kataoka, E. Takai, 
M. Mizuki, T. Machii, H. Wakao, and Y. Kanakura. Functional cooperation 
among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full 





56. Y. Maru. Molecular biology of chronic myeloid leukemia. Int J Hematol. 73:308-
322 (2001). 
 
57. B.J. Druker, C.L. Sawyers, H. Kantarjian, D.J. Resta, S.F. Reese, J.M. Ford, R. 
Capdeville, and M. Talpaz. Activity of a specific inhibitor of the BCR-ABL 
tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute 
lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 
344:1038-1042 (2001). 
 
58. M. Bocchia. Is there any role left for p210-derived peptide vaccines in chronic 
myeloid leukemia? Haematologica. 87:675-677 (2002). 
 
59. R. Hehlmann, H. Heimpel, J. Hasford, H.J. Kolb, H. Pralle, D.K. Hossfeld, W. 
Queisser, H. Loffler, B. Heinze, A. Georgii, and et al. Randomized comparison of 
busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of 
survival by hydroxyurea. The German CML Study Group. Blood. 82:398-407 
(1993). 
 
60. F. Guilhot, L. Roy, J. Guilhot, and F. Millot. Interferon therapy in chronic 
myelogenous leukemia. Hematol Oncol Clin North Am. 18:585-603 (2004). 
 
61. A. Ferrajoli, A.M. Liberati, P. Caricchi, E. Donti, E. Morra, M. Lazzarino, A.R. 
Betti, P. Bernasconi, and G. Saglio. Interferon-alpha plus low-dose cytosine 
arabinoside in advanced phase chronic myelogenous leukaemia patients. Eur J 
Haematol. 55:184-188 (1995). 
 
62. K.H. Antman. Introduction: the history of arsenic trioxide in cancer therapy. 
Oncologist. 6 Suppl 2:1-2 (2001). 
 
63. M.A. Essers and A. Trumpp. Targeting leukemic stem cells by breaking their 
dormancy. Mol Oncol. 4:443-450 (2010). 
 
64. E.M. Beauchamp, L. Ringer, G. Bulut, K.P. Sajwan, M.D. Hall, Y.C. Lee, D. 
Peaceman, M. Ozdemirli, O. Rodriguez, T.J. Macdonald, C. Albanese, J.A. 
Toretsky, and A. Uren. Arsenic trioxide inhibits human cancer cell growth and 
tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest. 
121:148-160 (2011). 
 
65. D. Douer and M.S. Tallman. Arsenic trioxide: new clinical experience with an old 
medication in hematologic malignancies. J Clin Oncol. 23:2396-2410 (2005). 
 
66. A. Burchert, M.C. Muller, P. Kostrewa, P. Erben, T. Bostel, S. Liebler, R. 
Hehlmann, A. Neubauer, and A. Hochhaus. Sustained molecular response with 
interferon alfa maintenance after induction therapy with imatinib plus interferon 
alfa in patients with chronic myeloid leukemia. Journal of Clinical Oncology : 
35 
 
Official Journal of the American Society of Clinical Oncology. 28:1429-1435 
(2010). 
 
67. V. Pitini, C. Arrigo, and G. Altavilla. How cells respond to interferons. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology. 
28:e439; author reply e440 (2010). 
 
68. S. Roychowdhury and M. Talpaz. Managing resistance in chronic myeloid 
leukemia. Blood Rev. 25:279-290 (2011). 
 
69. J. Sessions. Chronic myeloid leukemia in 2007. J Manag Care Pharm. 13:4-7 
(2007). 
 
70. J. Hasford, M. Pfirrmann, P. Shepherd, J. Guilhot, R. Hehlmann, F.X. Mahon, 
H.C. Kluin-Nelemans, K. Ohnishi, J.L. Steegmann, and J. Thaler. The impact of 
the combination of baseline risk group and cytogenetic response on the survival of 
patients with chronic myeloid leukemia treated with interferon alpha. 
Haematologica. 90:335-340 (2005). 
 
71. A. Lakshmikuttyamma, E. Pastural, N. Takahashi, K. Sawada, D.P. Sheridan, J.F. 
DeCoteau, and C.R. Geyer. Bcr-Abl induces autocrine IGF-1 signaling. 
Oncogene. 27:3831-3844 (2008). 
 
72. T. Ernst and A. Hochhaus. Chronic myeloid leukemia: clinical impact of BCR-
ABL1 mutations and other lesions associated with disease progression. Semin 
Oncol. 39:58-66 (2012). 
 
73. A.M. Kalle, S. Sachchidanand, and R. Pallu. Bcr-Abl-independent mechanism of 
resistance to imatinib in K562 cells: Induction of cyclooxygenase-2 (COX-2) by 
histone deacetylases (HDACs). Leuk Res. 34:1132-1138 (2010). 
 
74. W. Warsch, K. Kollmann, E. Eckelhart, S. Fajmann, S. Cerny-Reiterer, A. Holbl, 
K.V. Gleixner, M. Dworzak, M. Mayerhofer, G. Hoermann, H. Herrmann, C. 
Sillaber, G. Egger, P. Valent, R. Moriggl, and V. Sexl. High STAT5 levels 
mediate imatinib resistance and indicate disease progression in chronic myeloid 
leukemia. Blood. 117:3409-3420 (2011). 
 
75. M. Talpaz, N.P. Shah, H. Kantarjian, N. Donato, J. Nicoll, R. Paquette, J. Cortes, 
S. O'Brien, C. Nicaise, E. Bleickardt, M.A. Blackwood-Chirchir, V. Iyer, T.T. 
Chen, F. Huang, A.P. Decillis, and C.L. Sawyers. Dasatinib in imatinib-resistant 
Philadelphia chromosome-positive leukemias. N Engl J Med. 354:2531-2541 
(2006). 
 
76. H. Kantarjian, F. Giles, L. Wunderle, K. Bhalla, S. O'Brien, B. Wassmann, C. 
Tanaka, P. Manley, P. Rae, W. Mietlowski, K. Bochinski, A. Hochhaus, J.D. 
Griffin, D. Hoelzer, M. Albitar, M. Dugan, J. Cortes, L. Alland, and O.G. 
36 
 
Ottmann. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-
positive ALL. N Engl J Med. 354:2542-2551 (2006). 
 
77. J.M. Gozgit, M.J. Wong, S. Wardwell, J.W. Tyner, M.M. Loriaux, Q.K. 
Mohemmad, N.I. Narasimhan, W.C. Shakespeare, F. Wang, B.J. Druker, T. 
Clackson, and V.M. Rivera. Potent activity of ponatinib (AP24534) in models of 
FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol 
Cancer Ther. 10:1028-1035 (2011). 
 
78. D.W. Woessner, C.S. Lim, and M.W. Deininger. Development of an effective 
therapy for chronic myelogenous leukemia. Cancer J. 17:477-486 (2011). 
 
79. R. Tanaka, M.S. Squires, S. Kimura, A. Yokota, R. Nagao, T. Yamauchi, M. 
Takeuchi, H. Yao, M. Reule, T. Smyth, J.F. Lyons, N.T. Thompson, E. Ashihara, 
O.G. Ottmann, and T. Maekawa. Activity of the multitargeted kinase inhibitor, 
AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood. 
116:2089-2095 (2010). 
 
80. H. Sun, V. Kapuria, L.F. Peterson, D. Fang, W.G. Bornmann, G. Bartholomeusz, 
M. Talpaz, and N.J. Donato. Bcr-Abl ubiquitination and Usp9x inhibition block 
kinase signaling and promote CML cell apoptosis. Blood. 117:3151-3162 (2011). 
 
81. J. Zhang, F.J. Adrian, W. Jahnke, S.W. Cowan-Jacob, A.G. Li, R.E. Iacob, T. 
Sim, J. Powers, C. Dierks, F. Sun, G.R. Guo, Q. Ding, B. Okram, Y. Choi, A. 
Wojciechowski, X. Deng, G. Liu, G. Fendrich, A. Strauss, N. Vajpai, S. Grzesiek, 
T. Tuntland, Y. Liu, B. Bursulaya, M. Azam, P.W. Manley, J.R. Engen, G.Q. 
Daley, M. Warmuth, and N.S. Gray. Targeting Bcr-Abl by combining allosteric 
with ATP-binding-site inhibitors. Nature. 463:501-506 (2010). 
 
82. A.S. Dixon, G.D. Miller, B.J. Bruno, J.E. Constance, D.W. Woessner, T.P. Fidler, 
J.C. Robertson, T.E. Cheatham, 3rd, and C.S. Lim. Improved coiled-coil design 
enhances interaction with Bcr-Abl and induces apoptosis. Mol Pharm. 9:187-195 
(2011). 
 
83. E.A. Dubikovskaya, S.H. Thorne, T.H. Pillow, C.H. Contag, and P.A. Wender. 
Overcoming multidrug resistance of small-molecule therapeutics through 
conjugation with releasable octaarginine transporters. Proceedings of the National 
Academy of Sciences of the United States of America. 105:12128-12133 (2008). 
 
84. S.M. Tinsley. Safety profiles of second-line tyrosine kinase inhibitors in patients 
with chronic myeloid leukaemia. J Clin Nurs. 19:1207-1218 (2010). 
 
85. M.J. Mauro and M.W. Deininger. Management of drug toxicities in chronic 




86. P. Neelakantan, D. Marin, M. Laffan, J. Goldman, J. Apperley, and D. 
Milojkovic. Platelet dysfunction associated with ponatinib, a new pan BCR-ABL 
inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine 
kinase inhibitor therapy. Haematologica. Epub ahead of print (2012). 
 
87. M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. 
Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, A. Gratwohl, F. 
Guilhot, M. Horowitz, T. Hughes, H. Kantarjian, R. Larson, D. Niederwieser, R. 
Silver, and R. Hehlmann. Evolving concepts in the management of chronic 
myeloid leukemia: recommendations from an expert panel on behalf of the 
European LeukemiaNet. Blood. 108:1809-1820 (2006). 
 
88. L. Li, L. Wang, Z. Wang, Y. Ho, T. McDonald, T.L. Holyoake, W. Chen, and R. 
Bhatia. Activation of p53 by SIRT1 inhibition enhances elimination of CML 
leukemia stem cells in combination with imatinib. Cancer Cell. 21:266-281 
(2012). 
 
89. A. Perl and M. Carroll. BCR-ABL kinase is dead; long live the CML stem cell. J 
Clin Invest. 121:22-25 (2011). 
 
90. M. Greaves. Cancer stem cells: back to Darwin? Semin Cancer Biol. 20:65-70 
(2010). 
 
91. T. Lenaerts, J.M. Pacheco, A. Traulsen, and D. Dingli. Tyrosine kinase inhibitor 
therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. 
Haematologica. 95:900-907 (2009). 
 
92. S.A. Stuart, Y. Minami, and J.Y. Wang. The CML stem cell: evolution of the 
progenitor. Cell Cycle. 8:1338-1343 (2009). 
 
93. Y. Tabe, L. Jin, K. Iwabuchi, R.Y. Wang, N. Ichikawa, T. Miida, J. Cortes, M. 
Andreeff, and M. Konopleva. Role of stromal microenvironment in 
nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 
interactions in lipid rafts. Leukemia. 26:883-892 (2011). 
 
94. M. Copland, A. Hamilton, L.J. Elrick, J.W. Baird, E.K. Allan, N. Jordanides, M. 
Barow, J.C. Mountford, and T.L. Holyoake. Dasatinib (BMS-354825) targets an 
earlier progenitor population than imatinib in primary CML but does not 
eliminate the quiescent fraction. Blood. 107:4532-4539 (2006). 
 
95. Y. Hu, Y. Chen, L. Douglas, and S. Li. beta-Catenin is essential for survival of 
leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-
induced chronic myeloid leukemia. Leukemia. 23:109-116 (2009). 
 
96. C.H. Hui, K.Y. Goh, D. White, S. Branford, A. Grigg, J.F. Seymour, Y.L. Kwan, 
S. Walsh, R. Hoyt, A. Trickett, B. Rudzki, D.D. Ma, L.B. To, and T.P. Hughes. 
38 
 
Successful peripheral blood stem cell mobilisation with filgrastim in patients with 
chronic myeloid leukaemia achieving complete cytogenetic response with 
imatinib, without increasing disease burden as measured by quantitative real-time 
PCR. Leukemia. 17:821-828 (2003). 
 
97. G. Martinelli, N. Testoni, M. Amabile, F. Bonifazi, A. De Vivo, P. Farabegoli, C. 
Terragna, V. Montefusco, E. Ottaviani, G. Saglio, D. Russo, M. Baccarani, G. 
Rosti, and S. Tura. Quantification of BCR-ABL transcripts in CML patients in 
cytogenetic remission after interferon-alpha-based therapy. Bone Marrow 
Transplant. 25:729-736 (2000). 
 
98. J.C. Hernandez-Boluda, E. Carreras, F. Cervantes, P. Marin, E. Arellano-Rodrigo, 
M. Rovira, F. Sole, E. Lloveras, B. Espinet, A. Ocejo, and E. Montserrat. 
Collection of Philadelphia-negative stem cells using recombinant human 
granulocyte colony-stimulating factor in chronic myeloid leukemia patients 
treated with alpha-interferon. Haematologica. 87:17-22 (2002). 
 
99. H.G. Jorgensen, M. Copland, E.K. Allan, X. Jiang, A. Eaves, C. Eaves, and T.L. 
Holyoake. Intermittent exposure of primitive quiescent chronic myeloid leukemia 
cells to granulocyte-colony stimulating factor in vitro promotes their elimination 
by imatinib mesylate. Clin Cancer Res. 12:626-633 (2006). 
 
100. B. Fang, L. Mai, N. Li, Y. Song, and R. Chunhua Zhao. Imatinib plus 
Granulocyte Colony-Stimulating Factor in Chronic Myeloid Leukemia Patients 
Who Have Achieved Partial or Complete Cytogenetic Response while on 
Imatinib. Case Rep Oncol. 4:192-197 (2011). 
 
101. A.R. Walker, R.S. Komrokji, J. Ifthikharuddin, P. Messina, D. Mulford, M. 
Becker, J. Friedberg, J. Oliva, G. Phillips, J.L. Liesveld, and C. Abboud. Phase I 
study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-
CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate 
(Gleevec) in relapsed/refractory AML. Leuk Res. 32:1830-1836 (2008). 
 
102. M.W. Drummond, N. Heaney, J. Kaeda, F.E. Nicolini, R.E. Clark, G. Wilson, P. 
Shepherd, J. Tighe, L. McLintock, T. Hughes, and T.L. Holyoake. A pilot study 
of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients 
who have achieved a complete cytogenetic response. Leukemia. 23:1199-1201 
(2009). 
 
103. A.S. Corbin, A. Agarwal, M. Loriaux, J. Cortes, M.W. Deininger, and B.J. 
Druker. Human chronic myeloid leukemia stem cells are insensitive to imatinib 
despite inhibition of BCR-ABL activity. J Clin Invest. 121:396-409 (2011). 
 
104. M. Bocchia, S. Gentili, E. Abruzzese, A. Fanelli, F. Iuliano, A. Tabilio, M. 
Amabile, F. Forconi, A. Gozzetti, D. Raspadori, S. Amadori, and F. Lauria. Effect 
of a p210 multipeptide vaccine associated with imatinib or interferon in patients 
39 
 
with chronic myeloid leukaemia and persistent residual disease: a multicentre 
observational trial. Lancet. 365:657-662 (2005). 
 
105. M. Smahel. Antigens in chronic myeloid leukemia: implications for vaccine 
development. Cancer Immunol Immunother. 60:1655-1668 (2011). 
 
106. E. Feinstein, G. Cimino, R.P. Gale, G. Alimena, R. Berthier, K. Kishi, J. 
Goldman, A. Zaccaria, A. Berrebi, and E. Canaani. p53 in chronic myelogenous 
leukemia in acute phase. Proc Natl Acad Sci U S A. 88:6293-6297 (1991). 
 
107. H.G. Wendel, E. de Stanchina, E. Cepero, S. Ray, M. Emig, J.S. Fridman, D.R. 
Veach, W.G. Bornmann, B. Clarkson, W.R. McCombie, S.C. Kogan, A. 
Hochhaus, and S.W. Lowe. Loss of p53 impedes the antileukemic response to 
BCR-ABL inhibition. Proc Natl Acad Sci U S A. 103:7444-7449 (2006). 
 
108. F.X. Mahon, D. Rea, J. Guilhot, F. Guilhot, F. Huguet, F. Nicolini, L. Legros, A. 
Charbonnier, A. Guerci, B. Varet, G. Etienne, J. Reiffers, and P. Rousselot. 
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have 
maintained complete molecular remission for at least 2 years: the prospective, 
multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11:1029-1035 (2010). 
 
109. M. Tang, J. Foo, M. Gonen, J. Guilhot, F.X. Mahon, and F. Michor. Selection 
pressure exerted by imatinib therapy leads to disparate outcomes of imatinib 
discontinuation trials. Haematologica Epub ahead of print (2012). 
 
110. M. Deininger. Hematology: curing CML with imatinib--a dream come true? Nat 
Rev Clin Oncol. 8:127-128 (2011). 
 
111. O.O. Olabisi, G.M. Mahon, E.V. Kostenko, Z. Liu, H.L. Ozer, and I.P. 
Whitehead. Bcr interacts with components of the endosomal sorting complex 
required for transport-I and is required for epidermal growth factor receptor 
turnover. Cancer Research. 66:6250-6257 (2006). 
 
112. Y.J. Cho, J.M. Cunnick, S.J. Yi, V. Kaartinen, J. Groffen, and N. Heisterkamp. 
Abr and Bcr, two homologous Rac GTPase-activating proteins, control multiple 
cellular functions of murine macrophages. Mol Cell Biol. 27:899-911 (2007). 
 
113. X. Zheng, S. Guller, T. Beissert, E. Puccetti, and M. Ruthardt. BCR and its 
mutants, the reciprocal t(9;22)-associated ABL/BCR fusion proteins, 
differentially regulate the cytoskeleton and cell motility. BMC Cancer. 6:262 
(2006). 
 
114. E. Laurent, M. Talpaz, H. Kantarjian, and R. Kurzrock. The BCR gene and 





115. R.B. Arlinghaus. Bcr: a negative regulator of the Bcr-Abl oncoprotein in 
leukemia. Oncogene. 21:8560-8567 (2002). 
 
116. B. Perazzona, H. Lin, T. Sun, Y. Wang, and R. Arlinghaus. Kinase domain 
mutants of Bcr enhance Bcr-Abl oncogenic effects. Oncogene. 27:2208-2214 
(2008). 
 
117. J.R. McWhirter, D.L. Galasso, and J.Y. Wang. A coiled-coil oligomerization 
domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. 
Molecular and Cellular Biology. 13:7587-7595 (1993). 
 
118. D. Vigil, J. Cherfils, K.L. Rossman, and C.J. Der. Ras superfamily GEFs and 
GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer. 
10:842-857 (2010). 
 
119. S. Sahay, N.L. Pannucci, G.M. Mahon, P.L. Rodriguez, N.J. Megjugorac, E.V. 
Kostenko, H.L. Ozer, and I.P. Whitehead. The RhoGEF domain of p210 Bcr-Abl 
activates RhoA and is required for transformation. Oncogene. 27:2064-2071 
(2008). 
 
120. T. Daubon, J. Chasseriau, A. El Ali, J. Rivet, A. Kitzis, B. Constantin, and N. 
Bourmeyster. Differential motility of p190bcr-abl- and p210bcr-abl-expressing 
cells: respective roles of Vav and Bcr-Abl GEFs. Oncogene. 27:2673-2685 
(2008). 
 
121. J. Burthem, K. Rees-Unwin, R. Mottram, J. Adams, G.S. Lucas, E. Spooncer, and 
A.D. Whetton. The rho-kinase inhibitors Y-27632 and fasudil act synergistically 
with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells. 
Leukemia : official journal of the Leukemia Society of America, Leukemia 
Research Fund, UK. 21:1708-1714 (2007). 
 
122. Y. He, J.A. Wertheim, L. Xu, J.P. Miller, F.G. Karnell, J.K. Choi, R. Ren, and 
W.S. Pear. The coiled-coil domain and Tyr177 of bcr are required to induce a 
murine chronic myelogenous leukemia-like disease by bcr/abl. Blood. 99:2957-
2968 (2002). 
 
123. A.M. Pendergast. Stress and death: breaking up the c-Abl/14-3-3 complex in 
apoptosis. Nat Cell Biol. 7:213-214 (2005). 
 
124. P.J. Welch and J.Y. Wang. Abrogation of retinoblastoma protein function by c-
Abl through tyrosine kinase-dependent and -independent mechanisms. Molecular 
and Cellular Biology. 15:5542-5551 (1995). 
 





126. S. Gonfloni, L. Di Tella, S. Caldarola, S.M. Cannata, F.G. Klinger, C. Di 
Bartolomeo, M. Mattei, E. Candi, M. De Felici, G. Melino, and G. Cesareni. 
Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from 
chemotherapy-induced death. Nat Med. 15:1179-1185 (2009). 
 
127. R.V. Sionov, E. Moallem, M. Berger, A. Kazaz, O. Gerlitz, Y. Ben-Neriah, M. 
Oren, and Y. Haupt. c-Abl neutralizes the inhibitory effect of Mdm2 on p53. J 
Biol Chem. 274:8371-8374 (1999). 
 
128. G. Palacios, H.C. Crawford, A. Vaseva, and U.M. Moll. Mitochondrially targeted 
wild-type p53 induces apoptosis in a solid human tumor xenograft model. Cell 
Cycle. 7:2584-2590 (2008). 
 
129. A.E. Sayan, B.S. Sayan, V. Gogvadze, D. Dinsdale, U. Nyman, T.M. Hansen, B. 
Zhivotovsky, G.M. Cohen, R.A. Knight, and G. Melino. P73 and caspase-cleaved 
p73 fragments localize to mitochondria and augment TRAIL-induced apoptosis. 
Oncogene. 27:4363-4372 (2008). 
 
130. M. Mihara, S. Erster, A. Zaika, O. Petrenko, T. Chittenden, P. Pancoska, and 
U.M. Moll. p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 
11:577-590 (2003). 
 
131. S.Y. Choi, M.J. Kim, C.M. Kang, S. Bae, C.K. Cho, J.W. Soh, J.H. Kim, S. Kang, 
H.Y. Chung, Y.S. Lee, and S.J. Lee. Activation of Bak and Bax through c-abl-
protein kinase Cdelta-p38 MAPK signaling in response to ionizing radiation in 
human non-small cell lung cancer cells. J Biol Chem. 281:7049-7059 (2006). 
 
132. R.V. Sionov, S. Coen, Z. Goldberg, M. Berger, B. Bercovich, Y. Ben-Neriah, A. 
Ciechanover, and Y. Haupt. c-Abl regulates p53 levels under normal and stress 
conditions by preventing its nuclear export and ubiquitination. Mol Cell Biol. 
21:5869-5878 (2001). 
 
133. G. Wei, A.G. Li, and X. Liu. Insights into selective activation of p53 DNA 
binding by c-Abl. J Biol Chem. 280:12271-12278 (2005). 
 
134. L. Xiao, D. Chen, P. Hu, J. Wu, W. Liu, Y. Zhao, M. Cao, Y. Fang, W. Bi, Z. 
Zheng, J. Ren, G. Ji, Y. Wang, and Z. Yuan. The c-Abl-MST1 signaling pathway 
mediates oxidative stress-induced neuronal cell death. J Neurosci. 31:9611-9619 
(2011). 
 
135. T. Nakamaki, J. Okabe-Kado, Y. Yamamoto-Yamaguchi, K. Hino, S. Tomoyasu, 
Y. Honma, and T. Kasukabe. Role of MmTRA1b/phospholipid scramblase1 gene 
expression in the induction of differentiation of human myeloid leukemia cells 




136. S.C. Frasch, P.M. Henson, J.M. Kailey, D.A. Richter, M.S. Janes, V.A. Fadok, 
and D.L. Bratton. Regulation of phospholipid scramblase activity during 
apoptosis and cell activation by protein kinase Cdelta. J Biol Chem. 275:23065-
23073 (2000). 
 
137. K. Bailey, H.W. Cook, and C.R. McMaster. The phospholipid scramblase 
PLSCR1 increases UV induced apoptosis primarily through the augmentation of 
the intrinsic apoptotic pathway and independent of direct phosphorylation by 
protein kinase C delta. Biochim Biophys Acta. 1733:199-209 (2005). 
 
138. M. Kurokawa and S. Kornbluth. Caspases and kinases in a death grip. Cell. 
138:838-854 (2009). 
 
139. D. Raina, P. Pandey, R. Ahmad, A. Bharti, J. Ren, S. Kharbanda, R. 
Weichselbaum, and D. Kufe. c-Abl tyrosine kinase regulates caspase-9 
autocleavage in the apoptotic response to DNA damage. J Biol Chem. 280:11147-
11151 (2005). 
 
140. B.C. Oxhorn, A.R. Sanguinetti, C.C. Mastick, and I.L. Buxton. c-Abl is required 
for staurosporine-induced caspase activity. Proc West Pharmacol Soc. 48:110-117 
(2005). 
 
141. B.S. Westlund, B. Cai, J. Zhou, and J.R. Sparrow. Involvement of c-Abl, p53 and 
the MAP kinase JNK in the cell death program initiated in A2E-laden ARPE-19 
cells by exposure to blue light. Apoptosis. 14:31-41 (2009). 
 
142. F. Cong and S.P. Goff. c-Abl-induced apoptosis, but not cell cycle arrest, requires 
mitogen-activated protein kinase kinase 6 activation. Proceedings of the National 
Academy of Sciences of the United States of America. 96:13819-13824 (1999). 
 
143. R. Kamath, Z. Jiang, G. Sun, J.C. Yalowich, and R. Baskaran. c-Abl kinase 
regulates curcumin-induced cell death through activation of c-Jun N-terminal 
kinase. Mol Pharmacol. 71:61-72 (2007). 
 
144. Y. Ito, N.C. Mishra, K. Yoshida, S. Kharbanda, S. Saxena, and D. Kufe. 
Mitochondrial targeting of JNK/SAPK in the phorbol ester response of myeloid 
leukemia cells. Cell Death Differ. 8:794-800 (2001). 
 
145. M. Lasfer, L. Davenne, N. Vadrot, C. Alexia, Z. Sadji-Ouatas, A.F. Bringuier, G. 
Feldmann, D. Pessayre, and F. Reyl-Desmars. Protein kinase PKC delta and c-Abl 
are required for mitochondrial apoptosis induction by genotoxic stress in the 
absence of p53, p73 and Fas receptor. FEBS Lett. 580:2547-2552 (2006). 
 
146. S. Kharbanda, S. Saxena, K. Yoshida, P. Pandey, M. Kaneki, Q. Wang, K. Cheng, 
Y.N. Chen, A. Campbell, T. Sudha, Z.M. Yuan, J. Narula, R. Weichselbaum, C. 
43 
 
Nalin, and D. Kufe. Translocation of SAPK/JNK to mitochondria and interaction 
with Bcl-x(L) in response to DNA damage. J Biol Chem. 275:322-327 (2000). 
 
147. A.S. Dixon, J.E. Constance, T. Tanaka, T.H. Rabbitts, and C.S. Lim. Changing 
the subcellular location of the oncoprotein Bcr-Abl using rationally designed 
capture motifs. Pharm Res. 29:1098-1109 (2011). 
 
148. M. Preyer, P. Vigneri, and J.Y. Wang. Interplay between kinase domain 
autophosphorylation and F-actin binding domain in regulating imatinib sensitivity 
and nuclear import of BCR-ABL. PLoS One. 6:e17020 (2011). 
 
149. M. Preyer, C.W. Shu, and J.Y. Wang. Delayed activation of Bax by DNA damage 
in embryonic stem cells with knock-in mutations of the Abl nuclear localization 
signals. Cell Death Differ. 14:1139-1148 (2007). 
 
150. E. Tran. Nuclear Bcr-Abl Induces Apoptosis Independently of its Tyrosine Kinase 
Activity in K562 Leukemia Cells. Senior Honors Thesis in Chemistry. University 
of Utah: (2010). 
 
151. M.O. Nowicki, R. Falinski, M. Koptyra, A. Slupianek, T. Stoklosa, E. Gloc, M. 
Nieborowska-Skorska, J. Blasiak, and T. Skorski. BCR/ABL oncogenic kinase 
promotes unfaithful repair of the reactive oxygen species-dependent DNA double-
strand breaks. Blood. 104:3746-3753 (2004). 
 
152. R.A. Van Etten. c-Abl regulation: a tail of two lipids. Curr Biol. 13:R608-610 
(2003). 
 
153. O. Schmidt, N. Pfanner, and C. Meisinger. Mitochondrial protein import: from 
proteomics to functional mechanisms. Nature Reviews Molecular Cell Biology. 
11:655-667 (2010). 
 
154. R.I. Morimoto, A.J. Driessen, R.S. Hegde, and T. Langer. The life of proteins: the 
good, the mostly good and the ugly. Nat Struct Mol Biol. 18:1-4 (2011). 
 
155. T. Becker, L. Bottinger, and N. Pfanner. Mitochondrial protein import: from 
transport pathways to an integrated network. Trends Biochem Sci. 37:85-91 
(2012). 
 
156. S. Rao, O. Schmidt, A.B. Harbauer, B. Schonfisch, B. Guiard, N. Pfanner, and C. 
Meisinger. Biogenesis of the preprotein translocase of the outer mitochondrial 
membrane: protein kinase A phosphorylates the precursor of Tom40 and impairs 
its import. Mol Biol Cell. 23:1618-1627 (2012). 
 
157. N. Regev-Rudzki, E. Battat, I. Goldberg, and O. Pines. Dual localization of 





158. N. Pfanner and A. Geissler. Versatility of the mitochondrial protein import 
machinery. Nature Reviews Molecular Cell Biology. 2:339-349 (2001). 
 
159. A.L. Horwich, W.A. Fenton, K.R. Williams, F. Kalousek, J.P. Kraus, R.F. 
Doolittle, W. Konigsberg, and L.E. Rosenberg. Structure and expression of a 
complementary DNA for the nuclear coded precursor of human mitochondrial 
ornithine transcarbamylase. Science. 224:1068-1074 (1984). 
 
160. J.M. Herrmann. Putting a break on protein translocation: metabolic regulation of 
mitochondrial protein import. Mol Microbiol. 72:275-278 (2009). 
 
161. P. Dolezal, V. Likic, J. Tachezy, and T. Lithgow. Evolution of the molecular 
machines for protein import into mitochondria. Science. 313:314-318 (2006). 
 
162. K. Okamoto, A. Brinker, S.A. Paschen, I. Moarefi, M. Hayer-Hartl, W. Neupert, 
and M. Brunner. The protein import motor of mitochondria: a targeted molecular 
ratchet driving unfolding and translocation. EMBO J. 21:3659-3671 (2002). 
 
163. M.A. Robin, S.K. Prabu, H. Raza, H.K. Anandatheerthavarada, and N.G. 
Avadhani. Phosphorylation enhances mitochondrial targeting of GSTA4-4 
through increased affinity for binding to cytoplasmic Hsp70. J Biol Chem. 
278:18960-18970 (2003). 
 
164. W. Neupert and J.M. Herrmann. Translocation of proteins into mitochondria. 
Annu Rev Biochem. 76:723-749 (2007). 
 
165. G. Isaya, W.A. Fenton, J.P. Hendrick, K. Furtak, F. Kalousek, and L.E. 
Rosenberg. Mitochondrial import and processing of mutant human ornithine 
transcarbamylase precursors in cultured cells. Molecular and Cellular Biology. 
8:5150-5158 (1988). 
 
166. T. Ozawa, Y. Natori, Y. Sako, H. Kuroiwa, T. Kuroiwa, and Y. Umezawa. A 
minimal peptide sequence that targets fluorescent and functional proteins into the 
mitochondrial intermembrane space. ACS Chem Biol. 2:176-186 (2007). 
 
167. R. Rizzuto, A.W. Simpson, M. Brini, and T. Pozzan. Rapid changes of 
mitochondrial Ca2+ revealed by specifically targeted recombinant aequorin. 
Nature. 358:325-327 (1992). 
 
168. T. Kaufmann, S. Schlipf, J. Sanz, K. Neubert, R. Stein, and C. Borner. 
Characterization of the signal that directs Bcl-x(L), but not Bcl-2, to the 
mitochondrial outer membrane. The Journal of Cell Biology. 160:53-64 (2003). 
 
169. S. Karniely and O. Pines. Single translation--dual destination: mechanisms of dual 




170. B. Li. c-Abl in oxidative stress, aging and cancer. Cell Cycle. 4:246-248 (2005). 
 
171. B.N. Lyu, S.B. Ismailov, B. Ismailov, and M.B. Lyu. Mitochondrial concept of 
leukemogenesis: key role of oxygen-peroxide effects. Theor Biol Med Model. 
5:23 (2008). 
 
172. P. Storz. Reactive oxygen species in tumor progression. Front Biosci. 10:1881-
1896 (2005). 
 
173. G. Grosveld, T. Verwoerd, T. van Agthoven, A. de Klein, K.L. Ramachandran, N. 
Heisterkamp, K. Stam, and J. Groffen. The chronic myelocytic cell line K562 
contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript. 
Molecular and Cellular Biology. 6:607-616 (1986). 
 
174. C.M. Croce, K. Huebner, M. Isobe, E. Fainstain, B. Lifshitz, E. Shtivelman, and 
E. Canaani. Mapping of four distinct BCR-related loci to chromosome region 
22q11: order of BCR loci relative to chronic myelogenous leukemia and acute 
lymphoblastic leukemia breakpoints. Proceedings of the National Academy of 
Sciences of the United States of America. 84:7174-7178 (1987). 
 
175. J.H. Kim, S.C. Chu, J.L. Gramlich, Y.B. Pride, E. Babendreier, D. Chauhan, R. 
Salgia, K. Podar, J.D. Griffin, and M. Sattler. Activation of the PI3K/mTOR 
pathway by BCR-ABL contributes to increased production of reactive oxygen 
species. Blood. 105:1717-1723 (2005). 
 
176. M. Koptyra, R. Falinski, M.O. Nowicki, T. Stoklosa, I. Majsterek, M. 
Nieborowska-Skorska, J. Blasiak, and T. Skorski. BCR/ABL kinase induces self-
mutagenesis via reactive oxygen species to encode imatinib resistance. Blood. 
108:319-327 (2006). 
 
177. S.J. Stein and A.S. Baldwin. NF-kappaB suppresses ROS levels in BCR-ABL(+) 
cells to prevent activation of JNK and cell death. Oncogene. 30:4557-4566 
(2011). 
 
178. S. Fulda, L. Galluzzi, and G. Kroemer. Targeting mitochondria for cancer 
therapy. Nat Rev Drug Discov. 9:447-464 (2010). 
 
179. S.P. Chang, S.C. Shen, W.R. Lee, L.L. Yang, and Y.C. Chen. Imatinib mesylate 
induction of ROS-dependent apoptosis in melanoma B16F0 cells. J Dermatol Sci. 
62:183-191 (2011). 
 
180. M. Okada, S. Adachi, T. Imai, K. Watanabe, S.Y. Toyokuni, M. Ueno, A.S. 
Zervos, G. Kroemer, and T. Nakahata. A novel mechanism for imatinib mesylate-
induced cell death of BCR-ABL-positive human leukemic cells: caspase-
46 
 
independent, necrosis-like programmed cell death mediated by serine protease 
activity. Blood. 103:2299-2307 (2004). 
 
181. G. Kroemer, L. Galluzzi, P. Vandenabeele, J. Abrams, E.S. Alnemri, E.H. 
Baehrecke, M.V. Blagosklonny, W.S. El-Deiry, P. Golstein, D.R. Green, M. 
Hengartner, R.A. Knight, S. Kumar, S.A. Lipton, W. Malorni, G. Nunez, M.E. 
Peter, J. Tschopp, J. Yuan, M. Piacentini, B. Zhivotovsky, and G. Melino. 
Classification of cell death: recommendations of the Nomenclature Committee on 
Cell Death 2009. Cell Death and Differentiation. 16:3-11 (2009). 
 
182. K.M. Aird, J.L. Allensworth, I. Batinic-Haberle, H.K. Lyerly, M.W. Dewhirst, 
and G.R. Devi. ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-
induced apoptosis in inflammatory breast cancer cells. Breast Cancer Res Treat. 
132:109-119 (2012). 
 
183. X. Qian, J. Li, J. Ding, Z. Wang, W. Zhang, and G. Hu. Erlotinib activates 
mitochondrial death pathways related to the production of reactive oxygen species 
in the human non-small cell lung cancer cell line A549. Clin Exp Pharmacol 
Physiol. 36:487-494 (2009). 
 
184. S.C. Gupta, D. Hevia, S. Patchva, B. Park, W. Koh, and B.B. Aggarwal. Upsides 
and downsides of reactive oxygen species for cancer: the roles of reactive oxygen 
species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal. 
16:1295-1322 (2012). 
 
185. J.E. Constance, S.D. Despres, A. Nishida, and C.S. Lim. Selective Targeting of c-
Abl via a Cryptic Mitochondrial Targeting Signal Activated by Cellular Redox 













TARGETING MALIGNANT MITOCHONDRIA WITH 
THERAPEUTIC PEPTIDES 
 
The current status of peptides that target the mitochondria in the context of cancer 
is the focus of this review. Chemotherapy and radiotherapy used to kill tumor cells are 
principally mediated by the process of apoptosis which is governed by the mitochondria. 
The failure of anti-cancer therapy often resides at the level of the mitochondria. 
Therefore, the mitochondrion is a key pharmacological target in cancer due to many of 
the differences that arise between malignant and healthy cells at the level of this 
ubiquitous organelle. Additionally, targeting the characteristics of malignant 
mitochondria often rely on disruption of protein-protein interactions that are not generally 
amenable to small molecules. We discuss anti-cancer peptides that intersect with 




 The mitochondrion holds importance among cellular organelles in consideration 
of selective anti-cancer therapy because it is the nexus for propagating malignant 
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transformation and controls cell death. The mitochondrion is a universal target in all 
cancer cells, and new information about functional and structural differences between 
healthy and malignant cells continues to emerge (1). Peptides that specifically target 
malignant mitochondria offer advantages of low toxicity, high specificity and generally 
increase the range of interactions that are difficult to target with small molecules (e.g., 
protein-protein, protein-lipid and, protein-DNA) (2). However, the benefits of peptides 
are offset by difficulties in delivery such as degradation by proteases and rapid clearance. 
As such, the delivery of peptide/protein therapeutics is almost exclusively by the 
parenteral route, but the status quo is actively being challenged by broad efforts (e.g., 
liposomes, microparticles, nanoparticles, ‘smart’ polymers, hydrogels, chemical 
modifications to the peptide/protein) to achieve more convenient routes of administration 
(i.e., oral, nasal, transdermal) and improved pharmacokinetics (3-5). Yet, peptides, in 
many cases, are far from passive in the delivery process and through the maze that is drug 
delivery (from route of administration to perhaps a target residing within a specific 
organelle) peptides are employed as the vehicle, homing motif, and trans/intra-cellular 
passport (6). 
There is an emerging view in cancer therapy that the way in which a cancer cell 
dies (i.e., immunogenic cell death) is important for a durable response (7). However, 
traditional chemotherapy and immune response are in conflict because chemotherapy 
(e.g., DNA-damaging agents) often induces the substantial destruction of immune 
effectors (8). However, targeting the mitochondria may be the key to initiate or 
manipulate the type of death a cell dies and commit a cancer cell to ‘immunogenic 
apoptosis’ (9). Pairing therapeutic peptides targeting malignant mitochondria with 
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existing small molecule chemotherapy could lower dose requirements and curb 
traditional treatment-associated toxicity (10). Thereby combined therapy could spare the 
immune system, reduce patient side effects, sensitize cancer cells to death, and establish a 
durable response (11).  
The mitochondrion is now dually famous as both the cellular ‘powerhouse’ and as 
central regulator of the cell death pathway that bears its name. The outer membrane of the 
mitochondrion (OMM) is generally permeable to metabolites and ions, while the inner 
membrane (IMM) maintains a tightly regulated ion flux. Respiration-driven efflux of 
protons across the IMM during oxidative phosphorylation sets up a large electrochemical 
gradient comprised of a difference in both the voltage (ΔΨm) and the concentration of 
ions across the membrane (ΔpIon). This electrochemical gradient is the driving force for 
the production of ATP. Importantly, the negative interior, called the mitochondrial matrix 
(where the citric acid cycle and fatty acid beta-oxidation transpire), allows the 
accumulation of molecules with cationic character. The intermembrane space (IMS) hosts 
an array of cytotoxic proteins that are released upon OMM permeabilization (12). 
 Newer cancer therapies are expected to kill malignant cells while producing 
minimal or no toxicity to normal cells. This expectation is borne out of the tremendous 
pace at which our understanding of tumor-specific molecular profiles has occurred in the 
last decade. The identification of tumor markers has lead to the development of new 
selective cancer therapies such as trastuzumab which targets the overexpression of 
HER2/neu in 30% of patients with breast cancer (13). However, the search is on for more 
global cancer markers with the hope of generating a more generic cancer therapy. 
Peptides could properly be referred to as ‘smart’ nanoparticles because they are capable 
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of encoding targeting, entry, and therapeutic modality into one customizable unit (14). To 
this end, one of the emerging strategies is the therapeutic targeting of proteins that affect 
multiple downstream pathways (i.e., so-called nodal proteins) in cancer signaling (15). In 
this respect, the mitochondrion has become the focus of much interest for cancer therapy 
as it is the central ‘node’ of cell death induction (Fig. 2.1) (11). 
 The mitochondria of tumor cells are structurally and functionally different from 
those of untransformed cells (1). The alterations in malignant mitochondria or the 
metabolic pathways governing mitochondrial function vary by cancer type and level of 
disease progression (16). Mitochondrial adaptations that take place in cancer range from 
subtle (e.g., isoform switching) to profound dysfunction (17). Yet, any deviation between 
healthy and malignant cells is an opportunity to be therapeutically leveraged. Many of the 
current and emerging therapeutic mitochondrial targets are protein-protein/lipid/DNA 
interactions which are less amenable to small molecule intervention. Peptide (and 
protein) therapeutics, as a class of drugs, are well suited to exploit the often subtle 
differences between healthy and diseased mitochondria. This review focuses on current 
and potential mitochondrial anti-cancer targets in connection with therapeutic peptides. 
 
Mitochondrial cell death pathway 
Cell death is generally categorized into either subtypes of step-wise regulated 
programmed cell death (PCD) or a passive disintegration termed necrosis (18). PCD that 




Figure 2.1. Targeting the mitochondria with peptides. Selective targeting of the 
mitochondria of malignant cells can be achieved by engineering motifs that drive 
mitochondrial accumulation of the toxic peptide based on differences that commonly 
exist between cancerous and healthy cells. Internalization of the peptides can be mediated 
based on the nature of the peptide (e.g., CPPs) and its interaction with the plasma 
membrane or via receptor complex endocytosis (e.g., tumor homing motif). The internal 
milieu of malignant cells (e.g., pro-oxidative environment or upregulated enzymes, such 
as kinases) can provide the opportunity to customize the mitochondrial targeting of a 
peptide. For instance, a cryptic MTS can be employed that requires phosphorylation 
(highlighted “P”) prior to mitochondrial trafficking. Depending on the sequence, 
mitochondriotoxic peptides can be ‘addressed’ to individual or multiple submitochondrial 
locations. CPP, cell-penetrating peptide; MTS, mitochondrial targetingsequence; OMM, 








pathway. However, the mitochondrion ultimately plays a key role in all active PCD cell 
death pathways (18). Most cytotoxic anti-cancer agents, in spite of having diverse 
mechanisms of action, cause death through the mitochondrial pathway (19). More 
precisely, death induction signaling from chemotherapy funnels down to the activation of 
mitochondrial outer membrane permeabilization (MOMP) which, in turn, is controlled by 
the balance between positive or negative regulators of OMM integrity (Figure 2.2) (19). 
In many cancers (e.g., leukemia, melanoma, and hepatocellular carcinoma), resistance to 
chemotherapy has been directly attributed to the overexpression of the anti-apoptotic Bcl-
2 (B-cell lymphoma-2) family members (20). 
 The Bcl-2 family of proteins are categorized as members with four Bcl-2 
homology domains (BH1-BH4) or with only one BH domain, the BH3-only proteins. All 
of the BH3-only proteins (e.g., PUMA, NOXA, Bad, Bim, and Bid) are classified as pro-
apoptotic while Bcl-2 proteins with four BH3 domains are anti-apoptotic (e.g., Bcl-2, 
Bcl-xL, Bcl-w, Mcl-1, and Bfl1) with the exceptions of Bak and Bax. MOMP proceeds by 
activation and oligomerization of Bax and/or Bak ‘effectors’ to form pores in the 
mitochondrial outer membrane allowing the release of pro-apoptotic factors such as 
cytochrome c, apoptosis-inducing factor (AIF), second mitochondria-derived activator of 
caspase (Smac), endonucleases and HtrA2. Upon release of the apoptotic factors from the 
IMS, cytosolic caspases are activated, and the cell is committed to destruction (21). 
Bak is constitutively found at the OMM while Bax is cytosolic, until activated, 
whereupon it translocates via an N-terminal MTS to the OMM. The anti-apoptotic 
members of the Bcl-2 family, such as Bcl-2 and Bcl-xL, have been found to localize at the 
OMM, the endoplasmic reticulum, and nuclear membranes (21). Bax or Bak monomers 
54 
 
Figure 2.2. Mitochondriotoxic peptides. Mitochondriotoxic peptides facilitate 
mitochondrial dysfunction by either direct or indirect induction of MOMP through Bcl-2 
family interactions, PTP opening, or membrane disruption. MOMP initiated by 
manipulation of Bcl-2 family members converges on Bax and Bak homo- or hetero-
oligomerization in the OMM to form pores that allows the cytosolic release of IMS 
proteins such as cytochrome c, Smac, and AIF. Bax activation also inhibits the 
mitoKv1.3 IMM channel leading to IMM hyperpolarization and increased ROS 
production. Upon PTP opening is there is an unregulated influx of cytosolic solute, loss 
of Δψm, and mitochondrial swelling. Mitochondrial swelling bursts the OMM and 
releases the pro-death IMS proteins. The PTP is minimally comprised of the voltage-
dependent anion channel (VDAC), adenine nucleotide translocase (ANT), and 
cyclophilin D (CYPD). PTP opening can be suppressed by interaction with anti-apoptotic 
Bcl-2 family members, hexokinase (HK), translocator protein (TSPO), and the heat shock 
proteins Hsp90 and TNF receptor-associated protein (TRAP-1). MOMP and release of 
IMS apoptogenic factors can also occur through the direct disruption of membrane 
integrity. Therapeutic peptides are represented in red boxes. Solid red lines show peptide 
target. Dashed lines indicate peptides that have multiple targets.  
 MOMP, mitochondrial outer membrane permeabilization; PTP, permeability 
transition pore complex; OMM, outer mitochondrial membrane; IMS, intermitochondrial 
membrane space; IMM, inner mitochondrial membrane; Cyt c, cytochrome c; Smac, 
second mitochondria-derived activator of caspases; AIF, apoptosis-inducing factor; Endo 
G, endonuclease G; HtrA2,  high temperature requirement protein A2; OXPHOS, 
55 
 
oxidative phosphorylation; EGFR, epidermal growth factor receptor; HER2, human 







or hetero-oligomers of both proteins form aqueous channels in the OMM. The activation 
of Bak and Bax may be initiated by many different stimuli including direct interaction 
with p53 (22), BH3-only proteins such as Bid or Bim, and post-translational 
modifications (23). Bax inhibition of a IMM potassium channel (mitoKv1.3) also seems 
to be crucial to cytochrome c, AIF, and Endo G release from the IMS, unlike Smac and 
HtrA2 which are released independently of mitoKv1.3 function. It has been suggested 
that the release of cytochrome c, AIF, and Endo G are all dependent on a mechanism 
based on increased ROS and that this coincides with the inhibition of the mitoKv1.3 
channel (24). ROS increase is a central event in the release of cytochrome c release from 
the IMS where it is bound to the IMM in association with the unique mitochondrial 
phospholipid cardiolipin (21).  However, it remains unclear whether the efflux of 
cytochrome c occurs solely by oligomeric Bax and other protein channels and/or by the 
activation of a matrix to cytosol spanning permeability transition pore (PTP) and cristae 
remodeling (25, 26). 
The mitochondrial PTP may generally function as a mitochondrial Ca2+ release 
channel to regulate physiological Ca2+ dynamics; however, it also plays an important role 
in apoptosis. The PTP is comprised of the Translocator Protein (TSPO; formerly named 
peripheral-type benzodiazepine receptor (PBR)) located at the outer/inner mitochondrial 
membrane contact sites, the voltage-dependent anion channel (VDAC), and the adenine 
nucleotide translocase (ANT). The anti-apoptotic Bcl-xL interacts with the ANT, and it 
has been proposed that this interaction can prevent cell death. In addition, Bcl-2 and Bax 
may modulate VDAC activity (24). 
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In some cases, nonselective toxins kill malignant cells more readily than healthy 
cells (27). This phenomenon is analogous to non-specific cytotoxic drugs that attack 
common targets such as DNA or microtubule formation, but which nonetheless kill 
rapidly proliferating tumor cells preferentially. A recent study correlates cytotoxic 
chemotherapy efficacy with a ‘primed’ status of malignant cell mitochondria (28). 
However, like classical chemotherapy, any agent that is nonselective runs the risk of 
toxic side effects. The same reasons that make mitochondria an excellent anti-cancer 
target (i.e., cell death and oncogenic transformation functions) also suggests 
indiscriminate mitochondrial toxins will be unacceptable as chemotherapeutics. The 
strategy of mitochondrial targeting with intent to cause dysfunction ought to include a 
‘cancerotropic’ modality. Depending upon the mitochondrial toxin and type of 
malignancy, the mitochondria of cancer cells may be self-selecting by way of being in a 
so-called ‘primed’ state such that the therapeutic index between healthy and cancerous 
cells for a nonspecific mitochondrial toxin may be very broad. This is unlikely to be true 
across the typical heterogeneity of cancer, however, and developing selective agents is a 
prudent course.  
Peptide therapeutics can be readily designed to minimize off-target effects in 
three ways: first, by including a targeting moiety selective to cancer cells coupled to 
nondiscriminating mitochondriolytic entities; secondly, by using an agent that has a 
mechanism of action based on structural and/or functional differences inherent between 
healthy and malignant mitochondria; or third, using a therapeutic entity toxic to 
mitochondrial but which remains spatially segregated from the mitochondria unless 
intracellular pathologic conditions common to cancer cells initiate mitochondrial 
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translocation. Ideally, a combination of these approaches could be used to minimize off-
target effects (Fig. 2.1). 
 
Malignant mitochondria (the tumor signature) 
Recognition of a difference between the mitochondrial function of healthy cells 
and those of malignant cells was made by Otto Warburg in the late 1920’s. Warburg 
discovered malignant cells produce ATP via glycolysis even under aerobic conditions 
(i.e., the so-called Warburg effect) (12). Warburg’s attempt to attack malignant 
mitochondria on a bioenergetic basis was unsuccessful because the glycolytic shift in 
malignant cells is not (as presumed by Warburg) due to a fundamental dysfunction of 
mitochondrial oxidative phosphorylation but instead related to changes in metabolic 
signaling pathways (1). However, recent discoveries (including the mitochondrion as a 
central regulator of cell death) concerning bioenergetic alterations and malignant 
transformation have brought Warburg’s general strategy back into favor (12). In addition 
to corrupted bioenergetic pathways, mitochondrial proteins responsible for controlling the 
processes of apoptosis/necrosis, respiration, and mitochondrial membrane integrity are 
being exploited for the selective destruction of malignant cells over healthy cells (11).  
Even if mitochondrial function is not fundamentally impaired in cancer cells, 
mitochondrial activity is altered by environmental changes (e.g., low oxygen) and genetic 
reprogramming (1). Rapidly expanding tumor cells, in addition to adapting for continued 
survival, also exploit adaptive mechanisms to meet the vast energetic requirements for 
proliferation. Metabolic reprogramming is a way to increase ATP production in an 
oxygen-independent manner while supplying the necessary constituents for anabolism. 
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The shift between glycolysis and oxidative phosphorylation is controlled by two 
enzymes, mitochondrial pyruvate dehydrogenase (PDH) and lactate dehydrogenase 
(LDH), that control the catabolic fate of pyruvate (1). Hypoxia inducible factor-1 (HIF-1) 
plays a key role in metabolic adaption either to hypoxia itself or through loss-of-function 
mutations in oxygen-sensing genes. In connection to pyruvate catabolism, HIF-1 
upregulates pyruvate dehydrogenase kinase (PDK1) which inactivates PDH and 
suppresses oxidative metabolism of pyruvate in the TCA cycle. This glycolytic shift may 
also serve to protect cancer cells from producing cytotoxic levels of ROS (12). The 
success of a small molecule inhibitor of PDK1 (dicholoroacetate) has validated targeting 
cancer energy metabolism. This drug specifically acts on the mitochondria of cancer cells 
without disturbing the physiology of nonmalignant cells (29). 
 Other mitochondrial changes can also attend the metabolic adaptations in 
malignancy that impact mitochondrial function and can reinforce metastatic potential. For 
instance, increased superoxide formation (ROS), increased mitochondrial membrane 
potential, isoform switching, and alterations in ion channel expression levels have been 
linked to perpetuating malignancy or chemotherapeutic resistance (30). 
 
Mitochondrial reactive oxygen species 
Circumstances dealing with ROS and malignancy often seem contradictory (31). 
Increased ROS levels caused by oncogenic processes and perpetuating tumorigenicity 
seem inconsistent with therapeutic ROS generation leading to cell death induction (32). 
Elevated intracellular ROS can lead to the activation of transcription factors (e.g., HIF-1 
and NF-κB) leading to a host of protein expression profiles that contribute to malignancy 
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such as proliferation, survival, and metastasis (31). This situation leads to a seeming 
‘ROS paradox’ where many antineoplastic agents exert their cytotoxic effects through the 
generation of ROS (33). The underlying mechanisms for the essential ROS-mediated 
killing by chemotherapeutics and radiation therapy is not well understood (31). However, 
increased ROS magnitude from therapeutic treatment adds to the already high oxidative 
burden of the cancer cell overwhelming the antioxidant capacity and thereby causing cell 
death (34). Moreover, the elevated ROS condition is likely to contribute to cytochrome c 
mobilization in malignant cells (35). Unfortunately, the heterogeneity of cancer cell 
survival mechanisms can also operate by strongly suppressing ROS production as occurs 
in resistant breast cancer tumor stem cells (32). This often occurs through the 
overexpression of mitochondrial ROS scavenging enzymes such as peroxiredoxin 3, 
thioredoxin reductase and/or manganese superoxide dismutase (MnSOD) (36). 
The targeted delivery of a therapeutic fusion protein to the mitochondria has been 
used to exploit the production of cytotoxic levels of ROS in cancer models (37). One 
such protein that can generate ROS is fragile histidine triad protein (FHIT).  Across a 
variety of cancer types apoptosis is induced by transfection or transduction of the fragile 
histidine triad protein (FHIT) gene. The (FHIT) is a tumor suppressor that exerts its pro-
apoptotic action (in a complex with ferrodoxin reductase) at the mitochondria by 
generating ROS and stimulating calcium uptake (38). Recently, a HIV-Tat derived 
protein transduction domain fusion with FHIT (TAT-FHIT) was used to induce apoptosis 





Table 2.1. Anti-cancer proteins/peptides targeting the mitochondria 
Peptide/protein Mitochondrial target Mode of action Refs 
HIV-1 Tat Mitochondrial membranes MOMP (39) 
TAT-HK Hexokinase isoform 2 
associated with OMM 
Disruption of HK association with 
OMM and disinhibition of PTP 
opening 
(40) 
TAT-FHIT Ferrodoxin reductase Increased ROS and calcium flux (37) 
HIV-VpR VDAC/ANT/Bax mediated 
IMM and OMM 
permeabilization; reduced 
expression of mitofusin 2 
MOMP via disinhibition of PTP 
complex and/or Bax activation; 
interruption of mitochondrial-




VDAC/ANT mediated IMM 




 (bifunctional: contains an 
AHNP is anti-HER2 moti  
and (KLAKLAK)2) 
Mitochondrial membranes MOMP (44) 
RGD-4C-GG-D- 
(KLAKLAK)2 
Mitochondrial membranes MOMP (45,46) 
ATAP OMM MOMP (47) 
Ant-BH3 Bcl-xL MOMP (48) 
LHRH-BH3 Bcl-xL and Bcl-2 MOMP (49) 
SAHBs 
(e.g., BIM-SAHB) 
Anti-apoptotic and effector 
(Bak/Bax) Bcl-2 family 
proteins at the OMM 
MOMP (50) 
072RB 
 (Bim derived peptide 
fused to Ant 
internalization sequence) 
(Bcl-xL ) but likely other anti-
apoptotic and effector 
(Bak/Bax) Bcl-2 family 
proteins at the OMM 
Bax activation and MOMP (51) 
IP3R decoy peptides Bcl-2 (on endoplasmic 
reticulum) 
Pro-apoptotic calcium release (52) 
shepherdin Mitochondrial Hsp90 and 
TRAP-1 
Disinhibition of PTP opening, 
mitochondrial depolarization 
(53) 
Antp-TRP Hsp90 Apoptosis (54) 
Ant-tBid (111-125) and 
Ant-tBid (59-73) 
MTCH2 interaction at OMM Apoptosis (55) 
GSAO and PENAO ANT PTP opening, mitochondrial 
depolarization 
(56) 
VDAC decoy peptides Multiple targets: hexokinase, 
Bcl-2, and Bcl-xL 
Mitochondrial sensitization to 
apoptotic stimuli 
(57) 
p53-XL (p53 targeted to 
the OMM) 
Interaction with Bcl-2 family 





Unknown Apoptosis (59) 





Table 2.1 Continued 
  
ANT, adenine nucleotide translocase; VDAC, voltage-dependent anion channel; 
Mfn2, mitofusin 2; DRP1, dynamin-related protein 1; Bcl-2, B-cell lymphoma protein 
2; GSAO, 4-(N-(S-glutathionylacetyl)amino)phenylarsenoxide; PENAO, (4-(N-(S-
penicillaminylacetyl)amino) phenylarsonous acid); ant or antp, Antennapedia helix III, 
also called Penetratin; Hsp90, heat-shock protein, 90 kDa; ROS, reactive oxygen 
species; MOMP, mitochondrial outer membrane permeabilization; OMM, outer 
mitochondrial membrane; IMM, inner mitochondrial membrane; p53-XL, tumor 
suppressor protein p53 fused to the canonical MTS of Bcl-xL; cMTS, cryptic 
mitochondrial translocation sequence; mitoKv1.3, mitochondrial voltage-gated 
potassium channel 1.3; Δψm, potential difference across inner mitochondrial 
membrane; HIV-1, human immunodeficiency virus 1; TAT or Tat, transactivator of 
transcription; VpR, viral protein R; PTP, permeability transition pore; EGFR, 
epidermal growth factor receptor; MUC1, mucin 1; HK, hexokinase; BHAP, 
bifunctional, HER-2-blocking and apoptosis-inducing peptide; TEAM-VP, Targeted 
to Endothelial Apoptogenic Mitochondrio-active VpR-derived Peptide; BH3, Bcl-2  
homology domain 3; LHRH, luteinizing hormone-releasing hormone; SAHB, 
stabilized alpha-helices of Bcl-2 family protein; IP3R, inositol 1,4,5-trisphosphate 





The mitochondrion, like the nucleus, but unlike any other organelle contains 
DNA. The mitochondrial DNA (mtDNA) is thought to be particularly vulnerable to ROS-
mediated damage due to its proximity to ROS production via the ETC and less robust 
DNA repair mechanisms, as compared to the nuclear system of DNA repair (61). The 
susceptibility of mtDNA oxidative damage may be a key contributor to tumor cell 
formation where the overproduction of mitochondrial ROS can lead to a vicious cycle 
that increases metastatic potential. To this point, tumor cell development is associated 
with impaired production of ETC proteins which, in turn, are less efficient and generate 
increased ROS (30, 33). 
 
Mitochondrial membrane potential 
 Tumor progression and expansion has been correlated to increased mitochondrial 
membrane potential (ΔΨm). Within tumor cell subpopulations, the higher the ΔΨm, the 
more likely the contribution to tumor progression and expansion (62). In human 
epidermoid adenocarcinoma and hepatoma cancer cells, a higher ΔΨm defines resistance 
to cisplatin (63).  As th e ΔΨm increases, intracellular cationic entities will increasingly 
permeate the mitochondria. Therefore, even slight gains in ΔΨm may confer a greater 
killing capacity for cationic agents (including peptides; e.g., shepherdin, see below) in 







 Malignant cells adapt in many ways including isoform switching at the 
mitochondria to compensate for bioenergetic demands (e.g., M2 isoform of pyruvate kinase 
(17)) and to survive harsh environmental conditions (64). For instance, as a potential way 
of reducing the ROS burden, cellular adaptation to low oxygen conditions is often 
accompanied by isoform switching of the mitochondrial respiratory chain via activity of the 
hypoxia transcription factor, HIF-1 (64). In some forms of cancer, HIF-1 induces a more 
efficient COX4-2 (cytochrome c oxidase subunit IV isoform 2) expression and the 
degradation of COX4-1 isoform thereby allowing respiration to proceed with less ROS 
produced as a byproduct (64).  
Interestingly, Lacoeur et al. showed that a synthetic human immunodeficiency virus 
trans-activator of transcription (HIV-Tat) protein (86 residues) inhibits cytochrome c 
oxidase (COX) activity in disrupted mitochondria. The HIV-Tat protein also caused loss of 
ΔΨm and cytochrome c release independent of PTP and Bcl-2 family status (39). Also, an 
acetylated HIV-Tat (residue 28) was shown to stimulate the mitochondrial translocation of 
the pro-apoptotic Bim (39). HIV-Tat may be a useful platform for future investigations into 
MOMP/PTP-independent targeting of malignant mitochondria. The toxic consequences of 
HIV-Tat are related to another mitochondriotoxic HIV proteins (HIV-1 viral protein R or 






Mitochondrial ion channels 
Potassium channels, components of the permeability transition pore, and 
mitochondrial calcium uniporter are mitochondrial ion channels that have been 
recognized as therapeutically important targets in cancer (66). Peptide toxins have long 
been used for pharmacologic targeting of ion channels. Some of these may have utility in 
targeting aberrantly expressed mitochondrial potassium channels such as the mitoKv1.3 
(66). 
The expression profiles of voltage-gated potassium (Kv) channels, which have a 
role in controlling membrane potential, are remodeled in the majority of cancers with a 
correlation between Kv overexpression and grade of tumor malignancy in certain tumor 
types (66). Mitochondrial potassium (MitoK+) channels are also found to play important 
roles in both cytoprotection and apoptosis (recently reviewed in (67)). Because of this, 
mitoK+ channels are considered promising therapeutic targets in cancer (68). The IMM 
localized Kv1.3 is the best characterized mitochondrial Kv, and the Kv1.3 channel 
(mitochondrial and plasma membrane) is characterized by a very selective and potent 
peptide toxin pharmacology (25).  
Interestingly, mitoKv1.3 is inhibited by an interaction within the IMS with the 
OMM spanning pro-apoptotic Bax, leading to hyperpolarization of the IMM, resulting in 
increased ROS production, loss of cytochrome c, propagation of mitochondrial 
dysfunction and apoptosis (25). Bax inhibition of mitoKv1.3 was dependent on a specific 
highly conserved Bax residue, Lys 128. In spite of Bax inhibition of mitoKv1.3 being 
required for efficient induction of apoptosis, the absence of the mitoKv1.3 can cause 
resistance to apoptosis (25). Szabo et al. recently reported that the action of Bax at the 
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OMM can be substituted by peptide toxins of the mitoKv1.3 channel (67). The steadily 
increasing recognition of the role of MitoK+ channels in cancer and mitochondrial 
function puts a new emphasis on the importance of these channels in the development of 
targeted anti-cancer therapy (e.g., MitoK+ channel, TASK-3, is indispensable for survival 
of melanoma cells) (69, 70). 
After decades of searching, the mitochondrial calcium channel (mitochondrial 
calcium uniporter or MCU) has been newly discovered (71). Increased expression of the 
MCU increases mitochondrial calcium accumulation, and sensitizes cells to apoptotic 
stimuli (71). Since calcium is one of the triggers (ROS is another) for PTP opening, this 
channel is highly relevant in pathological conditions, such as cancer (72). The MCU will 
undoubtedly be intensely focused on as a target for modulating cell death (72). 
 
Plasma membrane to mitochondria protein translocation 
 Tumor cells re-program intracellular mitochondrial trafficking as a mechanism to 
escape apoptosis (73). Several cell surface proteins translocate to the mitochondria and 
elicit distinct biological functions in malignant cells (73). For instance, EGFR (epidermal 
growth factor receptor), MUC1-C (C-terminal portion of the oncogenic transmembrane 
glycoprotein mucin 1) (74), and HER2 (human epidermal growth factor receptor 2) 
aberrantly localize to the mitochondria and antagonize apoptosis (Figure 2.2). The EGFR 
family (e.g., EGFR/ERBB1, HER2/ERBB2, and HER3/ERBB3) are often overexpressed 
and associated with progression, proliferation, and drug resistance in many forms of 
cancer (75). However, EGFR tyrosine kinase inhibitor (TKI; e.g., gefitinib, lapatinib, 
erlotinib) and monoclonal antibody anti-EGFR therapeutic agents have met with only 
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modest efficacy in clinical trials (73). Unfortunately, the process of mitochondrial 
translocation and antagonism of apoptosis by EGFR is actually enhanced by TKI 
treatment (76). At the mitochondria, EGFR interacts with and inhibits the pro-apoptotic 
PUMA (p53-upregulated modulator of apoptosis) (76). The consequences are reduced 
efficacy of EGFR inhibitors and increased apoptotic threshold of cancer cells (73). 
Interestingly, in clinical trials, pre-treatment (more so than concomitant treatment) of 
medulloblastoma and glioblastoma cells with obatoclax (GX15-070), a small molecule 
inhibitor of Bcl-xL and Mcl-1, led to a greater than additive enhancement of TKI 
lapatinib-induced cell death (77), indicating that the disruption of the protein-protein 
interaction between EGFR and PUMA could be an important therapeutic modality in 
glioblastoma multiforme and possibly other cancers (76). 
 Abnormal expression of MUC1 in multiple types of cancer can be targeted with a 
peptide inhibitor, GO-203, which is in phase 1 clinical trials. GO-203 blocks the 
pleiotropic MUC1-C oncogene causing a derepression of ROS production (60, 78). 
 
Mitochondrial membranes 
One of the key differences between malignant and healthy mitochondria may be 
the lipid composition of the OMM (26). Mitochondrial membrane composition and the 
spatial organization of its components may fundamentally affect the processes of 
apoptosis (21). For instance, in healthy cells the cholesterol content in OMM (and 
possibly the shape) of the mitochondria may prevent Bax activation (21). Cardiolipin, a 
phospholipid found exclusively in mitochondrial membranes (primarily the IMM), 
interacts with the α-helices of tBid (79). A protein/lipid complex containing 
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cardiolipin/tBid (also, the protein MTCH2/MIMP, see section ‘MTCH2’) at the OMM are 
thought to facilitate pore formation by Bax oligomers (21). However, the exact protein 
structure/function relationship is not well understood in the context of proteins becoming 
embedded in the dynamic mitochondrial membrane environment, making the precise 
mechanistic elucidation of MOMP a challenge (21). As mentioned previously, Bax and 
Bak OMM localization in ‘primed’ malignant mitochondria is not random but likely 
coincides with mitochondrial fission sites for optimal MOMP formation (21). 
 
Membrane disrupting mitochondriotoxic peptides 
The 96-amino acid HIV-VpR protein, comprised of 3 α-helical domains, can 
integrate into and permeabilize mitochondrial membranes reducing the Δψm, causing 
fragmentation and cristae swelling (41). In addition, HIV-VpR can influence apoptosis by 
interactions with ANT, VDAC and/or Bax (42). In contrast to other viral proteins that 
target the mitochondria, the HIV-VpR lacks a canonical MTS, and its association with 
mitochondria is also independent of the translocase of the outer membrane (TOM) 
complex (80). 
An amphipathic tail-anchoring peptide (ATAP) derived from Bcl-2 family member 
Bfl-1 was effective in inducing MOMP, possibly by homo-oligomerization and pore 
formation. A green fluorescent protein fused ATAP was shown to target the mitochondria 
(via an intrinsic MTS) (47). However, as with other pore-forming peptides, ensuring 




Various cationic peptides exhibit an immediate cytotoxic effect against cancer cells, 
in many cases by binding and disrupting the plasma membrane (81, 82). However, due to 
the difference in potential at the mitochondria versus the plasma membrane, cationic 
peptides selectively disrupt mitochondrial membranes at concentrations hundreds of times 
lower that what is required to interfere with plasma membrane integrity (83). As one of the 
pathological hallmarks of cancer is a stably increased ΔΨm, even modest gains in attraction 
of cationic mitochondriolytic peptides, although nonselective, may confer a greater killing 
capacity for cancer cells (62). A common mitochondriotoxic peptide motif is the 
(KLAKLAK)2 (synthetic derivative of a natural antimicrobial peptide) which causes 
mitochondrial membrane damage and subsequent triggering of apoptosis. The 
(KLAKLAK)2 peptide does not efficiently cross the plasma membranes of eukaryotic cells 
and has low toxicity unless it is coupled to selective targeting domains allowing 
internalization by cells (45). For instance, the RGD-4C-GGD-(KLAKLAK)2 or ‘BHAP’ 
(HER-2-blocking and apoptosis-inducing peptide; exocyclic AHNP motif fused to 
(KLAKLAK)2) hybrid peptides allow targeting to endothelial cells of the angiogenic 
vasculature (45) or HER2-positive cells, respectively (44, 46). 
Screening is also ongoing for oncolytic peptides to be found among antimicrobial or 
host-defense peptides. Evolutionarily conserved mitochondriotoxic pore-forming peptides 
(e.g., colicins, and translocation domain of diphtheria toxin) exhibit a structural similarity 







The anti-apoptotic members of the Bcl-2 family (e.g., Mcl-1, Bcl-2 and Bcl-xL) are 
often relegated to merely having a redundant role in apoptosis. In recent years, however, 
each Bcl-2 family member (anti- and pro-apoptotic) have been found to have their own 
specialized niches within the apoptotic program (and in non-apoptotic cellular functions) 
(84). For instance, each anti-apoptotic Bcl-2 family member binds a distinct subset of the 
pro-apoptotic Bcl-2 members (85). This class of mitochondrial proteins is considered to 
have tremendous potential for both small molecule and peptide targeted therapies (11). 
BH3 domains of pro-apoptotic Bcl-2 family members or small molecule BH3 mimetics are 
currently used to neutralize the anti-apoptotic action of Bcl-xL, Bcl-w, and/or Bcl-2, 
thereby shifting the balance of power on the OMM from anti-apoptotic to pro-apoptotic to 
provoke MOMP (86). BH3 mimetics (e.g., ABT-263 (navitoclax), ABT-737, and GX15-
070 (obatoclax)) are currently being evaluated in phase 1/2 clinical trials for patients with 
hematologic malignancies. However, thrombocytopenia is a major side effect of this class 
of drugs due to their ability to antagonize the pro-survival function of Bcl-xL in platelets 
(86). 
Early work targeting the Bcl-2 family employed a BH3-only domain (Bak) fused to 
either a cell penetrating peptide (CPP; derived from the Antennapedia protein (48)) or 
receptor-specific sequence from luteinizing hormone-releasing hormone, creating Ant-BH3 
or LHRH-BH3, respectively (49). There are several variations on conformationally 
constrained BH3-only domains. For example ‘hydrocarbon-stapled’ peptides containing 
BH3 domains (stabilized alpha-helices of Bcl-2 family proteins or SAHBs; Bim-SAHB) 
are currently being developed as anti-cancer agents (50, 87). Also, modifications of the 
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BH3 domain using natural and non-natural amino acids to improve stability and enhance 
target specificity have been used as with the Bim-BH3 mimic, 072RB (51).  As certain 
neoplasias are likely the consequence of mutations or aberrant regulation exclusively of 
Bim (88), the restoration of a ‘therapeutic’ Bim is an attractive possibility. 
Bcl-2 itself is not a strictly mitochondrial protein and has several pro-survival 
functions including acting as a pro-angiogenic signaling molecule. Bcl-2 also controls 
cytoplasmic calcium levels via its BH4 domain in an interaction with inositol 1,4,5-
trisphosphate receptors (IP3Rs) on the endoplasmic reticulum (ER). This interaction 
suppresses pro-apoptotic calcium signaling and buffers cells against pro-apoptotic stimuli 
(89). The apoptotic suppression by the BH4 domain of Bcl-2 is more potent than that of 
the well recognized pro-survival BH4 domain from Bcl-xL against staurosporine 
treatment (90). The BH4 domain of Bcl-2 has been targeted with IP3R-mimetic peptides 
to trigger pro-apoptotic calcium signaling in malignant lymphocytes (in chronic 
lymphocytic leukemia) with suppressed IP3R Ca2+ signaling (52). Importantly, different 
iterations of the IP3R decoy peptide could alter the magnitude of the released calcium, 
and the calcium release was sufficient to kill these apoptosis-resistant lymphocytes (52). 
Noxa’s role in establishing the rate by which apoptosis occurs, in addition to its 
key role in changing the balance of autophagic processes toward cell death rather than 
survival, could provide a unique activity for a BH3-only protein if developed as a 
therapeutic entity (91). For instance, Noxa influences the kinetics in ABT-737- and 
TRAIL-induced apoptosis, since knockdown of Noxa delays the velocity of cell death 
induction in primary glioblastoma cultures derived from patient samples and in an in vivo 
tumor model (92). In light of Noxa’s ability to alter the rapidity of cell death, specifically 
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targeting Noxa may be a means to manage the type of cell death a cell undergoes (i.e., 
immunogenic apoptosis) (93). 
Mcl-1 is commonly associated with tumor cell resistance in several cancers, and 
certain therapies (radiation) can inadvertently cause resistance by increasing Mcl-1 
expression (90, 94). The corollary is that suppression of Mcl-1 restores sensitivity to 
apoptotic inducers. Introducing the Mcl-1 BH3 helix was sufficient to inhibit Mcl-1 and 
permit apoptosis (95) whereas several attempts to inactivate positive regulators (e.g., 
GSK-3β) upstream of Mcl-1 have been largely unsuccessful. Mcl-1, however, is not 
blocked by the BH3 mimetic ABT-737 (86). 
 
Permeability transition pore 
 Along with the Bcl-2 family, the members of the permeability transition pore 
(PTP) complex control mitochondrial membrane integrity. Therefore, the PTP is a key 
node for MOMP (96). Not surprisingly, dysregulation of the PTP is another mechanism 
allowing cancer cells to escape death (97). The PTP complex spans from the OMM to the 
matrix and primarily is thought to include: 1) Cyclophilin D (CYPD), a mitochondrial 
matrix constituent that is a peptidyl-prolyl cis-trans isomerase (and target for inhibition of 
cyclosporine A); 2) the adenine nucleotide translocase (ANT), an IMM protein, which is 
an example of isoform switching in cancer, through the overexpression of a MOMP 
resistant isoform ANT2 (96); and 3) the multifunctional voltage-dependent anion channel 
(VDAC), also called mitochondrial porin, which is localized to the OMM and serves as a 
key regulator of mitochondrial metabolite flux and apoptosis (98) (Figure 2.2). The PTP 
can also include the channel-like translocator protein (TSPO; formerly called the 
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peripheral benzodiazepine receptor) which contacts the VDAC and ANT from the OMM 
where it is localized and serves to transport cholesterol and other lipophilic molecules 
across the IMS in addition to possibly facilitating cytosolic to mitochondrial 
communication (99). Since TSPO basal expression is altered in a number of human 
pathologies including cancer, it is a promising drug target for a number of therapeutic 
applications (100). Another mitochondrial peculiarity that arises in cancer is the 
association of hexokinase (isoforms I or II) with the PTP at the surface of the OMM with 
VDAC. Upon displacement of hexokinase from PTP interaction (i.e., VDAC) on the 
mitochondrial surface by treatment with either small molecules or peptides (e.g., TAT-
HK peptide (40)), MOMP and apoptosis ensues (96, 101). One of the functions of ANT 
particularly relevant in cancer is the provision of ATP to hexokinase. This promulgates 
the pathologic metabolic shift to glucose and stabilizes the closed conformation of the 
PTP complex (96). 
 A peptide derived from the mitochondriotoxic HIV Vpr (Vpr67-82) was fused to 
a homing/internalization peptide sequence RGD (cysteine-cyclized peptide frame holds 
the RGD motif in a restricted conformation; also used with (KLAKLAK)2, see above, 
‘Membrane disrupting mitochondriotoxic peptides’ section) that recognizes the integrin 
αvβ3 receptor which is often upregulated in invasive tumor types. This fusion peptide 
(named TEAM-VP for Targeted to Endothelial Apoptogenic Mitochondrio-active Vpr-
derived Peptide) selectively induced IMM and OMM permeabilization in a mechanism 
associated with VDAC and ANT interaction (43). Interestingly, this group also noted that 
mitochondrial fission occurred with administration of TEAM-VP (43). 
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 Two peptide trivalent arsenical agents that target ANT are GSAO (4-(N-(S-
glutathionylacetyl)amino) phenylarsonous acid) and PENAO (4-(N-(S-
penicillaminylacetyl)amino) phenylarsonous acid, a cysteine mimetic analog of GSAO 
that is less prone to cellular efflux). ANT becomes inactivated upon the interaction 
between its matrix side cysteine residues and the arsenical component of GSAO or 
PENAO. The inactivation of ANT permits opening of the PTP and mitochondrial 
depolarization. Both GSAO and PENAO are currently in phase 1 clinical trials for 
patients with advanced solid tumors (56, 102). 
VDAC activity can be modulated by a variety of proteins, notably members of the 
Bcl-2 family. The pro-apoptotic Bax and tBid, upon interaction with VDAC, increase the 
channel pore size (103). Contrastingly, in cancer VDAC is usually inhibited by the anti-
apoptotic Bcl-2 proteins (e.g., Bcl-2 and Bcl-xL) and hexokinase I and II. Shoshan-
Barmatz et al. have developed a set of VDAC-mimetic peptides to relieve the anti-
apoptotic pressure on VDAC (57). This resensitizes the malignant cell to death signaling. 
VDAC-derived peptides have been optimized to act as VDAC decoys for hexokinase, 
Bcl-2 and Bcl-xL to restore apoptotic sensitivity to cancer cells. The addition of a cell 
penetrating peptide (CPP) motif to VDAC-mimetic peptides was effective in several 
cancer cell lines, including B-cell chronic lymphocytic leukemia (CLL) patient samples 
and chemo-resistant cell lines (57). Pharmacologic manipulation of the PTP/VDAC 
interactions may be an avenue to potentiate the efficacy of conventional chemotherapy 
(57). 
Recently, nicotinic acetylcholine receptors (nAChRs) have been found in the 
OMM and interact with VDAC to regulate PTP function in response to apoptogenic 
76 
 
stimuli (e.g., calcium overload or H2O2) (104). Typically, nAChRs are associated with 
the cell plasma membrane in synaptic transmission in the muscle and nervous system 
(104). However, with the discovery of nAChRs at the OMM paired with the wealth of 
pharmacological agents known to modulate this class of channel, it is likely that 
mitochondrial nAChRs will become a prime therapeutic target (104). 
 
Mitochondrial fission and fusion dynamics 
There is a link between Bak and Bax, pro-apoptotic members of the Bcl-2 family 
and the processes of mitochondrial fission in apoptosis (21).  To this point, Bax, Bak, and 
possibly Bcl-xL are required for normal mitochondrial dynamics (105). However, a direct 
mechanistic tie remains controversial between MOMP and the processes of mitochondrial 
fission. Upon apoptotic induction the mitochondrial fission protein dynamin-related 
protein (Drp1) is recruited, along with Bax, to the OMM. Both active Bax and Bak form 
foci at mitochondrial fission sites (21).  
One of the mechanisms whereby cancer cells evade death is by exploiting the 
pathway known as autophagy which is used by both normal and cancer cells to sustain 
metabolism and adapt to stressful conditions (106, 107). Typically under conditions of 
starvation, a cell can engage this lysosomal catabolic route to sustain metabolic demands 
(108). Autophagy is, paradoxically, considered both a cell death and cell survival 
mechanism, however, in the context of malignancy the true function of autophagy is 
thwarted and is therefore considered an escape route allowing survival (108). The 
engagement of this catabolic pathway is dependent on the mitochondria. Mitochondrial 
morphology determines the cellular response to autophagy (109) such that mitochondrial 
fusion spares the cell from death. Elongated mitochondria escape autophagic degradation 
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and exhibit optimized ATP production. Conversely, when elongation is blocked either 
genetically or pharmacologically the mitochondria consume ATP and trigger starvation-
induced death (109). This autophagic mitochondrial fusion is driven by phosphorylation 
events and cytoplasmic retention of the pro-fission Drp1 (110). Since mitochondrial 
fusion is integral to cell survival in the autophagic pathway proteins that are central to 
this process are viable therapeutic targets. Mitofusins (Mfn1 and Mfn2) and Opa1 (Optic 
atrophy 1) are OMM and IMM localized proteins, respectively, that are essential for 
mitochondrial fusion (21). Mfn2 in particular has been focused on as a therapeutic target 
because of its role in mitochondrial metabolism and calcium homeostasis (41, 111). 
The HIV Vpr (96 residues) has been shown to induce host cell death by increasing 
OMM permeability through interactions with VDAC and ANT (43) as well as by 
disturbing the OMM integrity (41), see above. However, HIV Vpr also depletes mitofusin 
2 (Mfn2; essential GTPase for the fusion of mitochondrial membranes) leading to 
mitochondrial membrane deformation, loss of Δψm and cell death (41). The loss of 
functional Mfn2 via HIV Vpr and consequent reduction in the frequency of fusion among 
mitochondria suggest that Vpr may confer a unique therapeutic potential in the context of 
pathologic autophagy (41). The mitofusin proteins are also of interest because they help 
to coordinate mitochondria-to-mitochondria docking as well as tethering the 
mitochondria and endoplasmic reticulum together to coordinate calcium flow (41). The 
intersection between mitochondrial dynamics and apoptosis may be a central leverage 





Pro-apoptotic mitochondrial targeting proteins 
dysregulated in malignancy 
 
p53 
p53 is a critical tumor suppressor protein that is dysregulated in over 50% of 
cancers (112). Recapitulating its function is central to many anti-tumor therapies. Under a 
wide variety of cell stress conditions p53 accumulates in the nucleus and mitochondria 
(reviewed in (113)). At the mitochondria p53 is found within multiple compartments, such 
as the OMM, IMS, and matrix (114). Mitochondrial p53 regulates apoptosis by acting in 
different cellular compartments by: 1) directly modifying propensity for MOMP by 
interacting with proteins of Bcl-2 family, 2) inhibiting manganese superoxide dismutase 
(MnSOD) activity, and 3) regulating mitochondrial physiology in proliferative conditions 
via interaction with mitofilin (115). Mitofilin is a multifunctional regulator of 
mitochondrial architecture and protein biogenesis (116) and has critical functions in 
mitochondrial morphology and mitochondrial fusion and fission (as well as protein import), 
specifically in the formation of tubular cristae and cristae junctions (117). And finally, 
there is increasing evidence for the role of p53 in metabolism regulation and mitochondrial 
respiration, which could be a major component of p53 oncosuppressive function (114, 
115). An advantage of targeting p53 to the mitochondria (versus the nucleus) may be the 
avoidance of nuclear negative regulators of p53 such as human double minute 2 (HDM2) 
and Fibroblast Growth Factor 1 (FGF1) which inhibit p53’s nuclear function and are often 
highly expressed in certain types of cancer (118). Recent work in our laboratory has shown 
that targeting p53 to the OMM of a breast cancer cell line (T47D) using the MTS derived 





Chronic myelogenous leukemia (CML) is defined by the expression of the 
oncoprotein Bcr-Abl through a reciprocal chromosomal translocation in a hematopoietic 
stem cell fusing the ABL and BCR genes (119) creating the constitutively active Bcr-Abl 
tyrosine kinase. Bcr-Abl thwarts the normal pro-death functions of c-Abl. c-Abl has been 
termed a “mitochondrial wracking factor” (120) because active c-Abl translocation to the 
mitochondria induces cell death (121, 122). Artificially targeting c-Abl (as a fusion to a 
cryptic MTS) to the mitochondria of leukemia cells (K562) recapitulated c-Abl’s pro-




Recent work has demonstrated the importance of the mitochondrial carrier 
homologue 2/Met-induced mitochondrial protein (MTCH2/MIMP) that resides on the 
surface of the OMM in tBid-mediated apoptosis (55). MTCH2 facilitates mitochondrial 
recruitment of tBid (in conjunction with OMM cardiolipin, see section ‘Mitochondrial 
membranes’) whereupon tBid activates Bax (21). MTCH2 is a conserved protein that 
belongs to the mitochondrial carrier protein (MCP) family, like ANT. Unlike ANT 
however, MTCH2 is localized to the OMM instead of the IMM (123). Peptides derived 
from the MTCH2 and tBid binding interface and fused to the Antennapedia CPP were 
able to induce apoptosis in cancer cells. While the mechanism of action is not yet clear, it 
is interesting that the tBid/MTCH2 interface-derived peptide does not include the BH3 
domain of tBid (55, 123). 
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Upregulated mitochondrial survival factors 
 
MnSOD 
The exclusively mitochondrial manganese superoxide dismutase (MnSOD) is a key 
enzyme involved in superoxide radical scavenging (124). In the context of oncogenic 
progression MnSOD has a bimodal expression profile (permitting oncogenic levels of ROS 
to persist but preventing overwhelming ROS toxicity), where its expression is lower at 
early stages of malignancy and higher at later stages (125). Inhibition of aberrantly elevated 
MnSOD is considered an effective strategy to selectively kill cancer cells and diminish 
resistance to standard chemotherapy (126). Mitochondrial p53 inactivates MnSOD, leading 
to mitochondrial dysfunction and initiation of apoptosis (124, 127). Additionally, targeting 
NF-κB with an inhibitory peptide suppressed MnSOD expression in aggressive breast 
cancer cell lines MDA-MB231 and SKBR3 (126).  
 
TRAP-1 
 Tumor necrosis factor receptor-associated protein-1 (TRAP-1) is a mitochondrial-
compartmentalized Hsp90-like chaperone that is strongly cytoprotective (128). High 
expression of TRAP-1 is consistently associated with malignancy and with resistance to 
chemotherapy while corresponding healthy tissues exhibit very low to undetectable levels 
of TRAP-1 (128). TRAP-1 associates with cyclophilin D, a component of the PTP, and 
inhibits PTP opening (as does aberrantly localized mitochondrial Hsp90, (Figure 2.2)). 
The ATPase activity of TRAP-1 can be inhibited by small molecules (e.g., 
geldanamycin), however none of these inhibitors could access the mitochondrial 
compartment. However, a peptide (shepherdin, antagonist of the interaction between 
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Hsp90 and the IAP survivin) was able to target and inhibit mitochondrial TRAP-1 
inducing MOMP and cell death selectively in cancer cells (128). Furthermore, the scope 
of TRAP-1/mitochondrial Hsp90 inhibition extended to the induction of a mitochondrial 
specific unfolded protein response (mUPR) program which can engage an autophagic 
type cell death mechanism (128). 
 
PDK-1 
 In many cancers the transcription and survival factor HIF-1 increases expression 
of the mitochondrial pyruvate dehydrogenase kinase (PDK1) (11). PDK1 inhibits 
pyruvate dehydrogenase which suppresses the TCA cycle (12). Consequently this 
reinforces the Warburg effect or glycolytic shift in cancer cells and may also protect cells 
from cytotoxic levels of ROS (12). Inhibition of this mitochondrial kinase with a small 
molecule (dichloroacetate or DCA) has met with good success with low/no toxicity to 
non-malignant cells (11). DCA is an excellent example of an agent acting specifically on 
the mitochondria of cancer cells without perturbing the physiology of nonmalignant cells 
(29). 
 
Survival factors that have special relevance 
when localized to the mitochondria. 
 
Hsp90 
Hsp90 is widely regarded as a pro-survival factor in cancer that affects multiple 
down-stream pathways (i.e., Hsp90 is a ‘nodal’ target (129)). Overexpression of Hsp90 is 
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typical in cancer cells in addition to an activity increase of nearly 100-fold (130). Hsp90 
stabilizes inhibitors of apoptosis (IAPs) such as survivin, inhibits MOMP via cyclophilin D 
(128), stimulates nitric oxide production through association with nitric-oxide synthase 
(NOS) (131) and has a role in the mitochondrial unfolded protein response (mUPR) (132). 
However, small molecule antagonists targeting Hsp90 ATPase have a low clinical response 
in patients (133). It has been confirmed that this is primarily due to the inability of the 
agents to access the mitochondrial compartment (133). A pool of mitochondrial Hsp90 was 
unexpectedly found localized to the mitochondria in prostate cancer samples while 
investigating the differential expression of TRAP-1 in cancer and healthy tissue (128). As 
with TRAP-1, the mitochondrial Hsp90 was undetectable in the normal corresponding 
tissue. Several peptides have been developed to target Hsp90 including, shepherdin 
(modeled on the interface between Hsp90 and the IAP survivin (53)) and Antp-TPR 
(modeled on the interface between Hsp90 and Hsp90 cofactor, Hop (54)). It has become 
clear that targeting the mitochondrial pool of Hsp90 is key for therapeutic efficacy, with 
applicability in genetically disparate tumors and provides a basis for tumor versus normal 
tissue selectivity in vivo (132). 
 
Peptides are uniquely suited to target 
malignant mitochondria 
 Current clinical cancer trials with agents targeting the mitochondria include 
obatoclax (small molecule BH3 mimetic) and the mitochondrial PDHK1 inhibitor DCA 
but as of yet, there are no peptides in this category (134). However, mitochondrial 
targeting antioxidant peptides are in phase 2 clinical trials for the indication of acute 
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myocardial infarction (135). Targeted peptides in cancer have primarily centered on 
tumor vasculature, inhibition of IAPs (136), monoclonal antibodies, anti-cancer vaccines 
(137), and plasma membrane disrupting peptides (138). Why are there no peptides 
targeted to the mitochondria for anti-cancer therapy? The technical problems of 
intracellular delivery and drug optimization are still formidable obstacles, and until 
recently intracellular protein-protein interactions have been considered to be “the most 
intractable of undruggable targets” (139).  
 Peptides have the distinct advantage of being able to discriminate between closely 
related targets with high affinity binding and low or no toxic effects (140). Evolutionarily 
refined natural peptides are a tremendous resource in the pursuit of selective anti-cancer 
agents that have the potential to extend the range of druggable targets beyond the scope 
of small molecules. The rapid development of synthetic peptides is a means to harness 
this evolutionarily cultivated specificity, subtlety, and low toxicity by bridging the 
problems of stability and delivery (139). Nonetheless, therapeutic peptide development is 
often complementary to improvement of targeted small molecules. In many cases, high 
affinity natural peptides (endogenous protein domains) already exist for many proteins of 
interest making libraries screening often unnecessary (140). Conversely, high affinity 
natural peptides can be used to efficiently screen small molecules for activity. For 
instance, a high-throughput screen for the anti-apoptotic Bcl-2 family member Bfl-1 used 
BH3-only domain binding to assess the displacement efficacy of small molecules (141). 
Going a step further, an iterative process of rational (e.g., BH3-only peptide) design can 
be used to refine and optimize target binding as a means to enhance screening for 
increasingly potent small molecules (142). 
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Targeting peptides intracellularly 
In order to reach the mitochondria, peptides and proteins must have a means to 
penetrate the plasma membrane. Cell penetrating peptides (also called protein 
transduction domains or PTDs) are highly versatile non-toxic sequences (as compared to 
liposomes and polymers) for intracellular delivery (143). CPPs generally come in two 
flavors, either as short amino acid sequences that are mainly composed of arginine, 
lysine, and histidine (cationic character mediates the interaction of the peptide with 
anionic/acidic motifs on the plasma membrane in a receptor-independent fashion) or as 
amphipathic peptides (lipophilic and hydrophilic tails) that mediate peptide translocation 
across the plasma membranes. However, the exact mechanism of uptake is controversial 
for this type of CPP (143). Recently a new class of CPPs with delocalized lipophilic 
cations incorporated into the peptide sequence have been created to specifically facilitate 
drug delivery to the mitochondria (144). Finally, CPPs have been widely used in animal 
models and can achieve systemic delivery in vivo (therefore deliverable to any type of 
cancer) (143). However, optimization testing is required for every modification because 
the orientation of peptide, cargo, and linkages can have a significant impact on 
therapeutic peptide efficacy (81, 143). 
 
Peptide toxicity: immunogenicity 
Immunogenicity of protein (and to a limited degree, peptide) therapeutics pose a 
risk that can possibly compromise safety and alter pharmacokinetics and bioavailability 
of the agent (145). The fast growing number of therapeutic proteins and related 
immunogenicity data shows that most of them induce formation of anti-drug antibodies 
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(ADA). Additionally, in silico assessment of peptide immunogenicity risk is becoming 
more common (145). In the case where ADA takes the form of neutralizing antibodies 
(NAb), these NAbs have a direct effect on the effector-function of the therapeutic 
proteins (146). Of special concern are fusion proteins composed of a foreign and self-
protein because of the potential of the foreign moiety to provoke an immune response to 
the self-protein (epitope spreading) (147). Risk of immunogenic response (esp. non-
human peptides (e.g., enfuvirtide)) can be mitigated by re-engineering to reduce the size 
and/or elimination of MHC-II epitopes (147) through standard humanization techniques. 
Standard strategies for increasing half-life can also reduce immunogenicity such as 
pegylation or the introduction of non-natural amino acids (143). 
 
While it is unclear if mitochondrial dysfunction directly contributes to 
tumorigenesis (or if mitochondrial dysfunction is co-opted in the process of cancer 
metabolic transformation) the key clinical point is that the mitochondria of cancer cells, 
as opposed to normal cells, are ripe for selective therapeutic targeting to overcome 
common mechanisms of resistance and augment current anticancer strategies (
Conclusion and future perspective 
1). Many 
of the current and emerging mitochondrial targets are dependent upon disruption of 
protein-protein interactions. There has been a general lack of progress in developing 
small molecules targeting protein-protein interactions and unlike therapeutic monoclonal 
antibodies, most peptides can function in an intracellular environment and are more 
amenable to synthesis/modification and delivery (148). Currently, an advancing 
developmental congruence exists between peptide drug design and delivery modalities 
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for peptides and proteins. Several recent reviews (3-6) cover important aspects of these 
advances and are illustrative of the creative energy being applied to the problems 
associated with peptide drug delivery. 
Peptides can harness the culmination of evolutionary processes that dictate 
specificity of interaction (139). Using peptides as therapeutics meets the highest standard 
(and arguably the most natural) for candidates to achieve the specificity and subtlety of 
interaction small molecules cannot. Even between highly homologous binding targets, 
peptides can discriminate due to their high-level complexity (149). Discovery of locations 
of protein-protein interaction sites can lead to a further refinement of targeted peptides 
and/or new screening targets for small molecule intervention. Multifunctional (e.g., 
targeting moiety combined with bioactive domain) peptides or multi-valency (e.g., more 
than binding modality) can be readily engineered while undesirable features (e.g., 
immunogenicity) can be virtually eliminated (148). Peptides offer low toxicity and highly 
malleable formats for creating tunable, multi-functional therapeutics (148). Peptides have 
advantages over large proteins (avoiding the necessity to employ complex cellular 
systems, problems of characterization, and higher immunogenic potential), small 
molecules (toxicity, target promiscuity, poor ability to target protein-protein and protein-
lipid interactions), and DNA/RNA aptamers (require rounds of screening using large 
libraries and purified target) (139).  
Some of the most promising mitochondrial targeted peptides are derivatives of a 
parent protein (150). Moreover, tremendous effort has been channeled into industrial 
scale development and production of synthetic peptides in recent years ramping up the 
capability to make larger and more complex peptides with improved physiochemical 
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properties (148). Furthermore, proteins, especially enzymes, have been in use as drugs for 
many years, and biologics are making an increasing contribution to the number of new 
drug approvals (151). A variety of FDA approved biologics have been in use for over 3 
decades, and the number of biologics continues to steadily increase (152). 
Drug efficacy and drug resistance are ultimately reconciled at the level of the 
mitochondrion, and many therapeutic efforts define success by achieving Bak/Bax 
oligomerization and MOMP (1). Also, it is not uncommon for resistance to be 
exacerbated by the very agents used to try to kill the malignant cells (i.e., induction of 
EGFR mitochondrial localization (73) or radiation therapy-induced resistance via Mcl-1 
stabilization (153)). Therefore strategies that engage the mitochondria directly bypass 
problems of resistance and upstream prosurvival pressures (11). For instance, if 
malignant cells overcome therapeutically induced ROS via up-regulated anti-oxidant 
mechanisms or RAF signaling, targeting MOMP using BH3-only peptides could restore 
cell death (154). Another complementary approach is to test the status of the 
mitochondria (e.g., overexpression of anti-apoptotic factors) to tailor therapeutic 
intervention. Recently, ‘BH3 profiling’  (originally defined as a pattern of mitochondrial 
apoptotic sensitivity based on peptides derived from BH3-only proteins (155)) has been 
performed as a companion diagnostic for determining the probability of drug efficacy 
(e.g., bortezomib) across cancer patients (19). Combining mitochondrially targeted 
peptides with conventional chemotherapy may be a powerful way to reduce the standard 
chemotherapeutic dose and associated toxicity, potentiate synergistic killing of tumor 




The term ‘mitocan’ has recently been coined to describe therapeutic agents within 
the rapidly developing and burgeoning field of mitochondrial focused anti-cancer therapy 
(157). In the near future we can expect peptide therapeutics to comprise an ever larger 
segment of the mitocan arsenal. 
 
1. Mitochondrial cell death pathway and malignant mitochondria 
Executive summary 
Cancer therapy is dependent on permeabilization of the mitochondrial outer 
membrane (MOMP). Directly targeting the mitochondria in cancer is an 
excellent universal therapeutic strategy especially because there are ‘targetable’ 
differences between malignant and healthy mitochondria. 
2. Peptides are uniquely suited to target malignant mitochondria 
Therapeutic peptide agents have the potential to open new vistas of traditionally 
“undruggable” targets (e.g., protein-protein interactions) and offer a subtlety and 
specificity of target interaction that cannot be matched by small molecules, all 
while decreasing side effects. Rapid advances in therapeutic peptide design are 
likely to soon surmount the major problems of stability and delivery. 
3. The mitochondria and immunogenic apoptosis 
The type of death a cell dies may be central to achieving a durable response to 
anti-cancer therapy. Targeting the mitochondria may be a means to kill cancer 
cells but be able to modulate the killing to invoke an “immunogenic apoptosis.” 
Pairing peptide therapeutics with traditional chemotherapy may be a way to 
preserve the immune effector cells (by using a sub-immune toxic 
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chemotherapeutic dose) to achieve tumor killing while engaging an anti-tumor 
immune response. 
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SELECTIVE TARGETING OF C-ABL VIA A CRYPTIC 
MITOCHONDRIAL TARGETING SIGNAL 
ACTIVATED BY CELLULAR REDOX 
STATUS IN LEUKEMIC AND 
BREAST CANCER CELLS 
 
The tyrosine kinase c-Abl localizes to the mitochondria under cell stress 
conditions and promotes apoptosis. However, c-Abl has not been directly targeted to the 
mitochondria. Fusing c-Abl to a mitochondrial translocation signal (MTS) that is 
activated by reactive oxygen species (ROS) will selectively target the mitochondria of 
cancer cells exhibiting an elevated ROS phenotype. Mitochondrially targeted c-Abl will 
thereby induce malignant cell death. Confocal microscopy was used to determine 
mitochondrial colocalization of ectopically expressed c-Abl-EGFP/cMTS fusion across 
three cell lines (K562, Cos-7, and 1471.1) with varying levels of basal (and 
pharmacologically modulated) ROS. ROS were quantified by indicator dye assay.  The 
Abstract 
                                                             
Reprinted with permission from J.E. Constance, S.D. Despres, A. Nishida, and C.S. Lim. 
Selective targeting of c-Abl via a cryptic mitochondrial targeting signal activated by 
cellular redox status in leukemic and breast cancer cells. Pharm Res. 29:2317-2328 
(2012). Copyright 2012 Springer. 
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functional consequences of mitochondrial c-Abl were assessed by DNA accessibility to 
7-AAD using flow cytometry. The cMTS and cMTS/c-Abl fusions colocalized to the 
mitochondria in leukemic (K562) and breast (1471.1) cancer phenotypes (but not Cos-7 
fibroblasts) in a ROS- and PKC-dependent manner. We confirm and extend oxidative 
stress-activated translocation of the cMTS by demonstrating that the cMTS and 
Abl/cMTS fusion selectively target the mitochondria of K562 leukemia and mammary 
adenocarcinoma 1471.1 cells. c-Abl-induced K562 leukemia cell death when targeted to 
the matrix but not the outer membrane of the mitochondria. 
 
A hyper-oxidative environment is a pathophysiologic hallmark of many disease 
states, including cancer (
Introduction 
1). Cell fate often rests on proteins (e.g., antioxidant enzymes or 
pro-apoptotic factors) that are responsive to oxidative stress and translocate to the 
mitochondria (2). However, oncoprotein signaling can disrupt, directly or indirectly, pro-
apoptotic signal transduction at the level of the mitochondria (3). For instance, the 
ubiquitously expressed non-receptor tyrosine kinase c-Abl has been termed a 
“mitochondrial wracking factor” (4) since active c-Abl translocation to the mitochondria 
induces cell death (5). In the context of chronic myelogenous leukemia (CML) though, 
the pro-death functions of c-Abl are prevented by the aberrantly active tyrosine kinase 
fusion oncoprotein Bcr-Abl (6). 
The functional specificity of c-Abl is dictated by subcellular location (7). The 
majority (70%) of c-Abl resides in the nucleus, with about 20% in the ER, 5-8% in the 
cytoplasm, and the remainder (~4%) found in the mitochondria (8). c-Abl can promote 
107 
 
mitogenesis when located in the cytoplasm, cell cycle arrest when activated in the 
nucleus, and upon translocation to the mitochondria c-Abl can induce the loss of 
mitochondrial membrane potential (ψMIT), depletion of ATP, and apoptotic/necrotic cell 
death (8, 9). Additionally, c-Abl was the first tyrosine kinase found to associate with the 
mitochondria (10) and is considered to be the key apoptotic tyrosine kinase (11). At 
present the submitochondrial location and substrates for c-Abl are unidentified (12). To 
our knowledge the consequences of c-Abl to mitochondrial targeting has only been 
examined in the context of a cellular insult (e.g., H2O2, genotoxic agents, and 
endoplasmic reticulum toxins), and direct targeting of c-Abl to the mitochondria through 
fusion to a mitochondrial targeting signal (MTS) has not been studied.  
Protein localization to different subcellular compartments is often directed by 
signal sequences encoded in the protein itself. Normally, death-directed c-Abl requires 
association with a chaperone protein (i.e., PKCδ) to reach the mitochondria as it does not 
contain an MTS of its own (9). MTSs are usually found at the N- or C-terminus of 
proteins (13) but fusions to the N-terminus of c-Abl (e.g., Bcr-Abl) disrupt its normal 
conformation (14). Therefore, in order to permit c-Abl to adopt its native conformation a 
C-terminal fusion is required. One such C-terminal MTS, that conditionally targets the 
mitochondria, is derived from murine glutathione-S-transferase A4-4 (GSTA4-4; C-
terminal residues 172-222) (15). 
The GSTA4-4 MTS is considered a ‘cryptic’ MTS (cMTS) and was previously 
shown to translocate from the cytosol to the mitochondria in Cos cells under 
pharmacological stimulation of oxidative stress or protein kinase activators (15, 16). The 
mitochondrial translocation of the cMTS is dependent upon activation, via 
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phosphorylation. Key cMTS residues, S189 and T193, are phosphorylated by the protein 
kinase A (PKA) and/or protein kinase C (PKC) family of ser/thr kinases, respectively. A 
dihydrofolate reductase/cMTS fusion was previously shown to localize in the 
mitochondria of Cos cells upon protein kinase activator stimulation (15). Therefore, this 
study aims to determine if the cMTS could provide a means to selectively target pro-
apoptotic c-Abl to the mitochondria based on the inherent level of intracellular reactive 
oxygen species (ROS) as a discriminating factor across cell types. 
Elevated intracellular ROS can lead to the activation of transcription factors (e.g., 
HIF-1 and NF-κB) leading to a host of protein expression profiles that contribute to 
malignancy such as, proliferation, survival, and metastasis. This situation leads to a 
seeming ‘ROS paradox’ where many antineoplastic agents, like imatinib, exert their 
cytotoxic effects through the generation of ROS. The underlying mechanisms for (the 
essential) ROS-mediated killing by chemotherapeutics and radiation therapy is not well 
understood (17). However, an increase in magnitude of the already elevated ROS in 
cancer cells is likely to exceed the antioxidant capacity of the cancer and cause cell death 
(18). 
A small selection of cell lines exhibiting different levels of basal ROS were used 
to test the selective mitochondrial accumulation of cMTS containing constructs. First, 
human leukemia K562 cells are characterized by elevated ROS and serve as a 
representative of a cell type in a pathologic pro-oxidative state. K562 cells have high 
basal levels of ROS due to Bcr-Abl’s stimulation of the PI3K/mTOR pathway leading to 
overactivation of the mitochondrial electron transport chain (19). The oncogenic Bcr-Abl 
(present in K562) engages signaling pathways that result in the production of ROS, 
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causing CML cells to have a high cellular oxidative stress background (20). Therefore, 
ROS levels are chronically elevated due to the presence of Bcr-Abl. Even when Bcr-Abl 
activity is blocked by tyrosine kinase inhibitor therapy, ROS production is induced via 
another (apoptotic) route (21). Secondly, both chronic ROS and PKC over-activation 
have been associated with breast cancer (22, 23), therefore, the murine mammary 
adenocarcinoma 1471.1 cell line was included.  Finally, the transformed monkey kidney 
fibroblast Cos-7 cell line was used as a negative control for background ROS. Within the 
context of the elevated ROS K562 cell line, antioxidants (α-tocopherol and N-
acetylcysteine) and an antineoplastic (imatinib) were used to modulate the level of ROS 
and the consequent effects on mitochondrial localization of constructs was determined. 
 
 
Materials and methods 
Materials 
 RPMI-1640 medium, MitoTracker Red CM-H2XRos (MitoTracker CMXros), 7-
aminoactinomycin D (7-AAD; DNA intercalating dye permeable to dying or dead cells), 
5-(and-6)-carboxy-2’,7’-dichlorofluoroescein (carboxy-H2DCFDA; general oxidative 
stress indicator), Lipofectamine LTX with Plus reagent, and phosphate-buffered saline 
(PBS) were purchased from Invitrogen (Carlsbad, CA). Penicillin-streptomycin-L-
glutamine (P-S-G; 100U/mL), DMEM media and trypsin were purchased from Gibco 
BRL (Grand Island, NY). Fetal bovine serum (FBS) and gentamycin were purchased 
from Hyclone Laboratories (Logan, UT). The (+)-α-tocopherol type VI (α-Toc), N-
acetyl-L-cysteine (NAC), and poly-L-lysine (0.01% solution) were purchased from 
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Sigma-Aldrich (St. Louis, MO). Imatinib (CT-IM001) was purchased from ChemieTek 
(Indianapolis, IN). QuikChange II XL Site-Directed Mutagenesis Kit was purchased from 
Agilent Technologies (Santa Clara, CA). Cell Line Nucleofector Kit V was purchased 
from Lonza Group (Basel, Switzerland). 
 
Cell lines and culture conditions 
 K562 cells (non-adherent human chronic myelogenous leukemia cell line), gift 
from Dr. K. Elenitoba-Johnson, University of Michigan, and Cos-7 (monkey kidney 
fibroblast adherent cell line; ATCC) were cultured in RPMI 1640 supplemented with 
10% FBS, 1% P-S-G (GIBCO BRL, Grand Island, NY), and 0.1% gentamycin. Murine 
mammary adenocarcinoma 1471.1 cells, (gift from Gordon Hager, PhD, NCI, NIH) were 
grown as monolayers in DMEM supplemented with 10% FBS, 1% P-S-G and 0.1% 
gentamycin. K562 cells were passaged at a density of 0.5 x 105/mL every other day, and 
discontinued at the tenth passage. Cos-7 and 1471.1 cells were passaged at 80% 
confluency and split 1:10 in fresh media and discontinued after passage 15. All cells were 
maintained in a 5% CO2 incubator at 37 oC. 
 
Expression of constructs in K562 leukemia, 
Cos-7 fibroblast, and 1471.1 breast  
cancer cells 
 Constructs were transiently transfected into K562 cells using the Amaxa 
Nucleofector II, as described previously (24). Briefly, 2 x 106 K562 cells, between 
passages 5 to 10, were pelleted prior to a 48 hour initial seed density of 0.5 x 105 
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cells/mL. Cells were resuspended in 100 µL Amaxa Solution V, combined with 2 µg of 
DNA and transfected in an Amaxa cuvette under program T-013. Transfected cells were 
immediately transferred to a 25 cm2 flask with 7 mL of pre-warmed complete RPMI. 
Transient transfections of 1471.1 and Cos-7 cells were carried out in two-well live-cell 
chambers (Lab-Tek chamber slide system, Nalge NUNC International, Naperville, IL) or 
sterile 6-well tissue culture plates (Greiner CellStar, Greiner Bio-one GmbH) using 
Lipofectamine LTX as per manufacturers’ instructions between passages 3 and 15 in 
antibiotic free media. 
 
Subcloning and construction of plasmids 
 The murine glutathione S-transferase A4-4 [Swiss-Prot:P24472.3] cMTS (N-
terminal residues, 172-222 (15); 51% sequence homology to human wherein S189 and 
T193 are conserved) was constructed by annealing four oligonucleotides (1: 
(5’phosphorylated) 5’ –AATTCCGCCCCCGTGCTGAGCGACTTCCCCCTGCTGCA- 
GGCCTTCAAGACCAGAATCAGCAACATCCCCACCATCAAGAAGTTCCTGCAG
CCC-3’, 2: 5’ –CTGCCGGGCTGCAGGAACTTCTTGATGGTGGGGATGTTGCTGA- 
TTCTGGTCTTGAAGGCCTGCAGCAGGGGGAAGTCGCTCAGCACGGGGGCGG-
3’, 3: 5’ –GGCAGCCAGAGAAAGCCCCCCCCCGACGGCCCCTACGTGGAGGTG- 
GTGAGAACCGTGCTGAAGTTCGGCGCCGGCTGCTGCCCCGGCTGCTGCTGA-
3’, 4: (5’ phosphorylated) 5’ –AATTTCAGCAGCAGCCGGGGCAGCAGCCGGCGC- 
CGAACTTCAGCACGGTTCTCACCACCTCCACGTAGGGGCCGTCGGGGGGGGG
CTTTCTCTGG-3’) simultaneously and then inserting the annealed product into the 
multiple cloning site (MCS) of EGFP-C1 vector (Promega Biotech, Madison, WI) at the 
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EcoRI (New England Biolabs, Ipswich, MA) site creating pE-cMTS. The pE-cMTS-SY 
(T186E/R187A/S189Y) and pE-cMTS-TY (P192I/T193Y) were created using site-
directed mutagenesis using primers, 5’-GCTGCAGGCCTCAAGGAGGCCATCTACA- 
ACATCCCCACC-3’ and 5’-GACCAGAATCAGCAACATCATCTACATCAAGAAG- 
TTCCTGCAGCCCGGCAGCCAGAGAA-3’, respectively, with corresponding reverse 
complements. Additionally, a tetracysteine motif tag present in the annealed 
oligonucleotide cMTS insert, was eliminated from being expressed by site-directed 
mutagenesis to incorporate a stop codon (Primer: 5’-CCGTGCTGAAGTTCTGAGCCG- 
GCTGCTGCC-3’ and reverse complement). Human c-Abl (ABL1 isoform a; 
NM_005157) was purchased from DF/HCC DNA Resource Core 
(http://dnaseq.med.harvard.edu/) as plasmid DNA in vector pJP1563 (clone ID 
HsCD00039065). DNA encoding c-Abl was amplified through PCR using the primers 5’- 
CGACGACACCGGTCGCCACCATGTTGGAGATCTGCCTG-3’ (includes Kozak 
sequence) and 5’- CAGTGACATAGTGCAGAGGGGCGCCGGCGGACCGGTCGAC- 
GAC-3’ and subcloned into pEGFP-C1 (Clontech, Mountain View, CA, USA) and pE-
cMTS at the blunted (Quick Blunting Kit, New England Biolabs Inc., Ipswich, MA, 
USA) Age1 restriction enzyme site. The pAbl-E-cMTS KD (kinase dead; isoform 1a 
K271A mutation (25)) mutant was created using site-directed mutagenesis with the 
primer 5’-CTGACGGTGGCCGTGGCGACCTTGAAGGAGGAC-3’ and its reverse 
complement. The MOM targeting sequence derived from Bcl-XL was constructed by 
annealing two complementary 5’ phosphorylated oligonucleotides each containing 




GTTCAGCAGAAAGTGA-3′) and inserting into the BamHI restriction enzyme site of 
pEGFP-C1 and pAbl-E to create pE-MOM and pAbl-E-MOM, respectively. All 
constructs were verified by sequence analysis. 
 
Mitochondrial staining 
 Aliquots of transfected K562 suspension cells (400µL) were plated into poly-L-
lysine coated 4-well live-cell chambers at least 4 hours in advance of microscopy. Cells 
were incubated with MitoTracker Red CM-H2XRos (K562; 100nM, Cos-7 and 1471.1; 
325nM) for 45 minutes at 37 oC and protected from light prior to imaging. 
  
Confocal microscopy 
 All images of K562, Cos-7, and 1471.1 live cells were acquired on an Olympus 
IX81 FV1000-XY spectral confocal microscope (Imaging Core Facility, University of 
Utah) equipped with 405 nm diode, 488 nm argon, and 543 nm HeNe lasers using a 60X 
PlanApo oil immersion objective (NA 1.45) using Olympus FluoView software. 
Excitation and emission filters were as follows: EGFP, 488 nm excitation, emission filter 
500-530 nm; MitoTracker Red CM-H2XRos, 543 nm excitation, emission filter 555-655 
nm. Images were collected in sequential line mode with exposure and gain of laser kept 
constant and below detected pixel saturation for each group of cells. No channel crosstalk 
was observed. Pixel resolution was kept at 1024 x 1024 (0-2.5-fold digital zoom) with a 





 Images were analyzed as previously described (26). Briefly, original images were 
saved as 16-bit files preserving meta-data. Images were converted to 8-bit, stacked as 
separate channels, and corrected for background noise using ImageJ plugin ‘BG 
subtraction from background’ in default mode (i.e., mean background intensity outside of 
cells was subtracted) (27). All experiments were completed in at least triplicate. ROIs, to 
be compared for colocalization, were constructed using individual cells to control for 
cell-to-cell intensity variation in colocalization analysis. Image and statistical analysis 
was performed with JACoP in ImageJ (28). Pearson’s correlation coefficient (PCC) was 
generated using Costes’ automatic threshold algorithm to eliminate manual thresholding 
bias, increase the accuracy in quantifying low level colocalization, and ensure 
reproducibility (29, 30). The PCC is dependent upon both the pixel intensity and overlap 
of signal and has a range of +1 (complete colocalization) to -1 (anti-correlation) with zero 
correlating with random distribution between comparators (28). The PCC threshold for 
defining colocalization (i.e., colocalization due to co-compartmentalization) is 0.6 as per 
Bolte and Cordelières (28) (see Fig. 3.1). Channel one (EGFP) and channel two 
(MitoTracker CMXros) have been false colored, using ImageJ LUT, cyan and magenta, 
respectively, for increased visual clarity. Additionally, spatial representation of intensity 
correlation was included between EGFP-tagged proteins and the mitochondria (stained 
with MitoTracker Red CM-H2XRos) using the Colocalization Colormap ImageJ plugin. 
‘Colormap’ displays positively correlated pixels in hot colors and negatively correlated 




Figure 3.1. Degree of colocalization. The degree of colocalization is based on Pearson’s 
correlation coefficient (PCC) generated using the method of Costes’. PCC values above 
0.6 (top dashed line) can be considered either co-compartmentalized or colocalized as 
established by Bolte and Cordelières while PCC values 0.5 or above (bottom dashed line) 
meet the threshold for co-compartmentalization only. The term colocalization is defined 
more stringently and implies that two fluorescent entities are associated based on both 
spatial overlap of pixels and matching intensity co-variation. Co-compartmentalization 
(also ‘partial-colocalization’) can be synonymous with colocalization however, if a 
comparator channel signal is from a compartment specific stain that is not expected to 
have any stoichiometric relationship or interaction with the other fluor then the PCC 
threshold value is adjusted down to 0.5 to compensate for the expected lack in intensity 
correlation. The interpretation of values between 0.5 and -0.5 (PCC range is from 1 to -1) 







Antioxidant treatment of K562 cells 
 Complete RPMI media containing 50 μM (+)-α-tocopherol or N-acetyl-L-cysteine 
(300 µM or 5 mM (dissolved in RPMI at 80 mM stock concentration (pH adjusted to 
7.4)) was added to freshly transfected cells. 
 
ROS detection assay 
 ROS production was measured according to the manufacturer’s instructions. 
Briefly, the cellular ROS level was measured by incubating approximately 106 cells with 
25 μM carboxy-H2DCFDA for 45 minutes and protected from light at 37˚C in a 5% CO2 
incubator in PBS. Immediately following incubation cells were pelleted via 
centrifugation and resuspended in 400 μL warmed PBS, split into two wells on a black 
Corning Costar 96-well plate and measured on a SpectraMax M2 fluorescence plate 
reader (Molecular Devices, Sunnyvale, CA) with excitation at 485 nm and emission 
collected at 530 nm wavelengths. Either raw arbitrary fluorescence units were reported or 
expressed as percent control. Positive controls were H2O2 (500 μM) treated cell lines 
(with and without carboxy-H2DCFDA) and negative controls were cells in PBS without 
carboxy-H2DCFDA and also PBS with carboxy-H2DCFDA. 
 
Cell death assay 
 Flow cytometric assay of cell death was done as previously described (32). 
Briefly, K562, Cos-7, and 1471.1 cells were collected 48 hours posttransfection and 
resuspended in 500 µL ice cold PBS containing 1 µM 7-aminoactinomycin D (7-AAD) 
for 30 minutes prior to analysis. Media from adherent Cos-7 and 1471.1 cells was 
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collected prior to trypsinization of cell monolayer and recombined with the enzymatically 
released cell population for centrifugation and subsequent resuspension. Analysis and 
gating was performed on a BD FACSCanto II (Flow Cytometry Core Facility, University 
of Utah) on BD FACSDiva software (BD Biosciences, Franklin Lakes, NJ). At least three 
separate experiments in duplicate were performed. Compensation controls were included 
with each experiment.  
 
Statistical analyses 
 Data are shown as mean ± S.E.M. Unpaired t-test, one-way ANOVA with 
Tukey’s (or Dunnett’s) post-test, two-way ANOVA with Bonferroni post-test, or two-
tailed correlation (as indicated in figure legends), were used to evaluate measurements 
between experimental data with an N of 3 or greater. Statistical significance was set at 
P<0.05 or adjusted lower in instances of multiple comparisons (by convention P<0.05 is 
represented with *; P< 0.01 with **; P< 0.001 with ***). GraphPad Prism Graph 4 




K562 leukemia and 1471.1 mammary adenocarcinoma cells exhibit 
elevated ROS backgrounds and cMTS mitochondrial 
localization compared to Cos-7 
 To assess differences in basal ROS level between K562 leukemia, mammary 
adenocarcinoma 1471.1, and the Cos-7 (negative control for oxidative stress (15, 33)) 
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Figure 3.2. The cMTS is mitochondrial in K562 and 1471.1 cells but cytosolic in Cos-7. 
A) Leukemic (K562) and Breast cancer (1471.1) cells exhibit elevated background ROS 
as compared to Cos-7. ROS detection assay using the general oxidative stress indicator 
carboxy-H2DCFDA conversion to DCF was monitored on a fluorescent plate reader with 
excitation at 485nm and emission at 530nm. Fluorescence signal was stable across 
samples and over time when the endpoint reading was collected. One-way ANOVA with 
Tukey’s post-test (error bars are ±S.E.M, N=3).  
B) Representative images of E-cMTS in K562, Cos-7 and 1471.1 cells. The cMTS is 
selectively targeted to the mitochondria in cells with elevated oxidative stress. ROS 
activate PKC kinases that, in turn, activate, via phosphorylation, the cMTS. The 
phosphorylated “active” cMTS translocates from the cytoplasm to the mitochondria. 
Channel one (EGFP) and channel two (MitoTracker) have been false colored, cyan and 
magenta, respectively, for increased visual clarity. Colocalized pixels in merged cyan and 
magenta images show as white. The ‘Colormap’ (far right column) displays positively 
correlated pixels in hot colors and negatively correlated pixels in cold colors that can be 
interpreted using the color scale bar (shown at bottom of the ‘Colormap’ column). Scale 
bars are 5 µm (mean Pearson correlation coefficient (PCC) values are ±S.E.M, N=3).   
C) Individual cell ROIs were selected from confocal images taken with live cells and 
analyzed using the PCC to quantify the degree of E-cMTS mitochondrial colocalization 
in K562, 1471.1 and Cos-7 cells. Signal from EGFP (tagged to cMTS) and MitoTracker 
Red CM-H2XRos staining were compared. One-way ANOVA with Tukey’s post-test 

























monkey kidney fibroblast cell lines, the conversion of carboxy-H2DCFDA to DCF was 
measured (Fig. 3.2; y-axis in arbitrary fluorescence units). K562 (left column, Fig. 3.2A) 
and 1471.1 mammary adenocarcinoma (right column, Fig. 3.2A) cells demonstrated an 
elevated background ROS compared to Cos-7 (middle column, Fig. 3.2A). The basal ROS 
level of 1471.1 cells fell between the K562 and Cos-7 reference cell lines. 
 Confocal fluorescence microscopy (Figure 3.2B) paired with statistical analysis 
was used to determine mitochondrial localization of the cryptic MTS derived from 
GSTA4-4 (cMTS), fused to EGFP, across cell types.  Despite the nearly two-fold higher  
basal ROS level of K562 over the 1471.1 cell line, the E-cMTS was equally colocalized 
to the mitochondria of both K562 (left column, Fig. 3.2C) and 1471.1 (right column, Fig. 
3.2C) cells 24 hours post-transfection whereas the E-cMTS remained cytosolic in Cos-7 
(Fig. 3.2C, middle column). Figure 3.2B shows representative images for each cell line 
transfected with E-cMTS (cyan) and stained with MitoTracker Red (magenta) with white 
scale bars in the E-cMTS images measuring 5 µm. Image analysis, from at least three 
separate experiments quantifying the degree of colocalization of the E-cMTS with the 
mitochondria was used to construct Figure 3.2C. The ‘degree of colocalization’ is 
represented by Pearson’s correlation coefficient (PCC) (29). EGFP-C1 was used as a 
negative control for colocalization studies (thresholded PCC values of EGFP-C1 and 
MitoTracker CMXros in the different cell lines were, K562: -0.20 ± 0.13, Cos-7: 0.04 ± 
0.03, and 1471.1: 0.12 ± 0.03). Mitochondrial colocalization of constructs was verified to 
be consistent at different cell depths (i.e., z-plane sections; data not shown). Although 
overlay of the E-cMTS and MitoTracker CMXros signals are provided (‘Merge’ column) 




Figure 3.3. Diagram of constructs. The C-terminal 50-amino acid sequence of mGSTA4-
4 was fused to the C-terminus of EGFP to create, E-cMTS. The PKA and PKC 
phosphorylation site-mutants are E-cMTS-SY and E-cMTS-TY, respectively. Abl-E 
serves as a negative control for mitochondrial translocation and a baseline for cell death 
upon mitochondrial targeting of c-Abl/MTS constructs. Abl-E was constructed with c-
Abl positioned N-terminally to the EGFP tag in order to maintain c-Abl’s ability to adopt 
a native auto-inhibitory conformation (14). Abl-E-MOM and E-MOM contain a 
canonical MTS derived from Bcl-XL that targets to the mitochondrial outer membrane 





showing spatial depiction of pixel overlap and relative intensity, can be seen in the 
‘colormap’ column (31). 
 As a control for baseline translocation efficiency across cell types, in a PKC- and 
PKA-independent manner, a canonical MTS derived from Bcl-XL was subcloned into 
EGFP-C1 (E-MOM), Figure 3.3. The Bcl-XL has been demonstrated to efficiently 
translocate heteroproteins to the mitochondrial outer membrane (MOM) (34). The MTSs 
from both the cMTS and Bcl-XL are C-terminal sequences. The Bcl-XL MTS targets to 
the MOM (35) whereas the cMTS targets to the mitochondrial matrix (15). Images in 
Figure 3.4A display the robust mitochondrial targeting efficiencies of E-MOM in each of 
the three cell lines used. Analysis of images evaluating E-MOM mitochondrial 
localization collected in three separate experiments (Fig. 3.4B) confirm that the 
translocation machinery of K562, 1471.1 and Cos-7 cells is sufficiently proficient for 
comparison of cMTS localization in these cell types. 
 
Requirement for threonine 193 but not serine 189 
for mitochondrial translocation of cMTS in 
K562 and 1471.1 cells 
 Two cMTS mutants were made in order to determine the importance, in K562 and 
1471.1 cells, of previously determined PKA (S189) and PKC (T193) phosphorylation 
sites that lead to the activation and mitochondrial accumulation of the cMTS (Table 3.1, 
E-cMTS-SY and E-cMTS-TY, respectively) (15). The mutations to the PKA and PKC 
phosphorylation sites were changed to minimal c-Abl tyrosine kinase recognition 






Figure 3.4. The translocation efficiency for the cell types tested is sufficient to determine 
mitochondrial localization of constructs. Using a canonical MTS derived from Bcl-XL 
fused to EGFP, the relative capability of each cell type was determined.  
A) Representative images of K562, Cos-7, and 1471.1 cells transfected with E-MOM 
construct at 24 hours.  
B) Signal from E-MOM and MitoTracker Red CM-H2XRos staining were compared. 
















Table 3.1. Names of cMTS constructs, corresponding residue sequences, relevant protein 
kinase, and key residue mutations. cMTS constructs names, corresponding residue 
sequences, relevant protein kinase, and key residue mutations. PKA (S189) and PKC 
(T193) phosphorylation sites are bolded. cMTS-SY has a key mutation (S189Y) creating 
a PKA-null site-mutant whereas cMTS-TY contains a key mutation (T193Y) creating a 
PKC-null site-mutant. Residues underlined in black were also mutated to incorporate the 
minimal c-Abl phosphorylation consensus recognition sequence while simultaneously 
ablating either the PKA or PKC phosphorylation sites. The cMTS-SY and cMTS-TY 
mutations, computationally analyzed for potential changes to the secondary structure via 
the MPI Bioinformatics Toolkit (36), did not alter the secondary structure (i.e., α-helicity, 
disordered regions, or solvent accessibility) as compared to wild-type cMTS. 
Incorporation of both the S189Y and T193Y mutations into the cMTS resulted in a 
strictly cytosolic distribution of the cMTS-SY/TY mutant generating a thresholded PCC 
of 0.14 ± 0.2 in K562 cells when compared to MitoTracker CMXros. 
  





cMTS APVLSDFPLLQAFKTRISNIPTIKKFLQPGSQRKPPPDGPYVEVVRTVLKF PKA/PKC none 
cMTS-SY APVLSDFPLLQAFKEAIY PKC only NIPTIKKFLQPGSQRKPPPDGPYVEVVRTVLKF S189Y 




Figure 3.5. The conserved threonine 193 is critical for mediating mitochondrial 
localization under oxidative conditions.  
A) EGFP-tagged cMTS-SY and cMTS-TY were compared to MitoTracker Red CM-
H2XRos staining in live cells. EGFP and MitoTracker channels were false-colored cyan 
and magenta, respectively, for increased visual clarity. Colormap displays spatial 
intensity correlation between channels. Scale bar is 5 µm. (mean PCC values are ±S.E.M, 
N=3)  
B) Mitochondrial localization of wild-type E-cMTS as compared to mutated E-cMTS-SY 
(S189Y) and E-cMTS-TY (T193Y) in K562 and 1471.1 cells. In both 1471.1 and K562 
cells the cMTS was not statistically different from E-cMTS-SY. Two-way ANOVA with 


































Figure 3.6. Imatinib increases, while antioxidants α-tocopherol and N-acetylcysteine 
attenuate, ROS and E-cMTS mitochondrial colocalization in K562 cells.  
A) Comparison of ROS levels between K562 cells treated with imatinib (10 µM, IM), α-
tocopherol (50 μM, α-toc), or N-acetylcysteine (300 µM or 5 mM, NAC) for 24 hours. 
Values are expressed as a percent of untreated K562 cells. Significance was determined 
using one-way ANOVA with Dunnett’s post-test (error bars are ±S.E.M, N=3).  
B) Representative images of live K562 cells transfected with E-cMTS and treated with 
imatinib, α-tocopherol, or NAC compared to MitoTracker Red CM-H2XRos staining. Scale 
bar is 5 µm. (mean thresholded PCC values are ±S.E.M, N=3)  
C) Mitochondrial association of the E-cMTS or E-cMTS-SY in K562 cells after 24 hours of 
treatment with imatinib (10 µM) or E-cMTS with α-tocopherol (50 μM) and N-
acetylcysteine (NAC; 300 µM and 5 mM). The imatinib induced ROS in K562 cells 
corresponds to the increased mitochondrial accumulation of both E-cMTS and E-cMTS-SY 
(mutant with PKC phosphorylation site only). Likewise, α-tocopherol and 5 mM NAC 
treated cells demonstrated lower overall mitochondrial association which corresponds to 
lower ROS levels. Statistical analysis for the E-cMTS transfected groups was (A and C): 
one-way ANOVA with Tukey’s post-test and E-cMTS-SY group (C): two-tailed unpaired 





















could modulate the mitochondrial localization of a mutant cMTS via tyrosine 
phosphorylation. However, Bcr-Abl does not activate the mutant cMTSs (Fig. 3.5B, 5th 
column to the right (E-cMTS-TY does not accumulate in the mitochondria of Bcr-Abl 
positive K562 cells) and Fig. 3.6C, 7th column (the kinase inhibitor imatinib does not 
prevent the mitochondrial accumulation of E-cMTS-SY)). Mutating the PKA 
phosphorylation site, S189 to tyrosine and further altering the three residues proceeding the 
serine at position at 189 (E-cMTS-SY, see Table 3.1, underlined) did not have an effect on 
mitochondrial localization in either 1471.1 or K562 cells as compared to E-cMTS (Fig. 
3.5B, compare 1st and 2nd  set of columns). However, the T193Y mutation (E-cMTS-TY), 
interrupting the PKC phosphorylation site, ablated mitochondrial localization in both K562 
and 1471.1 cell lines (Fig. 3.5B, compare 1st and 3rd set of columns). The cMTS mutant 
data implicate PKC, and not PKA, as a critical activator of the cMTS in K562 leukemia and 
1471.1 breast cancer cell lines. Qualitatively, the differences in mitochondrial localization 
between the E-cMTS-SY (Fig. 3.5A, top two rows) and E-cMTS-TY (Fig. 3.5A, bottom 
two rows) mutants in K562 and 1471.1 cells can be seen. Instead of tyrosine mutations we 
also tested alanine mutations (as done previously (15)) at positions 189 and 193 and 
obtained similar results (data not shown). 
 
ROS and mitochondrial localization 
of the E-cMTS in K562 cells 
 It is well established that imatinib (IM) treatment induces ROS production (37). 
Imatinib treatment (10 µM) produced a 160% rise in ROS after 24 hours in K562 cells 
(versus untreated K562 cells, Fig. 3.6A, compare 2nd to 1st column). The converse was 
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seen with antioxidant treatment, using either 50 µM α-tocopherol (α-Toc) or 5 mM N-
acetylcysteine (NAC) for 24 hours, which brought about a decline (~30%) in measured 
ROS relative to control K562 (Fig. 3.6A, compare 3rd and 4th columns to 1st). A 
concentration of 300 µM NAC was also used in K562 cells but it did not result in a 
significant decrease in ROS (Fig. 3.6A, 5th column). In addition to its antioxidant effects, 
α-tocopherol also has an independent inhibitory effect on PKC family members (38). 
Previously, a physiological concentration of α-tocopherol (50 μM) reduced phorbol ester-
stimulated cell adhesion in K562 cells to the same degree as a specific PKC inhibitor, 
Calphostin C (39). Hydrogen peroxide (500 µM, 24 hours), as a positive control, 
generated a 3-fold induction of ROS (data not shown) above that of untreated K562 cells. 
  Imatinib and antioxidant treatment altered E-cMTS mitochondrial localization 
corresponding to the assessed ROS levels (compare Fig. 3.6A, for the ROS level 
difference between imatinib- and antioxidant-treated K562 and corresponding degree of 
mitochondrial localization in Fig. 3.6C). Correlation analysis between E-cMTS 
mitochondrial localization and ROS level (Fig. 3.7) generated an R2 = 0.62 (P<0.05) 
across each cell type and K562 cells treated with imatinib and antioxidants. The 
correlation between E-cMTS mitochondrial localization and basal ROS level for the 
1471.1 breast cancer cell line falls outside of the 95% confidence band (dotted lines). 
This is not unexpected as high PKC activity or expression is associated with rapidly 
proliferating breast cancer cell lines (40). Higher mitochondrial localization of E-cMTS 
(PCC: 0.89 ± 0.01) was seen with imatinib while α-tocopherol (PCC: 0.50 ± 0.02) 
lowered E-cMTS mitochondrial localization as compared to untreated (PCC: 0.78 ± 0.02) 




Figure 3.7. Correlation analysis between ROS level and the ‘degree of colocalization’. 
Correlation analysis demonstrated a positive correlation between ROS level and 
mitochondrial localization of the E-cMTS. Since PKC mediates the ROS activation of the 
E-cMTS an altered ROS-to-mitochondrial localization relationship for E-cMTS, is to be 
expected to be contingent upon the varying level of PKC expression and activity of PKC 
within a given cell type. The R2 shown in the graph represents all points with the dotted 
lines indicating the 95% confidence interval. The R2 value for K562 data points only was 




decreased mitochondrial association when treated with either 5 mM NAC (Fig 3.6C, 4th 
column (PCC: 0.49±0.04)) or 300 µM NAC (Fig. 3.6C, 5th column (PCC: 0.60 ± 0.02)). 
The imatinib-related increase in mitochondrial association was also seen with the E-
cMTS-SY mutant (Fig 3.6C, compare 6th and 7th columns) but not with the E-cMTS-TY 
mutant which remained cytoplasmic (PCC: 0.35 ± 0.2 and 0.23 ± 0.2, with and without 
imatinib, respectively) in K562 cells. There was no difference in the mitochondrial 
distribution of E-cMTS-TY in imatinib-treated and untreated K562 cells. The E-cMTS-
SY mutant is exclusively phosphorylated by PKC at the T193 position (15). The contrast 
in mitochondrial localization between the E-cMTS-SY and E-cMTS-TY mutants, in the 
presence of imatinib, further clarifies the relative importance of PKC- over PKA-
mediated activation of the cMTS by antineoplastic-induced ROS.  
 As noted above, the mutants incorporating the minimal c-Abl tyrosine kinase 
consensus sequence (either at or around residue position 189 (E-cMTS-SY) or 193 (E-
cMTS-TY); Table 3.1) are not targeted to the mitochondria by the activity of Bcr-Abl (c-
Abl). This is confirmed by the increased mitochondrial colocalization of the E-cMTS-SY 
in the presence of the tyrosine kinase inhibitor, imatinib at a saturating concentration of 
10 μM. Representative images of E-cMTS mitochondrial localization in K562 cells upon 
imatinib (Fig. 3.6B, top row), α-tocopherol (Fig. 3.6B, middle row), or N-acetylcysteine 







Abl-E-cMTS selectively targets the 
mitochondria of cells with higher 
oxidative backgrounds 
 The c-Abl protein was fused to the N-terminus of the cMTS (Abl-E-cMTS) (see 
Fig. 3.4) and transiently transfected into K562, Cos-7, and 1471.1 cells. The Abl-E 
construct (no MTS) was used as a negative control in K562 (Fig. 3.8A, top row and 3.8B, 
first column) and Cos-7 cells (PCC: -0.26±0.06). The c-Abl fusion to the cMTS 
colocalized with the mitochondria in K562 and 1471.1 cells similar to cMTS alone 
(compare Fig. 3.2C, 1st and 3rd columns with Fig. 3.8B, 2nd and 4th columns). This was 
not expected for the c-Abl-E-cMTS because c-Abl has many cytosolic and nuclear 
binding partners (41). Also, as with the cMTS alone the Abl-E-cMTS remained cytosolic 
in Cos-7 cells (Fig. 3.2C, 2nd row (PCC = 0.18±0.06) and Fig. 3.8B, 3rd row (PCC = 
0.13±0.08), respectively). 
 The same C-terminal canonical MTS derived from Bcl-XL as used above, was 
also fused to c-Abl-E (Fig. 3.3) as a control for mitochondrial translocation efficiency of 
c-Abl across cell types and to assess of functional consequences accompanying ROS 
selective mitochondrial targeting via the cMTS. Although there was a significant 
difference in mitochondrial colocalization coefficients between K562 and Cos-7 (Fig. 
3.8D, compare 1st and 2nd columns; P<0.05), the PCC values for all three cell lines 
exceeded the 0.6 colocalization threshold for Abl-E-MOM. Importantly, there was no 
difference between E-MOM and Abl-E-MOM colocalization for any of the cell lines as 




Figure 3.8. The cMTS selectively targets c-Abl to the mitochondria of cells that have 
elevated oxidative backgrounds.  
A) Abl-E-cMTS and Abl-E were compared to MitoTracker Red CM-H2XRos staining in 
live cells. EGFP and MitoTracker channels were false-colored cyan and magenta, 
respectively, for increased visual clarity. Scale bar is 5 µm. (mean thresholded PCC 
values are ±S.E.M, N=3)  
B) Abl-E-cMTS localized to the mitochondria of 1471.1 and K562 but not Cos-7 cells. 
Without the cMTS, Abl-E does not localize to the mitochondria of K562 cells.  
C & D) In contrast to the cMTS, the MOM robustly directs c-Abl to the mitochondria of 
each cell type. C) Representative images of K562, Cos-7, and 1471.1 cells transfected 
with Abl-E-MOM construct at 24 hours. One-way ANOVA with Tukey’s post-test (error 



























E-MOM and stained with MitoTracker CMXros showing mitochondrial localization can 
be seen in Figure 3.8C. 
 
Targeting c-Abl to the mitochondrial matrix 
is toxic to K562 leukemia but not  
1471.1 breast cancer cell lines 
 To assess the functional significance at the level of cell death induction from 
mitochondrial c-Abl, cell lines were transiently transfected with the c-Abl-containing 
constructs or controls (Fig. 3.3), stained with 7-AAD, and fluorescence measured via 
flow cytometry at 48 hours after transfection. The effects of the constructs were analyzed 
for each cell type (Fig. 3.9, A-C). First, there was no difference between any of the 
constructs and measured cell death in Cos-7 cells (Fig. 3.9B). Secondly, 1471.1 cells 
(Fig. 3.9C) did not exhibit any significant difference in cell death between cytoplasmic c- 
Abl (i.e., Abl-E) and mitochondrially localized c-Abl (i.e., Abl-E-MOM and Abl-E-
cMTS). Finally, K562 cells (Fig. 3.9A) are killed by mitochondrial c-Abl but only if 
targeted to the matrix (Abl-E-cMTS). Targeting c-Abl to the outer membrane induces 
death to the same level as either cytoplasmic c-Abl (Abl-E) or the cMTS alone (E-
cMTS). A kinase dead mutant (25) of c-Abl (Abl-E-cMTS KD) trended lower but did not 
reach significance from Abl-E-cMTS nor was it different from cytoplasmic Abl-E. Taken 
together the data suggest a cell type dependent susceptibility to the cell death effects of c-
Abl targeted to the mitochondrial matrix. Although there is no statistical difference 
between the EGFP control and the E-cMTS (Fig. 3.9A, compare 1st and 2nd columns) in 
K562 cells, this "trend" in mild toxicity associated with the mitochondrial targeting of  
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Figure 3.9. c-Abl selectively induces cell death in K562 leukemia cells when targeted to 
the mitochondrial matrix.  
A) K562 leukemia cells: K562 leukemia cells were highly susceptible to cell death caused 
by c-Abl in the mitochondrial matrix (Abl-E-cMTS) but not at the mitochondrial outer 
membrane (Abl-E-MOM).  
B) Cos-7 fibroblast cells: In Cos-7 cells, neither cytoplasmic nor mitochondrially targeted 
c-Abl induced cell death.  
C) 1471.1 breast cancer cells: There was an increase (P<0.01) in cell death for Abl-E-
cMTS over the ‘non-toxic’ EGFP and E-MOM controls in 1471.1 cells. However, there 
was no difference between the mitochondrially localized c-Abl and cMTS. (B-D: One-









EGFP regardless of MTS is a common occurrence that we have noticed in several of our 
studies across multiple cell types (42). This trend, when viewed between K562 and 
1471.1 cells (Fig. 3.9, A and C) may be indicative of a phenomenon termed 
‘mitochondrial priming’ whereby the mitochondria set the cell death threshold via a 
balance between pro-survival and pro-apoptotic Bcl-2 family members, in a rheostat like 
manner (43). Cell death exhibited across constructs in 1471.1 cells was lower than 
expected (as compared to K562). However, overall profiles for cell death between K562 
and 1471.1 look very similar but the scale of cell death is reduced in 1471.1 cells. It is 
possible that the mitochondria of K562 cells are more susceptible to a mitochondrial 
insult such as c-Abl. Future studies investigating the level of ‘primed’ mitochondrial 
status between K562 and 1471.1 would be very useful for optimizing therapeutic agents 
targeted to the mitochondria. 
 This study represents (to our knowledge) the first time c-Abl has been directly 
targeted to the mitochondria (instead of indirectly by a pharmacological or UV/IR insult). 
Furthermore, we show that c-Abl may exert its pro-apoptotic effect at the mitochondrial 
matrix. Our laboratory has developed an intracellular chaperone designed to bind and 
target the oncoprotein Bcr-Abl to the mitochondria. This study served as a proof of 
concept for using the central etiologic agent of chronic myelogenous leukemia (Bcr-Abl) 
to, in essence, self-destruct the diseased cells via the mitochondrial apoptotic pathway. 
 
 Our laboratory has previously developed a protein switch capable of translocating 
a protein from the cytoplasm to the nucleus upon ligand induction (
Discussion 
44). Here we show 
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that, the cMTS acts as a mitochondrial protein switch, translocating from the cytoplasm 
to the mitochondria as a condition of elevated ROS inherent in K562 leukemic and 
1471.1 breast cancer line phenotypes. The C-terminal cMTS is particularly useful for 
targeting the sensitive proto-oncoprotein c-Abl to the mitochondria of K562 cells because 
any fusion to the N-terminus will disrupt the ability of c-Abl to adopt its native 
conformation (45). The fusion of the BCR gene to the ABL gene creates Bcr-Abl, 
etiological cause of chronic myelogenous leukemia, disrupting c-Abl’s autoinhibitory 
conformation and generating a constitutively active Abl tyrosine kinase (45). The kinase 
activity of c-Abl is necessary and sufficient for the induction of apoptosis and c-Abl has a 
critical role at the mitochondria in apoptotic induction (46, 47). Previous studies of c-Abl 
translocating to the mitochondria have been indirect, through the induction of 
apoptosis/cell stress (e.g., hydrogen peroxide, etoposide, tunicamycin (46)). This study 
investigated the in vitro cell death consequences of direct mitochondrial targeting of c-
Abl using MTSs in the context of varying levels of basal oxidative stress. 
  Likewise, protein kinase stimulators (e.g., cAMP and phorbol ester) were used 
previously for activating the mitochondrial targeting of the cMTS fused to a heteroprotein 
(dihydrofolate reductase) in Cos cells (15). However, we demonstrate that the cMTS can 
robustly target the mitochondria of K562 and 1471.1 cancer cell lines without 
pharmacological induction. Therefore, the cMTS may confer specific targeting of 
heteroproteins (c-Abl) to the mitochondria in cells exhibiting elevated ROS/PKC activity. 
Further work will need to be done to identify which PKC isoforms are contributing the 
phosphorylation of the cMTS and if these are the same isoforms that are often 
overexpressed in cancer (e.g., breast). Yet, the mitochondrial targeting of the cMTS can 
151 
 
be attenuated or enhanced by antioxidant or antineoplastic treatment, respectively. We 
are interested in elucidating the functional consequences of targeting c-Abl to the 
mitochondria in a leukemia-specific context, and the cMTS provides an effective way to 
accomplish this in a selective manner. To this end, we were intrigued to find the 
difference in cell death induction efficacy between c-Abl targeted to the mitochondrial 
matrix versus the outer membrane of the leukemia cell line. A similar cell death 
phenomenon occurred when p53 was directly targeted to the mitochondrial matrix and 
outer membrane using MTSs (48). There may be a correspondence between susceptibility 
to cell death when c-Abl is localized to the mitochondrial matrix and ROS level (1). 
However, this will require further investigation. 
 We used the cMTS as a vehicle to selectively deliver c-Abl under conditions of 
oxidative stress in a cancer context but the implications of the cMTS utility could be 
expanded upon. For instance, c-Abl’s role at the mitochondria is currently being 
investigated in other conditions with pathological ROS such as neurodegenerative disease 
(49) and diabetes (50). Additionally, the cMTS may be of benefit to selectively target 
either pro-apoptotic or pro-survival factors (e.g., BH3 mimetics or antioxidant enzymes) 
to the mitochondria to elicit or prevent cell death, respectively. 
 Considering future directions, if the Abl-cMTS were delivered in vivo, perhaps 
via adenoviral vector delivery, it would confer a level of selectivity for mitochondrial 
accumulation in cells with elevated oxidative stress. Additionally, our results indicate that 





 We acknowledge the use of the University of Utah, School of Medicine, Cell 
Imaging Facility and would like to thank the Director, Chris Rodesch, PhD, for scientific 
discussions. We would also like to thank Karina Matissek, Geoffrey Miller, and Dr. Andy 
Dixon for scientific discussions. The Core Facilities described in this project were 
supported by Award Number P30CA042014 from the National Cancer Institute. The 
content is solely the responsibility of the authors and does not necessarily represent the 
official views of the National Cancer Institute or the National Institutes of Health. The 
authors declare that they have no competing interests. This work was funded by NIH 














1. S.J. Ralph, S. Rodriguez-Enriquez, J. Neuzil, E. Saavedra, and R. Moreno-
Sanchez. The causes of cancer revisited: "mitochondrial malignancy" and ROS-
induced oncogenic transformation - why mitochondria are targets for cancer 
therapy. Mol Aspects Med. 31:145-170 (2010). 
References 
 
2. G. Szabadkai and R. Rizzuto. Chaperones as parts of organelle networks. Adv 
Exp Med Biol. 594:64-77 (2007). 
 
3. M. Certo, V. Del Gaizo Moore, M. Nishino, G. Wei, S. Korsmeyer, S.A. 
Armstrong, and A. Letai. Mitochondria primed by death signals determine 
cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 9:351-
365 (2006). 
 
4. J.Y. Wang. Nucleo-cytoplasmic communication in apoptotic response to 
genotoxic and inflammatory stress. Cell Res. 15:43-48 (2005). 
 
5. Y. Ito, P. Pandey, N. Mishra, S. Kumar, N. Narula, S. Kharbanda, S. Saxena, and 
D. Kufe. Targeting of the c-Abl tyrosine kinase to mitochondria in endoplasmic 
reticulum stress-induced apoptosis. Mol Cell Biol. 21:6233-6242 (2001). 
 
6. M. Gupta, L. Milani, M. Hermansson, B. Simonsson, B. Markevarn, A.C. 
Syvanen, and G. Barbany. Expression of BCR-ABL1 oncogene relative to ABL1 
gene changes overtime in chronic myeloid leukemia. Biochem Biophys Res 
Commun. 366:848-851 (2008). 
 
7. A. Sirvent, C. Benistant, and S. Roche. Cytoplasmic signalling by the c-Abl 
tyrosine kinase in normal and cancer cells. Biol Cell. 100:617-631 (2008). 
 
8. S. Kumar, A. Bharti, N.C. Mishra, D. Raina, S. Kharbanda, S. Saxena, and D. 
Kufe. Targeting of the c-Abl tyrosine kinase to mitochondria in the necrotic cell 
death response to oxidative stress. J Biol Chem. 276:17281-17285 (2001). 
 
9. X. Qi and D. Mochly-Rosen. The PKCdelta -Abl complex communicates ER 
stress to the mitochondria - an essential step in subsequent apoptosis. J Cell Sci. 
121:804-813 (2008). 
 
10. M. Salvi, A.M. Brunati, and A. Toninello. Tyrosine phosphorylation in 
mitochondria: a new frontier in mitochondrial signaling. Free Radical Biology & 
Medicine. 38:1267-1277 (2005). 
 
11. S. Kumar, N. Mishra, D. Raina, S. Saxena, and D. Kufe. Abrogation of the cell 
death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571. 




12. C. Horbinski and C.T. Chu. Kinase signaling cascades in the mitochondrion: a 
matter of life or death. Free Radical Biology & Medicine. 38:2-11 (2005). 
 
13. M.C. Sangar, S. Bansal, and N.G. Avadhani. Bimodal targeting of microsomal 
cytochrome P450s to mitochondria: implications in drug metabolism and toxicity. 
Expert Opin Drug Metab Toxicol. 6:1231-1251 (2010). 
 
14. A. Quintas-Cardama and J. Cortes. Molecular biology of bcr-abl1-positive 
chronic myeloid leukemia. Blood. 113:1619-1630 (2009). 
 
15. M.A. Robin, S.K. Prabu, H. Raza, H.K. Anandatheerthavarada, and N.G. 
Avadhani. Phosphorylation enhances mitochondrial targeting of GSTA4-4 
through increased affinity for binding to cytoplasmic Hsp70. J Biol Chem. 
278:18960-18970 (2003). 
 
16. H. Raza, M.A. Robin, J.K. Fang, and N.G. Avadhani. Multiple isoforms of 
mitochondrial glutathione S-transferases and their differential induction under 
oxidative stress. Biochemical J. 366:45-55 (2002). 
 
17. S.C. Gupta, D. Hevia, S. Patchva, B. Park, W. Koh, and B.B. Aggarwal. Upsides 
and downsides of reactive oxygen species for cancer: the roles of reactive oxygen 
species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal. 
16:1295-322 (2012). 
 
18. J.S. Bair, R. Palchaudhuri, and P.J. Hergenrother. Chemistry and biology of 
deoxynyboquinone, a potent inducer of cancer cell death. J Am Chem Soc. 
132:5469-5478 (2010). 
 
19. J.H. Kim, S.C. Chu, J.L. Gramlich, Y.B. Pride, E. Babendreier, D. Chauhan, R. 
Salgia, K. Podar, J.D. Griffin, and M. Sattler. Activation of the PI3K/mTOR 
pathway by BCR-ABL contributes to increased production of reactive oxygen 
species. Blood. 105:1717-1723 (2005). 
 
20. M. Sattler, S. Verma, G. Shrikhande, C.H. Byrne, Y.B. Pride, T. Winkler, E.A. 
Greenfield, R. Salgia, and J.D. Griffin. The BCR/ABL tyrosine kinase induces 
production of reactive oxygen species in hematopoietic cells. J Biol Chem. 
275:24273-24278 (2000). 
 
21. S.P. Chang, S.C. Shen, W.R. Lee, L.L. Yang, and Y.C. Chen. Imatinib mesylate 
induction of ROS-dependent apoptosis in melanoma B16F0 cells. J Dermatol Sci. 
62:183-191 (2011). 
 
22. N.S. Brown and R. Bicknell. Hypoxia and oxidative stress in breast cancer. 
Oxidative stress: its effects on the growth, metastatic potential and response to 




23. M. Morse-Gaudio, J.M. Connolly, and D.P. Rose. Protein kinase C and its 
isoforms in human breast cancer cells: relationship to the invasive phenotype. Int 
J Oncol. 12:1349-1354 (1998). 
 
24. A.S. Dixon, M. Kakar, K.M. Schneider, J.E. Constance, B.C. Paullin, and C.S. 
Lim. Controlling subcellular localization to alter function: Sending oncogenic 
Bcr-Abl to the nucleus causes apoptosis. J Control Release. 140:245-249 (2009). 
 
25. H.S. Ko, Y. Lee, J.H. Shin, S.S. Karuppagounder, B.S. Gadad, A.J. Koleske, O. 
Pletnikova, J.C. Troncoso, V.L. Dawson, and T.M. Dawson. Phosphorylation by 
the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective 
function. Proc Natl Acad Sci U S A. 107:16691-16696 (2010). 
 
26. A.S. Dixon, J.E. Constance, T. Tanaka, T.H. Rabbitts, and C.S. Lim. Changing 
the subcellular location of the oncoprotein Bcr-Abl using rationally designed 
capture motifs. Pharm Res. 29(4):1098-109 (2012). 
 
27. W.S. Rasband. BG subtraction from ROI plugin. Available from: 
www.uhnres.utoronto.ca/facilities/wcif/imagej/image_intensity_proce.htm#intensi
ty_BG.  (2004). 
 
28. S. Bolte and F.P. Cordelieres. A guided tour into subcellular colocalization 
analysis in light microscopy. J Microsc. 224:213-232 (2006). 
 
29. S.V. Costes, D. Daelemans, E.H. Cho, Z. Dobbin, G. Pavlakis, and S. Lockett. 
Automatic and quantitative measurement of protein-protein colocalization in live 
cells. Biophys J. 86:3993-4003 (2004). 
 
30. A.L. Barlow, A. Macleod, S. Noppen, J. Sanderson, and C.J. Guerin. 
Colocalization analysis in fluorescence micrographs: verification of a more 
accurate calculation of pearson's correlation coefficient. Microsc Microanal. 
16:710-724 (2010). 
 
31. F. Jaskolski, C. Mulle, and O.J. Manzoni. An automated method to quantify and 
visualize colocalized fluorescent signals. J Neurosci Methods. 146:42-49 (2005). 
 
32. A.S. Dixon, G.D. Miller, B.J. Bruno, J.E. Constance, D.W. Woessner, T.P. Fidler, 
J.C. Robertson, T.E. Cheatham, and C.S. Lim. Improved coiled-coil design 
enhances interaction with bcr-abl and induces apoptosis. Mol Pharm. 9:187-195 
(2012). 
 
33. M.G. Mediavilla, G.A. Di Venanzio, E.E. Guibert, and C. Tiribelli. Heterologous 
ferredoxin reductase and flavodoxin protect Cos-7 cells from oxidative stress. 




34. T.W. Owens, A.J. Valentijn, J.P. Upton, J. Keeble, L. Zhang, J. Lindsay, N.K. 
Zouq, and A.P. Gilmore. Apoptosis commitment and activation of mitochondrial 
Bax during anoikis is regulated by p38MAPK. Cell Death Differ. 16:1551-1562 
(2009). 
 
35. T. Kaufmann, S. Schlipf, J. Sanz, K. Neubert, R. Stein, and C. Borner. 
Characterization of the signal that directs Bcl-x(L), but not Bcl-2, to the 
mitochondrial outer membrane. J Cell Biol. 160:53-64 (2003). 
 
36. A. Biegert, C. Mayer, M. Remmert, J. Soding, and A.N. Lupas. The MPI 
Bioinformatics Toolkit for protein sequence analysis. Nucleic Acids Res. 
34:W335-339 (2006). 
 
37. S.P. Chang, S.C. Shen, W.R. Lee, L.L. Yang, and Y.C. Chen. Imatinib mesylate 
induction of ROS-dependent apoptosis in melanoma B16F0 cells. J Dermatol Sci. 
62:183-191 (2011). 
 
38. R. Ricciarelli, A. Tasinato, S. Clement, N.K. Ozer, D. Boscoboinik, and A. Azzi. 
alpha-Tocopherol specifically inactivates cellular protein kinase C alpha by 
changing its phosphorylation state. Biochem J. 334 ( Pt 1):243-249 (1998). 
 
39. I. Breyer and A. Azzi. Differential inhibition by alpha- and beta-tocopherol of 
human erythroleukemia cell adhesion: role of integrins. Free Radical Biology & 
Medicine. 30:1381-1389 (2001). 
 
40. G.K. Lonne, L. Cornmark, I.O. Zahirovic, G. Landberg, K. Jirstrom, and C. 
Larsson. PKCalpha expression is a marker for breast cancer aggressiveness. Mol 
Cancer. 9:76 (2010). 
 
41. A. Mitra and V. Radha. F-actin-binding domain of c-Abl regulates localized 
phosphorylation of C3G: role of C3G in c-Abl-mediated cell death. Oncogene. 
29:4528-4542 (2010). 
 
42. M. Mossalam, K.J. Matissek, A. Okal, J.E. Constance, and C.S. Lim. Direct 
induction of apoptosis using an optimal mitochondrially targeted P53. Mol Pharm. 
9:1449-58 (2012). 
 
43. J.C. Reed. Cancer. Priming cancer cells for death. Science. 334:1075-1076 
(2011). 
 
44. M. Kakar, J.R. Davis, S.E. Kern, and C.S. Lim. Optimizing the protein switch: 
altering nuclear import and export signals, and ligand binding domain. J Control 
Release. 120:220-232 (2007). 
 
45. O. Hantschel and G. Superti-Furga. Regulation of the c-Abl and Bcr-Abl tyrosine 




46. X. Qi and D. Mochly-Rosen. The PKCdelta -Abl complex communicates ER 
stress to the mitochondria - an essential step in subsequent apoptosis. J Cell Sci. 
121:804-813 (2008). 
 
47. Y. Ito, P. Pandey, N. Mishra, S. Kumar, N. Narula, S. Kharbanda, S. Saxena, and 
D. Kufe. Targeting of the c-Abl tyrosine kinase to mitochondria in endoplasmic 
reticulum stress-induced apoptosis. Mol Cell Biol. 21:6233-6242 (2001). 
 
48. G. Palacios, H.C. Crawford, A. Vaseva, and U.M. Moll. Mitochondrially targeted 
wild-type p53 induces apoptosis in a solid human tumor xenograft model. Cell 
Cycle. 7:2584-2590 (2008). 
 
49. S.D. Schlatterer, C.M. Acker, and P. Davies. c-Abl in neurodegenerative disease. 
J Mol Neurosci. 45:445-52 (2011). 
 
50. R. Hagerkvist, S. Sandler, D. Mokhtari, and N. Welsh. Amelioration of diabetes 
by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-















ENHANCED AND SELECTIVE KILLING OF CHRONIC 
MYELOGENOUS LEUKEMIA CELLS WITH AN 
ENGINEERED BCR-ABL BINDING 





  The oncoprotein Bcr-Abl stimulates pro-survival pathways and suppresses 
apoptosis from its exclusively cytoplasmic locale (1), but when forced to the mitochondrial 
compartment of leukemia cells, Bcr-Abl was potently cytotoxic. Therefore, we designed a 
protein construct to act as a mitochondrial chaperone to move Bcr-Abl to the mitochondria. 
The chaperone (i.e., intracellular cryptic escort (iCE)) consists of two previously characterized 
motifs: 1) An optimized Bcr-Abl binding motif that interacts with the coiled-coil domain of 
Bcr (2), and 2) A cryptic mitochondrial targeting signal that selectively targets the 
mitochondria in oxidatively stressed cells (i.e., Bcr-Abl positive leukemic cells) via 
phosphorylation at a key residue (T193) by protein kinase C (3). While the iCE colocalized 
with Bcr-Abl it did not significantly re-localize to the mitochondria. However, the iCE was 
selectively toxic to Bcr-Abl positive K562 cells as compared to Bcr-Abl negative Cos-7 
                                                             
Reprinted with permission from J.E. Constance, D.W. Woessner, K.J. Matissek, M. 
Mossalam, and C.S. Lim. Enhanced and Selective Killing of Chronic Myelogenous Leukemia 
Cells with an Engineered Bcr-Abl Binding Protein and Imatinib. Molecular pharmaceutics 
(2012). Copyright 2012 American Chemical Society. 
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fibroblasts and 1471.1 murine breast cancer cells.  The toxicity of the iCE to leukemic cells 
was equivalent to 10 µM imatinib at 48 hours and the iCE combined with imatinib potentiated 
cell death beyond imatinib or the iCE alone. Substitution of either the ccmut3 or the cMTS 
with another Bcr-Abl binding domain (derived from the tight binding Ras/Rab interaction 
protein 1 (RIN1)) or MTS (i.e., the canonical IMS derived from Smac/Diablo) could not 
recapitulate the cytotoxicity of the iCE. Additionally, a phosphorylation null mutant of the 
iCE also abolished the cytotoxic effect. The mitochondrial toxicity of Bcr-Abl and the iCE in 
Bcr-Abl positive K562 leukemia cells was confirmed by flow cytometric analysis of 7-AAD, 
TUNEL, and annexin-V staining. DNA segmentation and cell viability were assessed by 
microscopy. Subcellular localization of constructs was determined using confocal microscopy 
(including statistical colocalization analysis) (3). Figure 4.1 is the graphical abstract. 
 
  The fusion oncoprotein, and constitutively active tyrosine kinase, Bcr-Abl 
(autoinhibition of c-Abl kinase activity is lost in Bcr-Abl fusion) is the central etiologic agent 
of chronic myelogenous leukemia (CML) and is exclusively localized in the cytoplasmic 
space at the plasma membrane through interactions with cytoskeletal actin (
Introduction 
1). Forcing a 
change in Bcr-Abl’s subcellular location can change Bcr-Abl from an oncogenic agent into a 
pro-apoptotic factor (4, 5).  
  Normal c-Abl fulfills a terminal role as a pro-apoptotic factor when targeted to the 
mitochondria under a variety of cellular insults (6, 7). We previously demonstrated that direct 








Abl to the mitochondria would reinstate a version of death-directed mitochondrial c-Abl that 
is largely defunct in CML cells (8, 9). In this paper, as with c-Abl (3), the direct mitochondrial 
targeting of Bcr-Abl (by fusion to canonical MTSs targeting the mitochondrial matrix (10), 
inner mitochondrial membrane (11), and the intermitochondrial membrane space (12)) was 
potently cytotoxic. 
  In light of this, we designed a small protein, the intracellular cryptic escort (iCE), 
for the purpose of capturing and translocating Bcr-Abl to the mitochondria. The Bcr-Abl 
capture motif employed for the iCE, was a previously optimized coiled-coil (i.e., the ccmut3) 
(2) which demonstrated both the ability to bind and, when fused to four nuclear localization 
signals (NLS), move endogenous Bcr-Abl to the nucleus (13). The ccmut3 oligomerizes with 
the coiled-coil domain of the Bcr portion of Bcr-Abl while possessing a reduced affinity for 
homodimer formation (2). Since coupling the ccmut3 with a targeting signal (i.e., NLS) 
efficiently relocalized endogenous Bcr-Abl (to the nucleus), we paired the ccmut3 with a 
‘cryptic’ mitochondrial targeting signal (cMTS) (3) to operate on a similar principle.  
  Despite the lack of iCE/Bcr-Abl mitochondrial localization the iCE alone was 
selectively toxic to Bcr-Abl positive K562 cells to the same degree as 10 µM imatinib at 48 
hours. The killing capacity of the iCE was ablated by substitution of either the ccmut3 (with 
the Bcr-Abl binding domain of Ras and Rab interactor 1 (RIN1-BD) (14)) or the cMTS (with 
the canonical intermitochondrial membrane space targeting sequence (IMS) from 
Smac/Diablo (12)) in two ‘mock’ iCEs, the RIN-cMTS or the IMS-ccmut3, respectively. The 
combination of the iCE with imatinib was the most potent inducer of leukemic cell death. This 
work demonstrates the selective and enhanced killing of Bcr-Abl positive cells by a designed 
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Bcr-Abl coiled-coil interacting protein where phosphorylation (via PKC or PKA) is coincident 




Materials and methods 
Subcloning and construction of plasmids 
  pEGFP-Bcr-Abl was constructed as previously (5). Bcr-Abl DNA was also cloned 
into pmCherry-C1 (Clonetech, Mountain View, CA, USA) and pTagBFP-C (Evrogen, 
Moscow, Russia) at the EcoR1 site on both vectors creating pmCherry-Bcr-Abl and pBFP-
Bcr-Abl, respectively. The pOTC-EGFP-Bcr-Abl was created using an oligonucleotide 
encoding the MTS from OTC (incorporating the Kozak sequence), 5′-
CCGGTCGCCACCATGCTGTTTAATCTGAGGATCCTGTTAAACAATGCAGCTTTTAG
AAATGGTCACAACTTCATGGTTCGAAATTTTCGGTGTGGACAACCACTACAAAAT
AAAGTGCAGCGA-3′ which was annealed to its complementary strand and subsequently 
cloned into the Age1 site of EGFP-Bcr-Abl. The pIMS-EGFP-Bcr-Abl, pIMS-EGFP, and 
pIMS-EGFP-ccmut3 were made by annealing and ligating four oligonucleotides encoding the 
Kozak sequence and IMS signal (1: (5’phosphorylated) 5’-CCGGTGCCACCATGAGAAGC 
GTGTGCAGCCTGTTCAGATACAGACAGAGATTCCCCGTGCTGGCCAACAGCAA – 
3’, 2: 5’- GAAGAGATGCTTCAGCGAGCTGATCAAGCCCTGGCACAAGACCGTGCT 
GACCGGCTTCGGCATGACCCTGTGCGCCGTGCCCATCGGA-3’, 3: 5’- TGCCACCAT 
GAGAAGCGTGTGCAGCCTGTTCAGATACAGACAGAGATTCCCCGTGCTGGCCAAC




GACCGG-3’) followed by insertion into the Age1 site of pEGFP-Bcr-Abl, pEGFP, or 
pEGFP-ccmut3 (2), respectively. The inner mitochondrial membrane targeting sequence 
(IMM) was incorporated into the pIMM-EGFP-Bcr-Abl and pIMM-EGFP by annealing the 5’ 
phosphorylated oligonucleotide encoding the Kozak sequence and IMM signal, 5’-
CCGGTCGCCACCATGTCCGTCCTGACGCCGCTGCTGCTGCGGGGCTTGACAGGCT
CGGCCCGGCGGCTCCCAGTGCCGCGCGCCAAGATCCATTCGTTGA-3’ with its 
reverse compliment followed by ligation into the Age1 site of pEGFP-Bcr-Abl and pEGFP-
C1, respectively. The kinase dead mutant of pIMM-EGFP-Bcr-Abl (i.e., pIMM-EGFP-Bcr-
Abl-KD) was made using site directed mutagenesis with the primer 5’-
CTGACGGTGGCCGTGGCGACCTTGAAGGAGGAC-3’ and its reverse compliment. The 
pRIN-cMTS construct was made by PCR amplifying the binding domain of the human RIN1 
gene (NM_004292, OriGene, Rockville, MD, USA) with the primers 5′- GCGCGCGCGATC 
TATGGAAAGCCCTGGAGAGTCAGGCGCG-3′ and 5′- GCGCGCGAATTCCCGTACCC 
CACTGAGCTCTCCCTCCGTAGCAGCTGGC-3′ and inserted into pEGFP-cMTS using the 
BglII and EcoR1 sites. The murine glutathione S-transferase A4-4 [Swiss-Prot:P24472.3] 
cMTS (N-terminal residues, 172-222 (15); 51% sequence homology to human wherein S189 
and T193 are conserved) was constructed by annealing four oligonucleotides encoding the 
cMTS (1: (5’phosphorylated) 5’ –AATTCCGCCCCCGTGCTGAGCGACTTCCCCCTGCTG 
CAGGCCTTCAAGACCAGAATCAGCAACATCCCCACCATCAAGAAGTTCCTGCAGC
CC-3’, 2: 5’ –CTGCCGGGCTGCAGGAACTTCTTGATGGTGGGGATGTTGCTGATTCT 




ACCGTGCTGAAGTTCGGCGCCGGCTGCTGCCCCGGCTGCTGCTGA-3’, 4: (5’ 
phosphorylated) 5’ –AATTTCAGCAGCAGCCGGGGCAGCAGCCGGCGCCGAACTTCA 
GCACGGTTCTCACCACCTCCACGTAGGGGCCGTCGGGGGGGGGCTTTCTCTGG-3’) 
simultaneously and then inserting the annealed product into the multiple cloning site (MCS) of 
EGFP-C1 vector (Promega Biotech, Madison, WI), with or without the ccmut3 sequence 
present, at the EcoRI site creating pEGFP-cMTS (3) (cMTS) and pEGFP-ccmut3-cMTS 
(iCE), respectively. The pEGFP-ccmut3-cMTS null (S189A and T193A) was created using 
site-directed mutagenesis using primers, 5’- GACCAGAATCGCCAACATCCCCGCCATCA 
AGAAGTTCCTGCAGCCCGGCAGCCAGAGAA-3’ and its reverse complement. All 
constructs were verified by sequence analysis. 
 
Materials 
  RPMI-1640 medium, MitoTracker Red CM-H2XRos (MitoTracker CMXros), 
Hoechst 33342 (cell permeable nuclear stain), 7-aminoactinomycin D (7-AAD; DNA 
intercalating dye permeable in dying or dead cells), annexin-APC (annexin-V conjugated to 
allophycocyanin), staurosporine, Lipofectamine LTX with Plus Reagent, trypan blue 0.4%, 
phosphate-buffered saline (PBS), fetal bovine serum (FBS), and gentamycin were purchased 
from Invitrogen (Carlsbad, CA). Penicillin-streptomycin-L-glutamine (P-S-G; 100 U/mL), 
DMEM media, and trypsin were purchased from Gibco BRL (Grand Island, NY). The poly-L-
lysine (0.01% solution) was purchased from Sigma-Aldrich (St. Louis, MO). Imatinib (CT-
IM001) was purchased from ChemieTek (Indianapolis, IN). QuikChange II XL Site-Directed 
Mutagenesis Kit was purchased from Agilent Technologies (Santa Clara, CA). Cell Line 
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Nucleofector Kit V was purchased from Lonza Group (Basel, Switzerland). Restriction 
enzymes (EcoRI, AgeI, and BglII) were purchased from New England Biolabs (Ipswich, MA). 
 
Cell lines and culture conditions 
  As previously described (3), K562 cells (non-adherent human chronic myelogenous 
leukemia cell line), gift from Dr. K. Elenitoba-Johnson, University of Michigan, and Cos-7 
(monkey kidney fibroblast adherent cell line; ATCC) were cultured in RPMI 1640 
supplemented with 10% FBS, 1% P-S-G, and 0.1% gentamycin. Murine mammary 
adenocarcinoma 1471.1 cells, (gift from Gordon Hager, PhD, NCI, NIH) were grown as 
monolayers in DMEM supplemented with 10% FBS, 1% P-S-G and 0.1% gentamycin. K562 
cells were passaged at a density of 0.5 x 105/mL every other day, for ten passages. Cos-7 and 
1471.1 cells were passaged at 80% confluency and split 1:10 in fresh media and discontinued 
after passage 15. All cells were maintained in a 5% CO2 incubator at 37 oC. 
 
Expression of constructs in K562 leukemia, Cos-7 fibroblast, 
and 1471.1 breast cancer cells 
  Constructs were transiently transfected into K562 cells using the Amaxa 
Nucleofector II, as described previously (5). Briefly, 1 x 106 K562 cells, (initially seeded at a 
density of 0.5 x 105 cells/mL) between passages 5 to 10, were pelleted and resuspended in 100 
µL Amaxa Solution V, combined with 2 µg of DNA and transfected in an Amaxa cuvette 
under program T-013. Transfected cells were immediately transferred to a 25 cm2 flask with 7 
mL of pre-warmed complete RPMI. Transient transfection of 1471.1 and Cos-7 were carried 
out in two-well live-cell chambers (Lab-Tek chamber slide system, Nalge NUNC 
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International, Naperville, IL) or sterile 6-well tissue culture plates (Greiner CellStar, Greiner 
Bio-one GmbH) using Lipofectamine LTX as per manufacturers’ instructions between 
passages 3 and 15 in antibiotic free media. 
 
Cell proliferation 
  Trypan blue exclusion was used to determine cell proliferation (cell viability)(16) in 
K562 cells 48 hours posttransfection of EGFP-C1, cMTS, ccmut3, cMTS, and iCE, with and 
without the presence of imatinib (10 μM). 
 
Western blotting 
  As described previously (17), cell lysates were prepared by suspending 1 x 106 cells 
in 200 μL lysis buffer (62.5 mM Tris-HCl, 2% w/v SDS, 10% glycerol, 50 mM DTT, 0.01% 
w/v bromophenol blue) followed by standard western blotting procedures using antibodies to 
detect the total and/or phosphorylated forms of Bcr-Abl, Crk-L, STAT5, and elF4E as the 
protein loading control. Primary antibody labels (anti-pAbl (Y245), anti-pCrk-L (Y207), and 
anti-elF4E, Cell Signaling Technology; anti-pSTAT5 (Y694), Abcam) were detected with 
anti-rabbit (#7074, Cell Signaling Technology) HRP-conjugated secondary antibodies prior to 
the addition of ChemiGlo (AlphaInnotech, Cell Biosciences, Santa Clara, CA, USA) 
chemiluminescent substrate and detection using a FluorChem FC2 imager (AlphaInnotech). 







  As described previously (3), aliquots of transfected K562 suspension cells (400 µL) 
were plated into poly-L-lysine coated 4-well live-cell chambers at least 4 hours in advance of 
microscopy. Cells were incubated with MitoTracker Red CM-H2XRos (K562; 100 nM, Cos-7 
and 1471.1; 325 nM) for 45 minutes at 37 oC and protected from light prior to imaging. 
 
Microscopy 
  Fluorescent images of K562, Cos-7, and 1471.1 live cells were acquired on an 
Olympus IX81 FV1000-XY spectral confocal microscope (Imaging Core Facility, University 
of Utah) equipped with 405 nm diode, 488 nm argon, and 543 nm HeNe lasers using a 60X 
PlanApo oil immersion objective (NA 1.45) using Olympus FluoView software, as previously 
described (3). Excitation and emission filters were as follows: EGFP, 488 nm excitation, 
emission filter 500-530 nm; MitoTracker Red CM-H2XRos, 543 nm excitation, emission filter 
555-655 nm. Images were collected in sequential line mode with exposure and gain of laser 
kept constant and below detected pixel saturation for each group of cells. No channel crosstalk 
was observed. Pixel resolution was kept at 1024 x 1024 (0-2.5-fold digital zoom) with a pixel 
dwell time of 12.5 µs. Imaging of K562 cells for the analysis of DNA segmentation was 
acquired on an Olympus IX71F fluorescence microscope (Scientific Instrument Company, 
Aurora, CO) with a 60X PlanApo oil immersion objective (NA 1.4) on an F-view 
monochrome CCD camera. K562 cells were stained with the nuclear dye Hoechst 33342 






  Images were analyzed as described previously (3). Briefly, original images were 
converted to 8-bit, then stacked as separate channels, and corrected for background noise 
using ImageJ plugin ‘BG subtraction from background’ in default mode (i.e., mean 
background intensity outside of cells was subtracted) (18). Image and statistical analysis was 
performed with JACoP plugin in ImageJ (19). Pearson’s correlation coefficient (PCC) was 
generated using Costes’ automatic threshold algorithm (20, 21). The PCC is dependent upon 
both the pixel intensity and overlap of signal and has a range of +1 (complete colocalization) 
to -1 (anti-correlation) with zero correlating with random distribution between comparators 
(19). The PCC threshold for defining colocalization (i.e., colocalization due to co-
compartmentalization) is 0.6 as per Bolte and Cordelières (19). Channels have been false-
colored (cyan and magenta) using ImageJ LUT for increased visual clarity. Additionally, 
spatial representation of intensity correlation was included using the Colocalization Colormap 
ImageJ plugin. ‘Colormap’ displays positively correlated pixels in hot colors and negatively 
correlated pixels in cold colors that can be visually interpreted using the color scale bar (22). 
Identification of segmented nuclei was performed using the nuclear dye H33342 on K562 
cells displaying green fluorescence 24 hours posttransfection. 
 
7-AAD assay 
  Flow cytometric assay of cell death was done as previously described (2). Briefly, 
K562, Cos-7, or 1471.1 cells were resuspended in 500 µL ice cold PBS containing 1 µM 7-
aminoactinomycin D (7-AAD) for 30 minutes prior to analysis. Cells that have compromised 
membrane integrity (late apoptosis/necrosis) are permeable to 7-AAD (23). Media from 
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adherent Cos-7 and 1471.1 cells was collected prior to trypsinization of cell monolayer and 
recombined with the enzymatically released cell population for centrifugation and subsequent 
resuspension. Analysis and gating was performed on a BD FACSCanto II (Flow Cytometry 
Core Facility, University of Utah) using BD FACSDiva software (BD Biosciences, Franklin 
Lakes, NJ). At least three separate experiments (n≥3) in duplicate were performed. 
Compensation controls were included with each experiment. 
 
TUNEL assay 
  As previously described (24), detection of DNA strand breaks in the K562 cell line 
was performed using the In Situ Death Detection Kit, TMR red (Roche, Mannheim, Germany) 
as per the manufacturers’ protocol. Terminal deoxynucleotidyl transferase (TdT) dUTP nick-
end labeling (TUNEL) detects cells that have extensive DNA degradation in late stage 
apoptosis/necrosis (25). Samples were run on a Becton-Dickinson FACSAria-II (BD-
BioSciences, University of Utah Core Facility) using the 488 nm (for EGFP) and 563 nm 
(TMR red) laser lines with FACSDiva software. Analysis was performed on EGFP positive 
cells using preset gates. The TMR red positive cells were detected in the PE (phycoerythrin) 
channel. Each construct was assayed in at least triplicate (n≥3). 
 
Annexin-V assay 
  Annexin-V binding was assessed, as previously described (24), 48 hours post-
transfection in K562 cells. Externalized phosphatidylserine in the plasma membrane is 
indicative of early apoptosis and is bound specifically by annexin V (26). K562 cells were 
suspended in 100 μl Annexin binding buffer (Invitrogen) and incubated with 5 μl Annexin-V 
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conjugated to allophycocyanin (Annexin-APC, Invitrogen) for 10 minutes. The incubated 
cells were then diluted in 400 μl Annexin binding buffer and analyzed using the FACSCanto-
II (BD-BioSciences, University of Utah Core Facility) with FACSDiva software. EGFP (ex. 
488 nm and em. 507 nm) and APC (ex. 635 nm and em. 660 nm) fluorescence was collected. 
Analysis was conducted on EGFP-positive cells using preset EGFP gates. Each construct was 
tested in triplicate (n=3). 
 
Statistics 
  Data are shown as mean ± S.E.M., with one-way ANOVA using Tukey’s post-test 
or two-way ANOVA using Bonferroni post-test (as indicated in figure legends) to compare 
measurements between experimental data with an N of 3 or greater. Statistical significance 
was set at p<0.05 (by convention p<0.05 is represented with *; p<0.01 with **; p<0.001 with 





Targeting Bcr-Abl to the mitochondria induces 
cell death in K562 leukemia cells 
  Previously, we demonstrated that directly targeting c-Abl to the mitochondria is 
toxic to K562 leukemia cells (3). Based on this we have directly targeted the constitutively 
active and oncogenic form of c-Abl (i.e., Bcr-Abl) to the mitochondria. The IMM-Bcr-Abl 
was created by fusing Bcr-Abl to a canonical mitochondrial targeting signal (MTS; derived 
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from cytochrome c oxidase subunit VIII) that is widely used to direct proteins to the 
mitochondria and the inner mitochondrial membrane in particular (IMM; see Table 4.1) (11). 
Cell death evaluated by flow cytometric analysis of 7-AAD (DNA accessibility) and annexin-
APC (phosphatidylserine externalization) staining (Fig. 4.2) showed the toxic consequences 
of mitochondrially targeted Bcr-Abl (Fig. 4.2A, 3rd column) at 24 hours posttransfection in 
K562 cells. DNA segmentation analysis of mitochondrially targeted Bcr-Abl also revealed the 
same pattern (data not shown). Interestingly, the kinase dead version (i.e., mutation of a single 
critical lysine ablates the capacity for kinase activity) of mitochondrially targeted Bcr-Abl 
(IMM-Bcr-Abl-KD; see Table 4.1) yields no statistical difference in cell death to that of IMM-
Bcr-Abl (compare Fig. 4.2, 3rd and 4th columns). Furthermore, mitochondrially targeted Bcr-
Abl and Bcr-Abl-KD (Fig.4.2, 3rd and 4th columns) significantly induce more cell death as 
compared to the gold standard of current CML therapy, imatinib (IM; 10 μM) (Fig. 4.2B, 2nd 
column) at 24 hours. 
  Yet, the mitochondrial target(s) and submitochondrial localization of the pro-
apoptotic c-Abl are not known (3, 7). Therefore, in order to further investigate the potential 
toxicity of a ‘surrogate death-directed c-Abl,’ in the form of mitochondrial Bcr-Abl, we 
targeted exogenous Bcr-Abl to multiple submitochondrial regions (Table 4.1). Figure 4.3A 
shows representative images of E-Bcr-Abl or mitochondrially targeted Bcr-Abl in K562 cells 
compared to MitoTracker CMXros (MitoTracker) dye. The E-Bcr-Abl construct was not 
associated with the mitochondria (Fig. 4.3A, compare 1st column with 2nd ‘MitoTracker’ 
column) but each of the mitochondrially targeted Bcr-Abl constructs did localize (Fig. 4.3A, 
2nd through 4th rows) to the mitochondria. The corresponding EGFP-only constructs (i.e., 
IMM-EGFP, IMS-EGFP, and OTC-EGFP) were also tested and exhibited robust 
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Table 4.1. Canonical MTSs used to target Bcr-Abl to the mitochondria. MTSs targeting 
different mitochondrial compartments were fused to Bcr-Abl and tested for cellular toxicity. 
KD represents a kinase dead version of Bcr-Abl where a so-called ‘essential lysine’ residue is 
mutated at the ATP binding site, abolishing all kinase activity (27). 
Construct Target compartment Kinase Reference 
OTC-Bcr-Abl mitochondrial matrix active (10) 
IMS-Bcr-Abl mitochondrial intermembrane space active (12) 
IMM-Bcr-Abl mitochondrial inner membrane active (11) 
IMM-Bcr-Abl-KD mitochondrial inner membrane inactive (27) 
IMM-EGFP mitochondrial inner membrane N/A (24) 






Figure 4.2. Direct targeting of Bcr-Abl to the mitochondria causes leukemic cell death. Flow 
cytometric analysis of GFP positive K562 cells 24 hours posttransfection stained with 7-AAD 
and annexin-APC. Both IMM-Bcr-Abl and the kinase dead version (IMM-Bcr-Abl-KD) 
displayed higher cell death than imatinib or mitochondrially targeted EGFP (IMM-EGFP). 
Significance was determined using one-way ANOVA with Tukey’s post-test (error bars are 





Figure 4.3. Submitochondrial targeting of Bcr-Abl in K562 leukemia cells.  
A) Representative images of E-Bcr-Abl or Bcr-Abl fused to a canonical MTS in K562 cells 
and compared to MitoTracker CMXros staining. Each of the MTS-Bcr-Abl constructs localize 
to the mitochondria while the E-Bcr-Abl (no targeting signal) remains cytosolic. Channel one 
(EGFP) and channel two (MitoTracker) have been false-colored, cyan and magenta. 
Colocalized cyan and magenta pixels show as white in merged (‘composite’ column) images. 
The ‘Colormap’ (far right column) is a visual representation of pixel correlation both in space 
and intensity with positive correlation as hot colors and negative correlation in cooler colors 
and can be interpreted using the color scale bar (shown at bottom of the ‘Colormap’ column). 
Scale bars are 5 µm.  
B) Cell death in K562 cells 48 hours post-transfection. Each of the submitochondrially 
targeted Bcr-Abl species caused significantly more cell death than EGFP but only OTC and 
IMM conjugated Bcr-Abl were different from EGFP-Bcr-Abl. Significance was determined 
























mitochondrial localization and low-toxicity. Therefore, only data on the IMM-EGFP are 
shown (Fig. 4.2, IMM-EGFP). We further characterized the effects of targeting Bcr-Abl to the 
mitochondrial matrix with the OTC MTS in Cos-7 and 1471.1 cells (Fig. 4.4). 
  In K562 cells, the OTC and the IMM fused Bcr-Abl constructs were significantly 
more toxic (7-AAD positive) than the E-Bcr-Abl (Fig. 4.3B, compare 4th and 5th columns to 
2nd column) at 48 hours posttransfection. Yet, there was no difference in toxicity between the 
individual MTS-Bcr-Abl constructs (Fig. 4.3B, compare 3rd, 4th, and 5th columns). 
 
Designing a protein chaperone to bind and force Bcr-Abl 
to the mitochondria of leukemia cells 
  Since Bcr-Abl targeted to the mitochondria is toxic (Fig. 4.2, 3rd column), we 
designed a bimodal construct (intracellular cryptic escort (iCE)) using a previously 
characterized cMTS (that we used to directly target c-Abl to the mitochondria) (3) and our 
optimized Bcr-Abl binding domain, ccmut3 (2) (see Fig. 4.5 for description of constructs). 
The mitochondrial targeting of the cMTS is limited to cell types with an elevated ROS 
phenotype (3). K562 cells exhibit high basal levels of ROS which is a common 
pathophysiological feature of malignancy (28, 29). The elevated oxidative stress level leads to 
an increase in PKA and PKC activity which, in turn, phosphorylate and thereby ‘activate’ the 
cMTS at S189 (PKA) and/or T193 (PKC) to induce mitochondrial translocation in a Hsp70 
dependent manner (3, 15). 
 The ccmut3 Bcr-Abl binding protein oligomerizes in an antiparallel orientation with 






Figure 4.4. Bcr-Abl targeted to the mitochondria of K562, Cos-7, and 1471.1 cells.  
A) K562 leukemia and 1471.1 breast cancer cells were sensitive to mitochondrial Bcr-Abl 
whereas Cos-7 fibroblast cells were not. The OTC MTS was used because it is reportedly the 
‘stronger’ MTS as compared to the IMM sequence) (24).  One-way ANOVA with Tukey’s 
post-test was performed on individual cell types (error bars are S.E.M., N≥3; p<0.001***).  
B) Representative images showing OTC-Bcr-Abl colocalizing with the mitochondria 
(MitoTracker CMXros) in Cos-7 and 1471.1 cells (OTC-Bcr-Abl localizes to the 












Figure 4.5. Domain arrangement of constructs. RIN-BD = Abl binding domain from the Ras 
and Rab interactor 1 (RIN1; binds the SH3/SH2 domains of Bcr-Abl), CC = coiled-coil 
domain, IMS = intermitochondrial membrane space, ccmut3 = coiled-coil mutation set 3, 
cMTS = cryptic mitochondrial translocation sequence, Bcr = breakpoint cluster region, Abl = 
Abelson proto-oncogene, EGFP = enhanced green fluorescent protein. See Figure 4.6 for 










and force Bcr-Abl to the nucleus when fused to four strong nuclear localization signals (NLS) 
(13). However, cell death from nuclear entrapment or nuclear targeting of Bcr-Abl is 
relatively modest when compared to mitochondrially targeted Bcr-Abl. For instance, cell 
death assessed by nuclear segmentation analysis 24 hours post-transfection with 4NLS-Bcr-
Abl versus IMM-Bcr-Abl yielded a mean of 12% (5) versus 88%, respectively (data not 
shown). 
 The iCE is designed to bind Bcr-Abl in the cytoplasm and upon activation of the 
cMTS, translocate the Bcr-Abl/iCE complex to the mitochondria. Mutating the key phospho-
residues (i.e., S189A and T193A) on the cMTS ablates the capacity for mitochondrial 
translocation (3) and these mutations have been incorporated into the iCE Null (Fig. 4.5). The 
IMS-ccmut3 and RIN-cMTS are ‘mock’ iCEs where a canonical MTS (IMS) (12) has been 
substituted for the cMTS in the IMS-ccmut3 construct while the well known Bcr-Abl binding 
domain from RIN1 (i.e., RIN-BD) (14) has been substituted for the ccmut3 in the RIN-cMTS 
construct. 
 
The iCE exhibits selective and potent toxicity 
to Bcr-Abl positive K562 cells 
  The iCE and its component parts (i.e., EGFP, ccmut3, and cMTS; Fig. 4.5) were 
transfected into Bcr-Abl positive K562 and Bcr-Abl negative Cos-7 and 1471.1 cell lines. The 
cell death profiles, as measured by flow cytometric analysis of 7-AAD staining, demonstrated 
a cell type-dependent response to the constructs. The iCE was toxic only in the K562 cell line 
(Fig. 4.7A, K562, iCE column) as was imatinib (Fig. 4.7A, K562, IM column). There was no 
significant difference in Cos-7 or 1471.1 between treatment with imatinib or the constructs 
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Figure 4.7. Cell death in Bcr-Abl positive (K562 leukemia) and Bcr-Abl negative (Cos-7 
fibroblast and 1471.1 breast cancer) cells 48 hours post-transfection or treatment with 10 µM 
imatinib. Cell death was assessed by flow cytometric analysis of 7-AAD.  
A) K562 cells were sensitive to imatinib as expected but also to the iCE. The combination of 
the iCE with imatinib led to a significant increase in cell death over either imatinib or the iCE 
alone.  
B) In Bcr-Abl negative Cos-7 cells there was no significant toxicity from imatinib treatment 
or the constructs.  
C) In 1471.1 breast cancer cells there was no significant toxicity from imatinib or the 
constructs individually. Yet, the combination of the iCE and imatinib did cause toxicity when 
compared to imatinib or EGFP but not the iCE alone. One-way ANOVA with Tukey’s post-









individually with the exception of 1471.1 cells with the iCE combined with imatinib (Fig. 
4.7C, 1471.1, iCE+IM column). This was not evidenced in Cos-7 where combining imatinib 
and the iCE were not toxic (Fig. 4.7B, Cos-7, iCE+IM column). In contrast, within K562 cells 
imatinib and the iCE were not different from one another (Fig. 4.7A, K562, compare iCE to 
IM columns) but both were different from the EGFP control and the iCE components (Fig. 
4.7A, K562, EGFP, ccmut3, and cMTS columns). When the iCE was combined with imatinib 
(Fig. 4.7A, K562, iCE+IM column) an enhanced killing effect was observed. 
  Figure 4.8A includes the components comprising the iCE (i.e., EGFP, ccmut3, and 
cMTS) combined with imatinib. There was no difference between imatinib alone and the 
individual components of the iCE combined with imatinib (Fig. 4.8A, compare IM with 
EGFP+IM, ccmut3+IM, and cMTS+IM). As mentioned above the iCE alone was not different 
from imatinib (Fig. 4.8A, compare IM with iCE). The cMTS alone was not different from 
imatinib, however when compared to the iCE alone (Fig. 4.8A, compare cMTS to iCE) the 
difference was extremely significant (P<0.001). Overall, the iCE+IM was extremely 
significant in its killing potential when compared to all constructs regardless of imatinib 
treatment (Fig. 4.8A, compare iCE+IM to EGFP+IM, ccmut3+IM, and cMTS+IM). 
  Representative histograms (Fig. 4.8B) from a set of K562 cells transfected and/or 
treated (imatinib (10 µM) or positive control staurosporine (1 µM)) samples at 48 hours 
demonstrate the difference in dead cells when the iCE and imatinib are combined (Fig. 4.8B, 
compare staurosporine or imatinib to iCE+imatinib). The vertical line within the plot is the 
gate for 7-AAD positive cells for which the percent is listed in the shaded box. As expected, a 
similar cell death pattern was seen using a different cell permeable nuclear stain (H33342) to 
identify nuclear segmentation by microscopy (5) (Fig. 4.8C, compare imatinib only (top right 
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Figure 4.8. The iCE combined with imatinib is highly toxic to K562 cells.  
A) This figure is an expansion of the data set seen in Figure 4.7A, K562 (cell death in K562 at 
48 hours). Box and whisker plot showing percent 7-AAD positive cells 48 hours post-
transfection and/or treatment with imatinib. The darker shaded boxes (of the box plot) 
represent the presence of imatinib (10 µM).  One-way ANOVA with Tukey’s post-test (error 
bars are S.E.M., N≥4; p<0.05*, p<0.01**, p<0.001***).  
B) Representative set of flow cytometric histograms displaying cell count on the y-axis and 7-
AAD intensity on the x-axis. The percent 7-AAD positive population represents cells to the 
right of the vertical line and is listed in the shaded box. As each histogram only depicts a 
single sample, the mean (Fig. 4.7A, K562) and median values (Fig. 4.8A) across the entire 
experimental set are included for reference below the shaded box. ‘GFP Gated’ refers to the 
transfected subset of cells (> 103 intensity in the GFP channel) that were analyzed for 7-AAD 
staining analysis (staurosporine and imatinib samples were not subject to a GFP gate).  
C) Phase-contrast paired with fluorescent images using the nuclear dye, H33342, at 48 hours 
post-transfection (iCE) or imatinib treatment. Upper left, control K562 cells; lower left, cells 
transfected with iCE construct; upper right, cells treated with imatinib only; lower right, cells 
transfected with the iCE and treated with imatinib. White arrow in bottom, rightmost panel 
indicates a cell with a segmented nucleus. Scale bar is 20 µm.  
D) Evaluation of 7-AAD positive K562 cells at 8, 24, and 48 hours posttransfection and/or 













































 set) to iCE + imatinib (lower right set)). The relative health of the cells was revealed by 
phase contrast as well, where the cells treated with imatinib and the iCE evidence the sequelae 
of apoptosis/necrosis (e.g., cell shrinkage/swelling and membrane blebbing) (5) in comparison 
to the untreated control (e.g., round cells with intact membranes) (Fig. 4.8C, compare ‘Phase’ 
of iCE, ‘no treatment’ and ‘imatinib’ to control, ‘no treatment’). The combined treatment of 
imatinib and the iCE accelerates the progression to full blown DNA segmentation (Fig. 4.8C, 
compare the stained nuclei of the iCE, ‘no treatment’ and ‘imatinib’ to iCE, with ‘imatinib’). 
The peak time for iCE+IM killing of K562 is 48 hours (Fig. 4.8D) whereas it is later for 
imatinib alone (10 µM imatinib kills most K562 cells by approximately 72 to 96 hours, our 
unpublished observations). 
 
Cell viability decreases and apoptosis increases 
when the iCE is combined with imatinib 
  Trypan blue exclusion (cell viability), terminal deoxynucleotidyl transferase dUTP 
nick end labeling (TUNEL), and phosphatidylserine (PS) externalization (annexin-V binding) 
demonstrated the antileukemic activity associated with the iCE in K562 cells (Figs. 4.9A, 
4.9B, and 4.9C, respectively). Cell viability was significantly decreased for the iCE compared 
to EGFP and ccmut3 but not the cMTS (Fig. 4.9A, compare ‘no treatment’, iCE to EGFP and 
ccmut3 data points). However, the decline in cell viability with imatinib present (Fig. 4.9A, 
‘IM’) was extremely significant for the iCE when compared to the other component 
constructs. The cell viability assessment was completed 48 hours post-transfection but 24 
hours post-addition of imatinib (IM). Reducing the incubation time, for this assay, with 





Figure 4.9. Assessment of cell viability and apoptotic induction in K562 cells.  
A) Viability 48 hours posttransfection and 24 hours after addition of imatinib. One-way 
ANOVA with Tukey’s posttest was performed within each treatment type (i.e., ‘no treatment 
and ‘IM’).  
B) Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was assessed 48 
hours posttransfection and/or with imatinib treatment (dark shaded columns indicate with 
imatinib) by flow cytometry. One-way ANOVA with Tukey’s posttest.  
C) Phosphatidylserine externalization detection using annexin-APC and flow cytometric 
analysis 48 hours posttransfection and/or imatinib treatment. Dark shaded columns indicate 
imatinib treatment. One-way ANOVA with Tukey’s posttest (for all assays here, error bars are 






















 hour incubation period leaves very few cells to count in the iCE+IM treatment group (Fig. 
4.8C, bottom row, third column, ‘Phase’ for iCE + imatinib demonstrates the lack of cells 
with intact plasma membranes). The level of apoptosis as determined by TUNEL and 
annexin-APC staining (in contrast to 7-AAD staining which detects late-stage 
necrotic/apoptotic cells) (30) was extremely significant for the combined iCE+IM when 
compared to IM treated K562 cells (Fig. 4.9B, iCE+IM vs. IM; or Fig.4.9C compare iCE+IM 
to ccmut3+IM and cMTS+IM). Both assays were completed 48 hours post-transfection and/or 
imatinib (10µM) treatment and analyzed by flow cytometry. 
 
The iCE colocalizes with Bcr-Abl 
  Figure 4.10A shows the cellular localization of the EGFP-tagged iCE or its 
components (see Fig. 4.5 for domain arrangement of constructs) co-expressed with exogenous 
Bcr-Abl (either labeled with blue or mCherry fluorescent proteins) in Cos-7 cells. The iCE, 
like the ccmut3 alone, colocalizes (defined as a Pearson correlation coefficient (PCC) greater 
than 0.6) (19) with Bcr-Abl (Cos-7: Fig. 4.10A, 4th row; PCC=0.63±0.04 and 1471.1: Fig. 
4.10B; PCC=0.83±0.05). The colocalized iCE/Bcr-Abl exhibits a distinct punctate pattern in 
both Cos-7 and 1471.1 cells which was different from the typical diffuse pattern of 
colocalized ccmut3/Bcr-Abl (Fig. 4.10A, compare 2nd row, 1st column (Bcr-Abl with ccmut3 
present) to 4th row, 1st column (Bcr-Abl with iCE present)). In contrast, the cMTS or EGFP, as 
expected, do not colocalize with Bcr-Abl in either Cos-7 or 1471.1 cells (Cos-7: Fig. 4.10A, 
3rd row, PCC=0.3±0.1, for cMTS and Bcr-Abl and Fig. 4.10A, 1st row, PCC=0.02±0.03, for 
EGFP and Bcr-Abl: 1471.1 data not shown). As we previously demonstrated the cMTS alone 
robustly localizes to the mitochondria (Fig. 4.10C, cMTS in K562 (top) and 1471.1 (bottom)  
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Figure 4.10. Representative images of exogenous Bcr-Abl coexpressed with the iCE or its 
individual components and cMTS mitochondrial localization. Scale bars are 5 µm.  
A) Comparison of subcellular localization and association between Bcr-Abl (first column, 
cyan) and the iCE or iCE component parts (second column, magenta) in Cos-7 cells. The PCC 
values in the ‘Composite’ column represent the degree of colocalization between Bcr-Abl and 
the given construct.  
B) Co-expression of Bcr-Abl (first column, cyan) and the iCE (second column, magenta) in 
1471.1 cells with PCC value below the ‘composite’ image.  
C) The cMTS (first column, cyan) strongly localizes to the mitochondria (second column, 
magenta) in both K562 and 1471.1 (but does not in Cos-7; not shown), as previously 



























compared to MitoTracker) in K562 and 1471.1 cells with higher oxidative backgrounds but 
not in the ‘low ROS’ Cos-7 (3). 
 
The iCE did not associate with the mitochondria 
  Unlike the cMTS alone which strongly colocalized with the mitochondria in both 
K562 and 1471.1 cells (3) (Fig. 4.10C) the iCE remained cytoplasmic in its distribution across 
all three cell types (Fig. 4.11, compare ‘iCE’ column to ‘MitoTracker’ column, 1st through 3rd 
rows). Within the context of the Cos-7 cells (which have low inherent ROS levels and 
therefore do not activate the cMTS) (3), as with the cMTS, the iCE was not expected to 
localize to the mitochondria. However, the cMTS alone translocates to the mitochondria in the 
Bcr-Abl negative 1471.1 cell line that features an elevated level of basal ROS (3). Therefore, 
without Bcr-Abl to ‘keep’ the iCE cytoplasmic it was expected that the iCE would robustly 
localize to the mitochondria in this cell line. This was not the case however, and the iCE did 
not localize to the mitochondria of 1471.1 cells (Fig. 4.11, 3rd row). In K562 cells the ccmut3 
alone colocalized with Bcr-Abl and the cMTS alone colocalized with the mitochondria, but 
the iCE did not localize to the mitochondria (Fig. 4.11, 1st row). 
 Earlier studies have demonstrated the importance of the two conserved cMTS 
residues S189 and T193 for activating cytoplasmic-to-mitochondrial trafficking (3, 15). When 
these key phospho-acceptor residues are substituted with either tyrosine or alanine the cMTS 
no longer translocates to the mitochondria (3, 15). Incorporating S189A and T193A mutations 
(i.e., iCE-Null, see Fig. 4.5) led to a change in the qualitative distribution difference between 
the iCE (punctate looking) and the diffuse iCE Null (Fig. 4.11, compare ‘iCE’ in the 1st row 




Figure 4.11. Representative images of the subcellular localization of the iCE (or iCE Null, see 
Fig. 4.5) in K562, Cos-7, and 1471.1 cells and compared to MitoTracker CMXros. The iCE 




the S189A and T193A mutations preventing phosphorylation at these sites in the cMTS 
domain of the iCE Null (Fig. 4.5). 
 
The toxic effect of the iCE on K562 cells is not recapitulated upon 
substitution of the cMTS or the ccmut3 with another canonical 
MTS or Bcr-Abl binding domain 
  The ccmut3 and cMTS paired together uniquely confer the toxic effects of the iCE 
in K562 cells. When the ccmut3 is substituted for another Bcr-Abl binding domain (i.e., RIN-
BD) (14) to create a mock iCE (Fig. 4.5, RIN-cMTS), the cytotoxic effect remains equivalent 
to the cMTS alone, and the concomitant use of imatinib does not potentiate toxicity beyond 
that of imatinib alone (Fig. 4.12A, RIN-cMTS and RIN-cMTS+IM columns). Furthermore, 
substituting the cMTS with a canonical IMS MTS (12), (Fig. 4.5, IMS-ccmut3) diminished the 
induced toxicity to that of the ccmut3 alone, or upon the addition of imatinib, no more toxicity 
than imatinib alone (Fig. 4.12A, IMS-ccmut3 and IMS-ccmut3+IM columns). The mock iCEs 
localize to different subcellular compartments (Fig. 4.12B, compare top (IMS-ccmut3) and 
bottom (RIN-cMTS) rows). The IMS-ccmut3 colocalizes to the mitochondria (Fig. 4.12B, top 
row, compare ‘IMS-ccmut3’ to ‘MitoTracker’ columns) while the RIN-cMTS remains 
cytoplasmic (Fig. 4.12B, bottom row, compare ‘RIN-cMTS’ to ‘MitoTracker’ column). The 
cellular distribution of IMS-ccmut3 (mitochondrial) and RIN-cMTS (cytoplasmic) remained 




Figure 4.12. Domain substitution of either the ccmut3 or the cMTS in the iCE.  
A) The combination of the ccmut3 and cMTS to create the iCE is toxic to K562 cells and the 
substitution of the Bcr-Abl binding domain, ccmut3 with RIN-BD or the cMTS with a 
canonical MTS (IMS MTS) does not reproduce the toxicity of the original iCE. Flow 
cytometric analysis for 7-AAD positivity was measured 48 hours posttransfection and/or 
treatment. IM, iCE, iCE+IM, ccmut3, and cMTS values are also in Fig. 4A. Imatinib is 10 
μM. One-way ANOVA with Tukey’s post-test (error bars are S.E.M., N≥3; p<0.001***).  
B) Representative images of the subcellular localization of the mock iCE constructs, IMS-
ccmut3 (top) and RIN-cMTS (bottom), in K562 cells. Top row, the IMS-ccmut3 colocalizes 




























Altering the key phospho-residues in the cMTS 
domain of the iCE ablates toxic effect 
  We and others have shown that the cMTS no longer translocates to the 
mitochondria when the key phospho-acceptor residues of the cMTS are substituted with either 
tyrosine or alanine (3, 15). Incorporating S189A and T193A mutations (i.e., iCE-Null, see 
Fig. 4.5) into the cMTS domain of the iCE leads to a significant reduction in cell death (i.e., 7-
AAD) and apoptosis (e.g., annexin-APC) in K562 cells at 48 hours (Figs. 4.13A and C, 
compare iCE to iCE Null columns). However, this effect is more pronounced in combination 
with imatinib (Figs. 4.13A and C, compare iCE+IM to iCE Null+IM columns). The trend is 
similar for TUNEL staining but did not reach significance (Fig. 4.13B). 
 
  The oncogenic Bcr-Abl protein, a causative agent for the vast majority of CML 
cases, was directly targeted to the mitochondria by fusion with different MTSs as a proof of 
concept that Bcr-Abl directed to the mitochondria could effectively be used to destroy 
diseased cells. Bcr-Abl was targeted to three submitochondrial regions, since the 
mitochondrial locations and substrates of mitochondrially death-directed c-Abl are not known 
(
Discussion 
3). Similar to mitochondrial c-Abl, Bcr-Abl was highly toxic when targeted to the 
mitochondria of CML cells (Fig. 4.2, 3rd column). Interestingly, and unlike c-Abl (31), Bcr-
Abl’s mitochondrial cytotoxic effect was independent of its kinase activity (Fig. 4.2, 4th 
column). However, there are instances where the kinase activity of c-Abl is dispensable for the 
induction of apoptosis (e.g., via p38 MAPK) (32). Overall, the tyrosine kinase-independent 
killing of CML cells is compelling because it suggests that the strategy of targeting Bcr-Abl to  
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Figure 4.13. Reduction in cell death and apoptosis at 48 hours in K562 cells with phospho-
residue substitutions in the iCE. Cell death (7-AAD) and apoptosis (annexin-APC and 
TUNEL) were measured by flow cytometric analysis. Imatinib is 10 μM.  
A) 7-AAD staining reveals a marked attenuation in the iCE’s cell death effect with and 
without the presence of imatinib (10 μM). IM, EGFP, iCE, and iCE+IM, values are also in 
Fig. 4.7A. One-way ANOVA with Tukey’s post-test.  
B) Apoptosis as measured by TUNEL shows a similar trend to 7-AAD and annexin-APC. IM, 
EGFP, iCE, and iCE+IM, values are also in Fig. 4.9B. One-way ANOVA with Tukey’s post-
test.  
C) Annexin-APC staining corroborated cell death analysis (7-AAD) to show that S189 and 
T193 are essential for the toxic effect of the iCE. IM, EGFP, iCE, and iCE+IM, values are 
also in Fig. 4.9C. One-way ANOVA with Tukey’s post-test (for all assays here, error bars are 






























the mitochondria would be compatible with and complementary to current tyrosine kinase 
inhibitor (TKI) therapy. 
  This led to an attempt to forcibly translocate endogenous Bcr-Abl by means of a 
designed chaperone protein to exploit the toxicity of mitochondrial Bcr-Abl (Fig. 4.5, 
schematic of constructs). The intracellular cryptic escort (iCE) was constructed to bind to and 
move endogenous Bcr-Abl to the mitochondria. We have previously characterized two 
domains comprising the iCE (ccmut3 and cMTS) (2, 3). The ccmut3 Bcr-Abl binding domain 
demonstrated efficient relocalization of Bcr-Abl to the nuclear compartment when fused to 
four NLSs (i.e., 4NLS-ccmut3) (13) and the cMTS was used to directly and selectively target 
c-Abl to the mitochondria in K562 cells (i.e., Abl-cMTS) (3). 
  Consistent with the cytotoxicity (7-AAD positivity) elicited by the direct 
mitochondrial targeting of Bcr-Abl at 48 hours (Fig. 4.3B, 3rd – 5th columns), the iCE also 
induced cell death (Fig. 4.7A, iCE column) within a similar time range. However, subcellular 
compartmental analysis of confocal images comparing between the mitochondria (stained 
with MitoTracker) and fluorescent protein tagged iCE fluorescence and/or Bcr-Abl did not 
indicate any mitochondrial accumulation of the iCE or iCE/Bcr-Abl (Fig. 4.12, compare iCE 
column to MitoTracker column, K562 cells). Therefore, the cytoplasmically localized iCE and 
the mitochondrially targeted Bcr-Abl (MTS-Bcr-Abl) are likely inducing cell death by 
different mechanisms. 
 Our experience with NLSs (e.g., 1 NLS was insufficient to move Bcr-Abl but four 
NLSs were) (5) suggest that the ‘strength’ of the cMTS (within the iCE) was not sufficient to 
overcome the cytoplasmic interactions of Bcr-Abl for efficient translocation to the 
mitochondria. Anticipating that this could happen, we employed imatinib to better facilitate 
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iCE-to-mitochondrial targeting for two reasons. First, imatinib treatment increases the level of 
ROS/PKC activity which in turn leads to more robust mitochondrial localization of the cMTS 
(3). Secondly, imatinib bound Bcr-Abl undergoes a conformational change that decreases 
actin binding and frees Bcr-Abl for relocalization (33). Yet, even with the addition of 10 µM 
imatinib the iCE did not localize to the mitochondria in K562 cells. Furthermore, the iCE did 
not localize to the mitochondria in the elevated ROS, but Bcr-Abl-negative 1471.1 cell line 
revealing that the ccmut3 fusion to the cMTS may compromise the capacity for iCE 
mitochondrial translocation. 
 Nonetheless, the cell death effect caused by the iCE appears to be entirely 
dependent upon the combination of the ccmut3 and cMTS. Mock ‘iCE’s’ substituting either 
the ccmut3 with RIN-BD (RIN-cMTS; RIN-BD binds SH3/SH2 domains of Bcr-Abl) (14) or 
the cMTS with the canonical IMS MTS (IMS-ccmut3; IMS targets the intermitochondrial 
membrane space) (12) failed to restore cell death beyond control levels. The RIN-cMTS and 
IMS-ccmut3 results suggest that the toxicity of the iCE is not propagated by either ccmut3 
localization to the mitochondria or the cMTS remaining bound to Bcr-Abl (at least to the 
SH2/SH3 domains via RIN-BD, which would put the cMTS domain of the iCE on Bcr-Abl 
but at a different location) in the cytoplasm. Moreover, a phosphorylation null mutant version 
of the cMTS domain of the iCE lost cytotoxic potency. 
 The ccmut3 alone and imatinib, as expected (2), both reduced the level of phospho-
Bcr-Abl and Bcr-Abl substrate phosphorylation (i.e., p-Stat5 and p-Crk-L), but the iCE and 
iCE Null were unchanged from control in K562 cells (western blot; data not shown). 
Therefore, the iCE is not acting as a dominant-negative for Bcr-Abl kinase activity. Yet since 
the iCE colocalizes with Bcr-Abl it may be disrupting nonkinase Bcr-Abl 
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survival/antiapoptotic function. For instance, the iCE may increase the steric hindrance of 
kinase-independent signaling from Bcr-Abl such as Src kinase Hck phosphorylation of the 
Grb2 binding site on Bcr-Abl or Bcr’s RhoGEF activity (34, 35). 
 Alternatively, it may be possible that the ccmut3 (binding in an anti-parallel coiled-
coil) (17) positions the cMTS where the phosphorylation of the S189 (PKA) and/or T193 
(PKC) is central to the mechanism for cell death induction. Interestingly, cMTS mitochondrial 
translocation (i.e., not cytotoxic) must be ‘activated’, via phosphorylation (S189 and/or T193), 
and subsequently chaperoned to the mitochondria by Hsp70 (15). However, in K562 cells only 
phosphorylation of the T193 is critical for mitochondrial translocation whereas S189 is not 
(3). Perhaps the cytotoxic nature of the iCE is also primarily a function of PKC 
phosphorylation. Although beyond the scope of this paper, a negative feedback coupling of 
PKC and Bcr-Abl involving transient calcium influx may play a role in the essential nature of 
cMTS phospho-residues, and T193 in particular. Increased transient calcium influx can 
stimulate cellular proliferation while blocking calcium influx via PKC activation is toxic to 
Ph+ leukemia cells (36). Inhibition of Bcr-Abl activity with imatinib relieves negative 
regulation of PKC and thereby diminishes intracellular calcium flux (36). Perhaps increased 
stimulation or altered localization of PKC (due to the presence of the iCE) could further 
diminish transient calcium influx. A fascinating possibility that connects calcium homeostasis 
and iCE toxicity is depicted in Fig. 4.14. (36). 
 In this report, we demonstrate that direct targeting of Bcr-Abl to the mitochondria 
elicits potent cell death induction in a cell type specific and kinase-independent manner. 
Additionally, we attempted to the harness Bcr-Abl’s mitochondrial death induction activity 
with the use of a designed protein chaperone (i.e., iCE) in order to restore the defunct  
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Figure 4.14. Possible mechanisms for iCE induced toxicity to K562 leukemia cells. With 
imatinib (IM) present, Bcr-Abl kinase activity is eliminated (1) and the iCE may be 
potentiating leukemic cell death by altering calcium status and/or blocking kinase-independent 
oncogenic functions of Bcr-Abl. Bcr-Abl tyrosine kinase (Y kinase) activity stimulates 
transient calcium influx (which stimulates proliferation) while PKC activation, at the plasma 
membrane, can have the opposite effect on calcium transients which has been shown to be 
toxic to leukemia cells (36-38). Another cause of iCE enhanced cell death may be through a 
more complete blockade of Bcr-Abl signaling by steric restriction of kinase-independent 
pathways (34, 39). Steric effects may be caused by the presence of PKA and/or PKC, a 
conformational change in the cMTS domain, and/or binding of Hsp70 to the phosphorylated 
cMTS (15).  iCE toxicity requires interaction with Bcr-Abl via the CC domain and the cMTS 
(S/T phospho-residues). The ccmut3 competes with Bcr-Abl for oligomerization at the N-








apoptotic avenue of ‘mitochondrially death directed c-Abl’ in CML cells. Though the iCE 
bound to Bcr-Abl, the iCE/Bcr-Abl complex did not translocate to the mitochondria. 
However, the iCE combined with imatinib treatment is a potent killer of leukemic cells. We 
observed robust killing as measured by 7-AAD (late apoptosis/necrosis), TUNEL 
(apoptosis/necrosis), annexin-V (apoptosis) and trypan blue exclusion assay (cell viability). 
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 Chronic myelogenous leukemia (CML) is the disease for which the first triumph 
of rational drug design turned a near certain death sentence at diagnosis into a 
manageable chronic condition for many people (1). Nonetheless, the following decade 
has revealed that instances of resistance and relapse necessitate continued vigilance and 
effort on behalf of CML researchers (1). Toward this effort, we confirm our hypothesis 
that forcing Bcr-Abl to the mitochondria will selectively induce the death of leukemic 
cells by converting Bcr-Abl into an apoptotic factor.  
 While remaining embedded in the cytoplasmic space Bcr-Abl exerts proliferative, 
survival, and anti-apoptotic signaling via its multifunctional domain structure and 
aberrantly active tyrosine kinase domain (2). However, the c-Abl portion of Bcr-Abl is an 
inducer of apoptosis when it is active and localized to the mitochondria (3) (Chapter 3). 
Following this we have shown that Bcr-Abl can be turned into a potent 
mitochondriotoxic agent (Chapter 4). Our ultimate goal was to transition from proof of 
concept (i.e., mitochondrial Bcr-Abl is toxic to leukemia cells) to a therapeutic entity (the 
intracellular cryptic escort (iCE)) that could move endogenous Bcr-Abl to the 
mitochondria. The iCE was modeled after the normal mitochondrial ‘death-directed’ c-
Abl chaperone mechanism (4). However, the attempt to relocate Bcr-Abl with the iCE 
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failed. Still, we discovered that the Bcr-Abl binding iCE had an unexpected leukemia 
specific toxicity which was potentiated by imatinib. We conclude that the iCE kills (at 
least in part) by a tyrosine kinase-independent mechanism and also that mitochondrial 
Bcr-Abl is toxic regardless of kinase status. Both of these findings have implications for 
opening new angles of attack on CML. 
 
 The cMTS sequence is derived from the C-terminal 50-amino acid sequence from 
glutathione S-transferase A4-4 (GSTA4-4) and is only revealed for mitochondrial 
targeting upon phosphorylation by PKA at Ser-189 and/or PKC at Thr-193. This cMTS is 
sensitive to the cellular oxidative state and readily translocates from the cytoplasm to the 
mitochondria under conditions of oxidative stress, as found in CML cells (
Cryptic mitochondrial translocation signal (cMTS) 
5). Ph+ cells 
have elevated levels of ROS and consequently increased levels of active PKC (6). 
 Therefore, it was hypothesized that the oxidative background in Ph+ cells would 
better facilitate iCE cytoplasmic-to-mitochondrial targeting, over cells with normal 
homeostatic control, while permitting sufficient iCE/Bcr-Abl interaction time. Results 
from other studies had previously demonstrated that unless stimulated, with PKA or PKC 
inducers/activators, the cMTS translocates to the mitochondria only modestly (~6% 
actually being imported into the matrix at 48 hours posttransfection) (5). We initially 
expected that some level of optimization (between PKA/PKC stimulation/inhibition) may 
be required to find a balance between sufficient binding and mitochondrial targeting. 
However, the robust level of activation and mitochondrial localization of the cMTS just 
from the inherent conditions in K562 (and in 1471.1 breast cancer cells) was unexpected. 
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Moreover, our study revealed that T193 (PKC) was the critical residue for mitochondrial 
targeting in K562 and 1471.1 cells. Therefore, we were able to confirm and extend the 
oxidative stress activated translocation of the cMTS (and cMTS fused to c-Abl) in K562 
and 1471.1 cells. 
 
In order to target native c-Abl to the mitochondria any MTS fusion must be 
located at the C-terminus to prevent disruption of c-Abl’s autoinhibitory conformation 
(
c-Abl targeted to the mitochondria 
2). The cMTS is a C-terminal MTS as is the MTS derived from Bcl-XL. Therefore, these 
two MTSs allowed the direct targeting of native c-Abl to the mitochondrial matrix and 
outer membrane, respectively (5, 7). While c-Abl has been stimulated to localize to the 
mitochondria by myriad cellular insults (8), it has not, to our knowledge, ever been 
directly targeted to the mitochondria. We were able to confirm that c-Abl is a pro-
apoptotic factor when localized to the mitochondrial matrix but not the OMM in K562 
cells (9). The mitochondrial matrix-localized c-Abl was relatively (compared to controls) 
more toxic to K562 than 1471.1 cells (c-Abl did not accumulate in the mitochondria of 
Cos-7 because the cMTS is not activated in this cell line (5, 9)). The difference in 
toxicity, from mitochondrial matrix-targeted c-Abl, may be may be due to a different 
balance in inhibitory (protein-protein) interactions in the matrix (leading to a less 
inhibited c-Abl) (10) or perhaps be connected to the level of endogenous ROS in these 
cell lines (9).  
With respect to the OMM-targeted c-Abl, we reasoned that by using an MTS 
derived from Bcl-XL it would put c-Abl in the right ‘neighborhood’ of the OMM for 
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apoptotic activity. Full length c-Abl (in complex with PKCδ) associates with Bcl-XL at 
the OMM under genotoxic stress (11). However, a c-Abl/Bcl-XL interaction at the 
mitochondria may not be pro-apoptotic without PKCδ present as Bcl-XL is likely a 
substrate of PKCδ and not c-Abl (Bcl-XL was shown to be phosphorylated on serine) 
(11). Additionally, since both c-Abl and PKCδ lack any known MTS the OMM seemed 
the more likely site for pro-apoptotic activity. c-Abl’s lack of toxicity at the OMM may 
have been due to a lack of activity. Perhaps direct targeting of the constitutively active 
Bcr-Abl would yield a different result (an OMM direct targeted version of Bcr-Abl was 
attempted but the MTS (from BCS protein (12)) was insufficient to translocate Bcr-Abl 
to the mitochondria).  
c-Abl is also proteolytically processed by caspases (Fig. 5.1). It is highly likely 
that two different forms (full length and a truncated version) of c-Abl are translocated to 
the mitochondria under conditions of cell stress (13). Even so, the probability of c-Abl 
being mitochondrially imported appears to be low. Using MITOPROT (14) to calculate 
the probability of a functional MTS, full length c-Abl yields a probability of 0.154 and 
the truncated c-Abl (non-NLS containing version) was 0.215. For reference, OTC-EGFP 
got a probability score of 0.995 while the EGFP-cMTS was 0.072, yet both of these 
proteins are imported into the mitochondrial matrix (5, 15). 
 
By using previously characterized (i.e., canonical) MTSs demonstrated to target 
various heteroproteins to specific submitochondrial regions, we established the apoptotic 
potential of mitochondrially targeted Bcr-Abl in K562 cells. Since cytoplasmic Bcr-Abl  




Figure 5.1. Caspases and c-Abl. Caspase cleavage of c-Abl at residues D565 and D958 
create either a nuclear targeted version of c-Abl or a cytosolic version that could also be 




obstructs the apoptotic pathway at so many levels (16, 17) we assessed late stage 
apoptosis/necrosis (e.g., 7-AAD and DNA segmentation) in order to ensure that MTS-
Bcr-Abl apoptotic induction was irreversible and can be carried all the way through to the 
destruction of the leukemic cell. Targeting the IMM with Bcr-Abl induced cell death as 
early as 20 hours posttransfection as measured by annexin-APC and 7-AAD (Fig. 5.2). 
Since there are reports that the apoptosis-resistant K562 cell line can appear ‘normal’ 24 
hours after treatment with DNA damaging agents (18) it was a little surprising to find that 
targeting Bcr-Abl to the mitochondria of K562 cells so robustly induced cell death even 
before 24 hours using a construct that requires time (as early as ~4 - 6 hours (19)) for 
protein expression. Bcr-Abl (OTC-Bcr-Abl) and c-Abl (Abl-cMTS) targeted to the 
mitochondrial matrix were similar in their toxicities in both K562 and 1471.1 cells at 48 
hours (Fig 5.3) with no statistical difference using a two-way ANOVA.  Nonetheless, it is 
unclear if OTC-Bcr-Abl (or Abl-cMTS) is acting as an authentic surrogate for death-
directed c-Abl. The kinase activity has been reported to be essential for the pro-apoptotic 
function of c-Abl at the mitochondria (20). Yet death induction from kinase-dead forms 
of mitochondrial targeted c-Abl and Bcr-Abl were not statistically different from the 
wild-type versions. 
The K562, 1471.1, and Cos-7 cell lines were differentially susceptible to death by 
mitochondrial c-Abl and Bcr-Abl. This may possibly reflect an underlying state of 
mitochondrial apoptotic ‘priming’ (i.e., BH3 profiles) where the Bcl-2 family proteins 
(with over a dozen members) are arrayed to trigger MOMP in certain types of cancer cell 
but not in most normal cells (21). However, K562 are considered a chemoresistant cell 




Figure 5.2. Cell death in K562 at 20 hours posttransfection with IMM targeted Bcr-Abl 
(Mito BA). ‘Mito’ label indicates the IMM targeting MTS derived from cytochrome c 






Figure 5.3. Comparison of cell death from mitochondrial matrix targeted c-Abl and Bcr-




BH3 mimetic (ABT-737) in order to achieve chemotherapeutic sensitivity (21). The 
priming status of 1471.1 and Cos-7 cells is not known and could be lower than K562. 
Nonetheless, unlike the response to standard chemotherapeutics (e.g., etoposide and 
vincristine) K562 seem uniquely vulnerable to mitochondrial matrix targeted c-Abl and 
Bcr-Abl. Alternatively, the level of cell death across these cell types may have some 
correspondence to inherent ROS levels (Fig 5.4). 
 
The iCE selectively induced leukemic K562 cell death (as compared to 1471.1 
breast cancer and Cos-7 cell lines) to the same level as imatinib alone and had a more 
than additive killing effect when combined with imatinib (Fig. 5.5). Imatinib showed 
similar absolute toxicity to 1471.1 cells as to K562. To this point, imatinib has been 
shown to be effective in killing certain breast cancer cell lines that are dependent on the 
expression of c-Kit or PDGFR (
iCE is selectively toxic to leukemia cells 
22). Though, the expression of receptor tyrosine kinases 
in 1471.1 cells has yet to be characterized. Therefore, the 1471.1 cell line may be 
susceptible to imatinib either due to receptor (e.g., c-Kit or PDGFR) or non-receptor (c-
Abl) tyrosine kinase inhibition. However, the added cell death (e.g., 7-AAD) values of 
imatinib and iCE were greater than that for the combination of iCE and imatinib 
demonstrating the lack of potentiation in the 1471.1 cell line.  
Despite the killing effect of the iCE in K562, colocalization analysis demonstrated 
that Bcr-Abl and the iCE were not targeted to the mitochondria as expected. The 
mechanism of leukemic cell killing by the iCE remains obscure. Since the iCE 




Figure 5.4. Level of cell death compared to ROS level. The iCE is not targeted to the 






Figure 5.5. The combination of the iCE+IM has a more than additive killing effect on 
K562 cells. The IM treated K562 7-AAD values (first column) were added to those of 
iCE alone (third column) to generate the ‘added ice to IM’ column.  Statistical difference 




localization of the iCE itself or from a Bcr-Abl/iCE interaction. We suspect that the iCE 
may exert its killing activity by more than a one mechanism. While the iCE does not 
significantly inhibit the tyrosine kinase activity of Bcr-Abl itself, the ccmut3 domain 
disruption of Bcr-Abl homo-oligomerization may reinforce imatinib efficacy by shifting 
Bcr-Abl’s conformational equilibrium to one in which imatinib is more readily bound. 
Additionally, the iCE, through the cMTS domain, possibly recruits a PKC (perhaps 
PKCβ) or PKA isoform to the plasma membrane which results in reduced pro-
proliferative calcium transients (via G-protein coupled receptor desensitization) (23) 
PKCβ upregulation and activity was uniquely toxic for CML cells compared to normal 
stem cells (24) and the leukemia-specific toxicity occurs upon PKCβ translocation to the 
plasma membrane (25). Moreover, iCE binding to Bcr-Abl may interfere with tyrosine 
kinase independent oncogenic signal transduction through Bcr-Abl (e.g., disruption of 
signaling from Src kinase phosphorylation of Y177 on the Bcr portion of Bcr-Abl that 
leads to Grb2 binding and ultimately Ras activation) (26, 27) or block Bcr-Abl RhoGEF 
domain activity (28). 
Alternatively, wild-type Bcr should also be considered as a potential source for 
mediating the iCE’s killing effect since the ccmut3 binds to the Bcr portion of Bcr-Abl. 
Targeting Bcr has not been well studied in leukemia but the overexpression of Bcr 
reduces the leukemogenicity of Bcr-Abl. The novel S/T kinase activity of Bcr is required 
for the antileukemic activity of overexpressed Bcr. In addition, the tyrosine kinase 
activity of Bcr-Abl suppresses the S/T kinase activity of Bcr (29). It may be possible that 
the iCE binds to Bcr and prevents Bcr-Abl phosphorylation of Bcr thereby creating a 
condition of disinhibition for a negative regulator of Bcr-Abl. 
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While cell death may be effectively recapitulated in the Ph+ and not in Ph- cell 
lines used in this study, these cell lines are not be meant to model all of Ph- or Ph+ cells 
and it is unlikely that the results obtained with the iCE in this study can be extrapolated 
too broadly. Two of the most important Ph+ cell populations to target in a curative design 
for CML will be the TKI refractory stem cell population and CML cells expressing TKI-
resistant Bcr-Abl (e.g., T315I). Until these unique cell populations can be tested it will 
remain uncertain whether or not iCE type therapy would confer benefits beyond current 
CML therapies. Although the K562 line is a considered to be a blast phase cell it is still 
dependent upon Bcr-Abl for survival and therefore, more closely serves as a model of 
chronic phase CML. Nonetheless, the activity of the iCE and mitochondrial Bcr-Abl may 
represent two separate and selectively leukemotoxic mechanisms compared to 1471.1 
breast cancer and Cos-7 fibroblast cell lines (Fig 5.6). Moreover, each of these 
mechanisms may have particular relevance in CML stem or TKI resistant cells due to the 
kinase-independent killing activity they both exhibit. 
The iCE (in combination with imatinib) and mitochondrially targeted Bcr-Abl 
killing modalities may yet be highly relevant in chronic phase CML. After more than a 
decade of experience with TKI therapy, current clinical strategies are largely focused on 
gaining better long-term patient outcomes and preventing TKI resistance from emerging. 
The durability of a patient’s response is thought to correspond to achieving a critical 
threshold level of CML cell burden elimination with the initial TKI therapeutic challenge. 
The potentiation of imatinib efficacy when combined with the iCE may offer an avenue 
to achieving a better ‘up-front’ patient response and lead to improved rates of sustained 




Figure 5.6. K562 cells are more susceptible to the iCE and mitochondrial c-Abl/Bcr-Abl 
than Cos or 1471.1 cells. Overall, the K562 cell line demonstrated selective sensitivity to 
imatinib (as expected) and the targeting of Bcr-Abl or c-Abl to the mitochondria. The 
iCE, through an unknown mechanism is also selectively and highly toxic to K562 cells. 
Red asterisks indicate difference from Cos-7 cell line and Black asterisks indicate 
difference from 1471.1 cell line. Two-way ANOVA with Bonferroni post-test (error bars 




Mitochondrial Bcr-Abl and c-Abl 
Future work 
There are several questions that could be addressed now that Bcr-Abl has been 
demonstrated to be a mitochondrial toxin. For instance, the intention to mimic c-Abl’s 
“mitochondrial wracking factor” (MWF) (30) potential is complicated by not knowing c-
Abl’s mitochondrial substrate(s) and submitochondrial translocation site (31). 
Determining the submitochondrial location of death-directed wild-type c-Abl is an 
important next step. The use of endoplasmic reticulum toxins (e.g., tunicamycin) that 
have been shown to target c-Abl to mitochondria and immunoelectron microscopy to 
determine Abl submitochondrial localization (immunocytochemical staining for 
transmission electron microscopy (TEM)) could resolve this question. Furthermore, once 
the optimal (or correct) submitochondrial location and protein interactions are 
determined, a refinement of the amount of c-Abl (Bcr-Abl) that is required to meet a 
particular ‘death induction threshold’ could be explored. Once the question of 
submitochondrial compartment is resolved, truncation or point mutants that disable 




Since the iCE failed to relocalize Bcr-Abl it could be re-engineered for that end. 
The ccmut3 was selected from a set of binding domains to Bcr-Abl because it had been 
the most effective in moving Bcr-Abl from the cytoplasmic space to the nucleus (32). 
This indicates that the MTS (i.e., cMTS) was the limiting factor. However, other Bcr-Abl 
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binding domains may be better at ‘dislodging’ Bcr-Abl from its cytoplasmic interactions. 
The cytoplasmic retention of Bcr-Abl is primarily determined by the C-terminal actin 
binding domain (ABD) in the Abl portion of Bcr-Abl (33). The ABD is also central to 
Bcr-Abl’s transformative potential (34).  Interrupting Bcr-Abl’s actin interaction leads to 
the release and nuclear translocation (through the NLSs (Fig 1.3) of Bcr-Abl (35). Andy 
Dixon, PhD of the Lim Laboratory developed a Bcr-Abl actin binding domain specific 
iDab (i.e. single domain antibody) (36, 37) that colocalizes with and can facilitate Bcr-
Abl nuclear localization (32). 
 iDabs take advantage of the ability of a single variable fragment of an antibody 
(heavy or light chain) to bind an antigen with the same specificity and affinity as a full 
size (e.g. IgG) antibody but at a tenth the size (38, 39). Furthermore, iDabs do not 
require, as do full antibodies, disulfide bonds that are incompatible with the intracellular 
reducing environment (40). An iDab has been generated (41) against the ABD of Bcr-Abl 
(Andy Dixon, Lim Laboratory (32)). The ABD-iDab could be fused to the C-terminal 
cMTS before the EGFP (or other fluorescent tag) and this will produce a relatively small 
~36-37 kDa protein. 
 Creating a multi-valent binding protein is almost certainly necessary to achieve 
translocation of Bcr-Abl to the mitochondria (32).  Since the nuclear trafficking of Bcr-
Abl was increased when the 4NLS-ccmut3 was paired with the 4NLS-ABD iDab (32), a 
set of iCEs with different Bcr-Abl binding moieties may be effective in mitochondrially 
relocating Bcr-Abl. 
 A potential limitation concerning the ABD-iDab containing iCE is that since the 
ABD pertains to the Abl portion of Bcr-Abl there exists the possibility that there may be 
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binding (and mitochondrial translocation) of both Bcr-Abl and c-Abl. As c-Abl activation 
is carefully controlled and our results show that c-Abl is not toxic at the OMM it is 
unlikely that, if it is translocated to the mitochondria of CML or non-CML cells, it would 
induce apoptosis (20). 
 An interesting alternative approach is the substitution of the two PKA/PKC (S189 
and T193) target residues with tyrosine creating the condition that Bcr-Abl may be able 
to ‘activate’ its own chaperone (just like active c-Abl phosphorylates PKCδ for 
translocation(4)). This may allow for both increased selectivity (i.e., no iCE transport of 
inactive c-Abl) and (perhaps) improved rates of mitochondrial targeting of Bcr-Abl post-
binding of the iCE. 
 If the iCE were made to function as intended, the amount of Bcr-Abl in a given 
cell will not be a limiting factor to iCE therapeutic efficacy but rather a condition leading 
to an intensification of apoptotic pressure. Likewise, an iCE would not be as vulnerable 
to mutations in Bcr-Abl or cellular efflux mechanisms and likely to have a minimal side 
effect profile (42). On the other hand if an iDab/cMTS construct (like the ccmut3) does 
not localize to the mitochondria it may help to elucidate the mechanism behind the 
toxicity of the iCE. 
 
In vivo studies: cMTS 
Koeffler and Golde, in a 1980 review of leukemia cell lines, predicted that K562 
cells as a model of CML would “shed new light on the cell biology and perhaps lead to 
new therapeutic modalities.” (43) However, CML is a disease of hematopoietic stem cells 
and can therefore give rise to multiple lineages of tumor cells. Cell line lineage is 
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considered to be a central factor in the determination of therapeutic response to TKIs 
(imatinib) (44). This necessitates prudent caution when extrapolating experiences with 
immortalized cell lines in culture to potential in vivo activities. Our work in vitro 
demonstrates that the cMTS can be activated by the physiologically relevant inherent 
levels of oxidative stress found in transformed cells. However, it will be necessary to 
replicate the findings for the cMTS (inherent ROS level-activated translocation) in vivo. 
An in vivo approach would most likely employ a mouse xenograft model of leukemia 
(45). The cMTS is small enough (and could potentially be further truncated) to be viable 
as a peptide therapeutic when conjugated to a cell-penetrating peptide motif (e.g., HIV 
TAT). However if conjugated to, say c-Abl, it would be better to adopt a gene therapy 
strategy for delivery.  
We used the cMTS as a vehicle to selectively deliver c-Abl under conditions of 
oxidative stress but the implications of the cMTS utility could be expanded upon. For 
instance, in many pathophysiological conditions (e.g., neurodegeneration (46) and 
diabetes (47)) that manifest increased oxidative stress the cMTS could be used to 
selectively target the mitochondria with an antioxidant payload/enzyme. The cMTS may 
be of benefit to selectively target either pro-apoptotic or pro-survival factors to the 
mitochondria to elicit or prevent cell death, respectively. Additionally, the cMTS may 
find utility beyond conditions of elevated ROS but also in many breast cancers where 
PKC (of various isoforms) are overexpressed (48). 
The genetic diversity of CML cells has dampened the early optimism surrounding 
targeted therapeutics (49). Turning Bcr-Abl back on itself to cause leukemic cell death is 
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more likely to circumvent the ‘newer’ problems brought about by genetic diversity in 
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Exploiting the aberrant tyrosine kinase activity of Bcr-Abl to 
control a cryptic mitochondrial targeting peptide 
 The optimized Bcr-Abl peptide substrate EAIY[XX]PFAKKK (also called 
Abltide (1)) is routinely used as a sensor for Bcr-Abl activity in vitro and has been 
suggested as a highly selective reporter for use in an activity-based diagnostic for CML 
(2-4). The phosphorylation of Abltide can be significantly increased by linking Abltide to 
modular recognition domains (e.g., such as a proline rich region, as found in the cMTS) 
that can interact with Bcr-Abl’s SH2/SH3 domains (2, 5). The cMTS translocates from 
the cytoplasm to the mitochondria upon PKA/PKC mediated phosphorylation at key 
residues (S189/T193, respectively). We hypothesized that by altering the substrate 
consensus sequence and phosphoresidue (i.e., the enzyme-substrate specificity) at S189 
and/or T193 of the cMTS we could uncouple ROS/PKA/PKC induced phosphorylation of 
the cMTS and, generate a peptide that is predominantly cytoplasmic unless 
phosphorylated by Bcr-Abl. Our therapeutic goal is to subvert Bcr-Abl’s oncogenic 
activity and convert it into a pro-apoptotic agent. Engineering a Bcr-Abl inducible 









Materials and methods 
Subcloning and construction of plasmids 
Each MTS plasmid construct is derived from the wild-type cryptic mitochondrial 
translocation sequence (N-terminal residues, 172-222) from glutathione S-transferase A4-
4 (cMTS-wt) with iterative mutations to introduce tyrosines with minimal or strict v-Abl 
consensus phospho-substrate sequence specificity at the critical 189 or 193 residue 
positions (6), see Table A.1. The cMTS-wt was constructed cloned into the pEGFP-C1 
vector as previously (7). Cell lines and culture conditions, expression of constructs, 
mitochondrial staining, microscopy, image, and statistical analysis were all as previously 
(7). 
 
 In a measure to alter the activating phosphorylation of the cryptic mitochondrial 
translocation sequence (cMTS) from the protein kinase A and C family of kinases to Bcr-
Abl itself, several cMTS mutants were made (Table A.1).  However, few of the cMTS 
mutants target the mitochondria (Fig. A.1, A). The mutations seem to influence an 
equilibrium between mitochondrial translocation and binding to Bcr-Abl. In a few 
mutants the equilibrium is strongly shifted to association with Bcr-Abl (Fig. A.1, A and 
B). The Bcr-Abl binding protein RIN1 (RIN1 binding domain (RIN-BD) was used as a 
positive control for Bcr-Abl binding domain optimization in our previous studies (i.e. 
ccmut3) (
Summary of results 
8)) sets a mechanistic precedent for the type of binding hypothesized to be 
occurring with the cMTS mutants (Fig. A.2). RIN1 is phosphorylated on tyrosine by Bcr-
Abl leading to binding to the SH2 domain of Bcr-Abl. The interaction between RIN1 and 
247  
Bcr-Abl is further stabilized through a poly-proline rich region in RIN1 binding to the 
SH3 domain of Bcr-Abl (Fig A.2, D) (9). A few of the cMTS mutants achieved equal 
colocalization with RIN-BD to Bcr-Abl and even led to the displacement of RIN-BD 
from Bcr-Abl (i.e., OPT MTS ‘2’; Fig. A.3 and Table A.2). 
 Substitution of glutamate at positions 189 or 193 as a phosphomimetic (10) may 
provide a means to balance mitochondrial targeting and Bcr-Abl binding with the cMTS 










Figure A.1. cMTS mutant subcellular associations and Bcr-Abl activity.  
A) Comparison of cMTS mutant association with either Bcr-Abl (exogenously co-
expressed with cMTS mutant or EGFP constructs in Cos-7 cells) or the mitochondria (in 
K562 cells). All experiments were completed in at least triplicate (n ≥ 3) and images were 
collected in ≥ 4 fields with ≥ 10 cells per z-plane.,  
B) Bcr-Abl activity is essential for association of the cMTS mutants. Bcr-Abl-KD and 
Bcr-Abl were co-expressed in Cos-7 cells with the cMTS mutants or EGFP. Error bars 









































Figure A.2. Wild-type PKA/PKC activated cMTS (50 C-terminal residues of GSTA4-4) 
and the Bcr-Abl activated cMTS.  
A) The cytosolic versus mitochondrial pool of GSTA4-4 is modulated through an 
approximately 50 residue C-terminal cryptic mitochondrial targeting signal (MTS) 
domain that is responsive to the oxidative state of the cell (8). Mitochondrial targeting of 
GSTA4-4 is induced by phosphorylation by protein kinase A (PKA) at S189 or Protein 
kinase C (PKC) at T193.  Phosphorylation of Ser-189 or Thr-193 increases affinity for 
cytoplasmic Hsp70 and subsequently leads to the translocation of GSTA4-4 to the 
mitochondrial matrix (8). The integration of an Abltide-like Bcr-Abl recognition 
sequence within the GSTA4-4 MTS created a Bcr-Abl inducible cryptic MTS.  
B) Integrating an Abltide-like sequence within the ‘activation’ region, where S189 and 
T193 are located (shown in bold), should change the substrate specificity from PKA/PKC 
to Bcr-Abl. The full consensus sequence for c-Abl was arrayed with the tyrosine at 
position 189 (‘Y-OPT’) or 193 (‘2X’ cMTS). A sequence that meets the minimum 
consensus was made around position 189 (‘Y-mut’) and 193 (‘OPT MTS 2’; not shown, 
see Table 2).,  
C) Using fluorescent confocal microscopy and statistical colocalization analysis Y-OPT 
(Full consensus sequence at position 189)  did (unexpectedly) colocalize with Bcr-Abl 
(mCherry tagged and coexpressed) in K562 cells and in Cos-7 cells (Cos-7 cell shown on 
left). Red dashed line is the threshold for meeting colocalization (11). The correlation of 
Y-OPT with the mitochondria was highly variable and not strong, unlike the wild-type 
cMTS. Cytosolic distribution profiles often looked similar to Bcr-Abl and this prompted 
the colocalization analysis with Bcr-Abl. In addition, when the Y189 was mutated to 
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alanine the association with Bcr-Abl was abolished. Likewise, the association between 
the Y-OPT and Bcr-Abl (or between Y-OPT and the mitochondria) ceased when imatinib 
was present (data not shown). Based on interaction studies with the RIN1 binding domain 
(N-terminal 295 residues of RAS interaction/interference 1 protein) we hypothesized that 
our Y-OPT was being retained in the cytoplasm through binding to Bcr-Abl. At least 
three independent experiments (n ≥ 3) were completed and images were collected in ≥ 4 
fields with ≥ 10 cells per z-plane. Error bars are S.E.M.,  
D) Hypothesized mode of Bcr-Abl binding. The Y-OPT structure may facilitate a RIN1 
type binding interaction with Bcr-Abl where it is thought binding is mediated first 
through tyrosine phosphorylation and SH2 binding followed by SH3 binding of a poly-
proline sequence (12). There are two potential Bcr-Abl interaction regions in Y-OPT. 
First, an Abl SH2 binding motif (10) is present upon phosphorylation at Y189 and 
second, a poly-proline sequence (matching a class II SH3 recognition sequence (11)) is 
present immediately c-terminal to the Abltide-like sequence.  
E) Example of the heterogeneity in the mitochondrial association results in K562 cells. 
Top row, Y-OPT is clearly colocalized with MitoTracker dye signal while, on the bottom 
row, Y-OPT is strongly associated with Bcr-Abl. It is unclear what conditions favor 
mitochondrial versus Bcr-Abl association of the Y-OPT.  
F) Cytofluorogram (scatterplot) generated using JaCOP (ImageJ) comparing EGFP-Y-
OPT (y-axis) to mCherry-Bcr-Abl (x-axis). The separate pixel populations (solid and 
dashed lines) may represent different stoichiometries between the fluors and thereby 
indicate interaction in different subcellular compartments. The PCC is insufficient and 
inappropriate for distinguishing subpopulation relationships between channels. The 
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variability in PCC values generated among the cMTS mutants can be explained by 
different populations of interacting fluors as revealed in the cytofluorograms. 
   




































Figure A.3. OPT MTS 2 binds to Bcr-Abl like RIN-BD.  
A)  The minimum c-Abl consensus sequence at position 193 (OPT MTS 2; two residues 
different from wild-type, see Table 5.2) strongly associates with Bcr-Abl.,  
B) Kinase dead mutant of Bcr-Abl abolishes association with the OPT MTS 2 but a SH3 
domain mutant (P1013L) does not. Error bars are S.E.M and dashed red line indicates 
colocalization (A and B)., 
C) Representative western blot image (false colored ‘fire’ in ImageJ) of Bcr-Abl activity 
in Cos-7 cells. Bcr-Abl (or a kinse dead mutant) was expressed in Cos-7 with or without 
RIN-BD or OPT MTS 2 present. RIN1 reportedly increases the activation of Bcr-Abl (by 
keeping Bcr-Abl in an ‘active’ conformation (9)) but the smaller RIN-BD and the OPT 













Figure A.3: Continued 
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A practical guide to evaluating colocalization in biological microscopy (2011) 
 Dunn et al. 
Prior to the processing, images should be coded for blinded analysis. 
ImageJ: 
i) Open .tif z-stack file [FILE:OPEN] 
ii) Convert to 8-bit [IMAGE:TYPE] 
iii) Stack to images [IMAGE: STACK TO IMAGES] 
(1) Make a list of parallel channel images (i.e., which images correspond 
each other) 
(2) Minimize all images 
(3) Expand two parallel images (i.e. GFP channel and MitoTracker channel) 
(a) Subtract background (WCIF – Wright Cell Imaging Facility: ROI 
Background correction plugin) 
(i) Subtract background from each image (and channel) throughout 
the stack individually – look for a region without cells. This can be 
verified even when a phase contrast is not available by using 
IMAGE:ADJUST:THRESHOLD. Use the histogram to determine 
all pixels present (displayed in red) and hit RESET prior to 
background subtraction or image analysis.                                                         
1 Special thanks to Chris Rodesch, PhD. Director, University of Utah Cell Imaging Core Facility for scientific 
discussions. 
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1. Open ROI Manager [ANALYZE:TOOLS:ROI MANAGER] 
and save ROI that does not contain cells (This is the 
Background or BG ROI) 
2. Select/highlight saved BG ROI within each channel image (and 
all images across stack – watch for moving cells (i.e., non-
adherent lines)) 
3. Run Plugins/ROI/BG subtract from ROI – [subtracts mean of 
ROI form image plus an additional value equal to the sd of the 
ROI multiplied by a scaling factor [mean + (sd*scaling 
factor)]] 
a. Leave on default of 3 for scaling factor 
(4) Expand parallel images (if multi-tiff) 
(a) Select an ROI, import to the ROI manager [ROI MANAGER:ADD], 
copy ROI to parallel image [click on parallel image, double-click the 
ROI # in ROI MANAGER] 
(b) ‘Duplicate’ each channel ROI [IMAGE:DUPLICATE:’OK’] 
(c)  OPTIONAL: Remove pixels outside ROI [EDIT:CLEAR OUTSIDE] 
– do this for each duplicated image. ONLY use this if you are certain 
that 0:0 pairs are excluded – JACOP does NOT exclude 0:0 pairs. 
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(5) Open JACOP [PLUGINS:JAR:JACOP] 
(a) Select each channel duplicate image [By convention (i.e., my way 
which is moving from blue through red in the spectrum) - Select GFP 
channel as A and Mitotracker as B] (always make note of which 
channel is which) 
(b) In JACOP have these analysis checked: Pearson’s correlation 
coefficient, M1 & M2, K1 & K2, Costes’ automatic threshold, 
cytofluorogram, and Van Steensel’s CCF. This is the output to the 
‘data log’. Evaluate cytofluorogram for ‘lobeness’ (more than one 
linear relationship amongst pixels suggests association in different 
ratios or compartments). 
(6) Open Colocalization Colormap [PLUGINS:COLOCALIZATION 
COLORMAP] – This is a modification of Li’s ICA and is a representation 
of spatial co-variation (“cross view of biological compartments”). This is 
highly sensitive to background noise. 
(a) ‘display nMDP statistics’ should be checked.  
(7) Open Colocalization Finder [PLUGINS:COLOCALIZATION FINDER] 
An advantage to this feature is to select ROIs within the scatterplot. This 
can be used to identify ‘compartments’ in the generated overlap image 
where only ROI pixels show as white. 
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(a) In order to visualize pixels in the interactive scatterplot you may
(i) If more than one lobe is present or a nonlinear association is 
evident select a ROI in the scatterplot and save in the ROI 
Manager for use in identifying that ‘compartment’. 
 need 
to open [IMAGE:ADJUST: BRIGHTNESS AND CONTRAST]: click 
on AUTO. Now the selected pixels in the scatterplot can be identified 
spatially in the image. 
(b) OPTIONAL (in JACOP): Manually set the channel A and B thresholds 
to predetermined values for the given image stack. (however, you must 
specify how threshold was arrived at for reproducibility) 
(8) Save: [FILE with original z-stack image should have: 1) data log, 2) the 
duplicated images of ROI in tiff format, 3) the cytofluorogram as JPEG, 
and 4) the Costes’ mask as tiff. Each analyzed image ought to have five 
items in a folder]. 
(9) Compile all log data (by ‘copy and paste’ into a Word document) 
(a) Save the complete document into the file that contains the individual 
‘CELL ROI’ folders. 
(10) Select the relevant statistic(s) and graph data 
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